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Chapter 1 





The present thesis is focused on the development of a novel therapeutic system by 
which anti-fibrotic drugs can be delivered selectively to the kidneys. Renal fibrosis is a 
final common process of many chronic renal diseases. It is characterized by 
over−deposition of the extracellular matrix, which eventually leads to the end-stage renal 
disease (ESRD)(1). Several renal disorders such as diabetic nephropathy, chronic 
glomerulonephritis, tubulointerstitial fibrosis and hypertensive nephrosclerosis can result 
into ESRD (2). The ultimate therapy for ESRD is dialysis or renal transplantation but these 
treatments have many medical and social disadvantages and are not always successful (2,3). 
The escalating prevalence of ESRD demands therefore for novel therapeutical strategies. 
Renal−selective delivery aims to increase the therapeutic efficacy of drugs by increasing 
the amount of drugs locally within kidneys. In addition, renal targeting can avoid the 
interaction of drugs with other organs which can prevent the extra-renal side-effects.  
 In 1991, Franssen et al. demonstrated that low molecular weight proteins (LMWPs) 
such as lysozyme (LZM) could be used as a carrier to deliver drugs specifically to kidneys 
(4). LMWPs are small in size approximately below 20 KDa so that they can freely filter 
through glomerulus. Filtered proteins are taken up by proximal tubular cells through 
megalin receptors via receptor−mediated endocytosis. In lysosomes, the protein is degraded 
enzymatically into small peptides and amino acids. By conjugating drugs to such proteins, 
drugs will follow the same route of disposition of LMWPs and get released within tubular 
cells of the kidney after lysosomal degradation of the constructs (Fig. 1). This 
renal−specific drug delivery approach was further explored to enhance the therapeutic 
efficacy of drugs and to reduce the systemic side-effects (5,6). Later on, Kok et al. showed 
that renal targeting of the angiotensin converting enzyme (ACE) inhibitor captopril was 
successfully achieved using LZM (7). It was shown that intravenous injection of captopril-
LZM increased the renal captopril levels and inhibited renal ACE activity specifically in 
comparison to non-targeted captopril.  
The treatment of chronic renal diseases implies the use of our protein-based constructs 
for a prolonged period of time. Intravenous administration would not be a favorable option 
then and therefore we investigated the possibility of delivering the drug−targeting 
conjugates such as captopril-LZM using subcutaneous route of administration (Chapter 2). 
We compared the time−course of renal uptake of captopril-LZM conjugate after 
administering it intravenously and subcutaneously in healthy and nephrotic rats. In addition, 
plasma and renal ACE activity were measured to delineate the effect of the conjugate after 
administration via both routes. Furthermore, we evaluated the efficacy of subcutaneously 
administered captopril-LZM conjugate in proteinuric rats which has been described in 
Chapter 3. In adriamycin−induced nephrotic rats, the effect of the captopril-LZM 
conjugate was studied after the treatment with subcutaneous doses for 10 days. Blood 
pressure, proteinuria and renal and plasma ACE activities were measured to determine the 
pharmacological effects. Results of the studies presented in chapter 2 and 3 show that the 
Introduction 
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subcutaneous route is available for our constructs. Selective delivery of captopril to the 
kidneys is achieved and significant effects were found in this organ. 
Chapter 4 of this thesis reviews the pathophysiology of renal fibrosis and focuses on 
novel therapeutic targets to treat this disease. It describes the role of different factors such 
as cytokines and growth factors as well as signaling pathways involved in the pathogenesis 
of renal fibrosis. Moreover, it includes the description of several kinase inhibitors that 
interfere in these signaling pathways and that have been examined for the treatment of renal 
diseases in recent years. Several of these compounds have been investigated in the 
subsequent chapters.  
 
Figure 1. General scheme showing renal drug targeting using LZM. After injecting the drug-LZM 
conjugates, they accumulate rapidly in the kidneys. In this organ, drug-LZM conjugates are freely 
filtered through glomerulus and are reabsorbed by proximal tubular cells via a megalin 
receptor−mediated endocytosis process. After endocytosis, the drug is released from the conjugate 
either by the low pH or by enzymes within lysosomes. Thereafter, free drug exhibit its 
pharmacological action inside the target cells. 
To find the most effective antifibrotic drug that can be combined with a renal drug 
targeting approach, we screened several signaling inhibitors in cultured renal tubular cells. 
We activated profibrotic pathways in the cell culture by incubating with albumin or 
transforming growth factor-beta (TGF-β). We identified the p38 mitogen-activated protein 
kinase (MAPK) inhibitor SB202190 and the TGF-β receptor type I kinase inhibitor (TKI) 
as highly potent anti-inflammatory and antifibrotic compounds in vitro. To study the 
pharmacokinetics of SB202190, we established a drug measurement method using high- 




performance liquid chromatography (HPLC) analysis as described in Chapter 5. We used a 
liquid-liquid extraction method to isolate the drug from tissues, serum and urine. The 
method was developed and validated according to FDA guidelines. Thereafter, we studied 
the pharmacokinetics of SB202190 using this analytical method. We found that free 
SB202190 was eliminated rapidly from systemic circulation and poorly distributed to the 
kidneys.  
To achieve renal−selective delivery of SB202190, we coupled this drug to LZM and 
studied the pharmacokinetics and therapeutic effects of the conjugate as described in 
Chapter 6. We used two different linkage methods to couple SB202190 to LZM and 
examined the drug release profiles of these conjugates (Fig. 2). On the basis of drug release 
properties, we selected the most suitable conjugate for renal targeting which was coupled 
with a new platinum−based linker called Universal Linkage System (ULS™). This system 
provided efficient drug delivery to the kidneys and effective release of drug in target cells. 
We examined the platinum-related cytotoxicity of the conjugate both in vitro and in vivo 
and found no adverse effects. In addition, we studied the pharmacokinetics of the conjugate 
until 72 h and evaluated its efficacy in vitro in tubular cells and in vivo in a renal 
ischemia−reperfusion injury model in rats. A single dose of the conjugate provided 
antifibrotic effects at day 3 after the induction of fibrosis, as identified by 
immunohistochemical evaluation of fibrosis markers. 
Since TGF-β is considered to be directly involved in the pathogenesis of renal fibrosis 
(8), blockade of its action locally within kidneys could be an interesting approach to treat 
fibrosis. In our in vitro studies, we already identified that TGF-β receptor kinase inhibitor 
TKI is a potent compound and application of the ULS linker made it possible to couple this 
TKI to LZM (Chapter 7). We investigated whether TKI-LZM conjugate accumulated in a 
pharmacokinetic profile similar to SB202190-LZM in the kidneys. In addition, we 
evaluated the efficacy of the conjugate in vitro in tubular cells and in vivo in the unilateral 
ureteral obstruction model in rats. Similar to the SB202190-LZM conjugate, rapid homing 
and significant antifibrotic effects were observed after a single dose of the TKI-LZM 
conjugate.  
Another relevant target in renal fibrosis is the Rho kinase (ROCK) pathway which 
plays a pivotal role in the regulation of cytoskeletal organization and transdifferentiation of 
tubular cells (9-11). Moreover, it also participates in the infiltration of immune cells during 
inflammation (12). ROCK signaling can be counteracted by the inhibitor Y-27632. We 
investigated whether it is possible to deliver Y-27632 to the kidneys (Chapter 8). Y-27632 
was coupled to LZM using the ULS linker and drug release properties and 
pharmacokinetics of the Y-27632-LZM conjugate were studied. Furthermore, we evaluated 
the efficacy of the conjugate on ischemia-reperfusion−induced renal injury by 
administering 4 daily doses. We observed a potent anti-inflammatory and antifibrotic effect 
of the conjugate, and no effects were observed after the equivalent dose of free drug. This 
Introduction 
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Figure 2. Different type of linkages used to couple drugs 
To summarize, the objective of the studies described in the present thesis is to deliver 
different anti-fibrotic compounds to kidneys and evaluate their efficacy. In this frame-work, 
we investigated the selective treatment of renal tubular cells with various signaling 




inhibitors in renal fibrosis. The thesis also attempts to provide a general overview of drug 
targeting approach as it includes different linking techniques to couple drug to LZM, 
different characterization techniques of drug-carrier conjugates, studies on in vitro drug-
release and in vivo pharmacokinetic profiles of the conjugates. In addition, the 
pharmacological evaluation of the conjugates as described in the present study provides 
further insight in the role of the targeted kinases and profibrotic mediator systems, and thus 
may contribute to the development of novel therapies for renal fibrosis.  
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In previous studies, we have demonstrated that the low molecular weight protein 
lysozyme can be used as a renal-selective drug carrier for delivery of the angiotensin 
converting enzyme (ACE) inhibitor captopril. Typically, such macromolecular drug 
targeting preparations are administered intravenously. In the present study, we investigated 
the fate of captopril-lysozyme following subcutaneous administration, a convenient route 
for long-term treatment. The absorption from the subcutaneous injection site and renal 
uptake of lysozyme were determined by gamma-scintigraphy in rats. Bioavailability, renal 
accumulation and stability of the captopril-lysozyme conjugate were evaluated by HPLC 
analysis and by ACE activity measurements. Lysozyme was absorbed gradually and 
completely from the subcutaneous injection site within 24 hours and accumulated 
specifically in kidneys. After subcutaneous injection of the captopril-lysozyme conjugate, 
higher renal captopril levels and lower captopril-lysozyme levels in urine indicated the 
improved renal accumulation in comparison to intravenous administration of the conjugate, 
as well as its stability at the injection site. After both treatments, captopril-lysozyme 
conjugate effectuated renal ACE inhibition, while plasma ACE was not inhibited. In 
conclusion, our results demonstrate that we can use the subcutaneous route to administer 
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Introduction 
Drug targeting technology aims at delivering higher amounts of drug specifically to the 
desired site of action and at minimizing potential adverse effects in non-target organs. In 
recent years, we have evaluated this concept using low molecular weight proteins 
(LMWPs) as drug carriers for selective delivery to the kidneys of various drugs, such as the 
angiotensin converting enzyme (ACE) inhibitor captopril or the non-steroidal anti-
inflammatory agent (1). Although these drugs are being used routinely for different 
indications without serious side-effects in the majority of patients, renal delivery may 
improve their effectiveness by increasing drug concentrations locally within the kidney 
without effectuating systemic effects such as blood pressure reduction. Eventually, this 
approach may help in understanding the contribution of organ-specific effects to the overall 
therapeutic profile of the drug. In the kidneys, LMWPs are freely filtered through the 
glomerulus and reabsorbed by receptor-mediated endocytosis into the proximal tubular 
cells and subsequently catabolized intralysosomally into small peptides and single amino-
acids (2,3). Our studies demonstrated that drug-lysozyme conjugates selectively 
accumulated in the kidneys after intravenous administration (4-7). However, it is not 
feasible to administer such conjugates intravenously for long-term therapy in animal or 
human subjects. Although several routes of administration have been used for oligopeptides 
and proteins, such as oral, nasal and pulmonary route, the inconsistent and low 
bioavailability, local irritation and immunogenicity imply major limitations (8,9). We now 
propose subcutaneous administration as an alternative dosage regimen for macromolecular 
drug targeting conjugates. In fact, this route of administration has been used for the 
systemic delivery of LMWPs and other macromolecules such as insulin and heparin and 
has proven to be valid for extensive periods of time without serious side effects. Yet, the 
local stability at the subcutaneous site of injection and the rate of absorption of proteins 
from the subcutaneous tissue can be quite unpredictable and variable (8,10,11).  
In the present study, we determined the absorption of the renal-selective carrier 
lysozyme from the subcutaneous injection site and studied the renal handling in the 
physiological and pathological (proteinuria) state using gamma camera scintigraphy in 
healthy and adriamycin-induced proteinuric rats. In these studies, we used a radiolabeling 
technique (123I-tyramine-cellobiose labeling), which ensures entrapment of the radiolabel in 
the cells in which the product is internalized and degraded, thus allowing clear visualization 
of the distribution of the protein to the organs. In addition, we studied the pharmacokinetic 
fate of captopril-lysozyme conjugate following subcutaneous and intravenous injections. 
The captopril concentrations in kidneys and urine were estimated to assess the extent of 
renal uptake and loss of the conjugate in the urine, while plasma and renal ACE activities 
were determined to assess the formation of pharmacologically active drug from the 
captopril-lysozyme conjugate. Together, these analyses allowed us to evaluate the 
feasibility of the subcutaneous administration route as well as the fate of the targeted drug 
once accumulated in the kidneys. 




Materials and Methods 
Radiolabeling of lysozyme 
As described previously, lysozyme was labeled with radioactive iodine via tyramine-
cellobiose, a label that is retained intracellularly after lysosomal degradation of the protein 
(12). Briefly, the synthesis of tyramine-cellobiose (TC) was performed by reductive 
amination of cellobiose with tyramine (13). 10 mmol Cellobiose, 10 mmol tyramine 
hydrochloride and 10 mmol propionic acid were dissolved in 40 ml methanol. Sodium 
cyanoborohydride was dissolved in 15 ml methanol and added drop-wise. The mixture was 
refluxed overnight. Acetone (300 ml) was added and the precipitate was filtered. The 
precipitate was dissolved in water overnight and applied to a cation exchange column 
(Dowex W50-X4; size 0.25×20 cm). The column was eluted with 0.5 M ammonia and the 
absorbance measured at 279 nm. The first peak was collected and lyophilized twice in order 
to remove traces of ammonia. The yield was about 40%. For gamma camera studies, 123I 
labeling of TC and subsequently coupling to lysozyme (Sigma-Aldrich, St. Louis, MO, 
USA) was carried out. In short, in an iodogen-coated tube, 10 ml TC (0.01 M) in phosphate 
buffer (0.02 M, pH 7.2) and 80 MBq Na123I were incubated for 30 minutes at room 
temperature. The reaction was stopped by addition of 10 ml sodium sulfite (0.05 M) and 5 
ml potassium-iodine (0.1 M). The solution was transferred to a clean tube to couple the 
iodinated TC to lysozyme. Cyanuric chloride (30 nmol) in 20 ml acetone and 5 ml NaOH 
(0.01 M) were added and the mixture was vortex-mixed for 30 seconds. Next, 10 ml of 
lysozyme solution (100 mg/ml in 10 mM sodium carbonate buffer, pH 9.0) was added and 
the solution was mixed gently. The 123I-TC-lysozyme complex was purified by sephadex 
G25 gel filtration. After gel filtration, the radiolabeled protein contained less than 5% free 
123I as determined by protein precipitation with 10% trichloroacetic acid. The protein 
fraction was used within 24 hours after purification. 
Synthesis and characterization of captopril-lysozyme 
The synthesis and characterization of captopril-lysozyme were performed as described 
elsewhere (7). Typically, lysozyme (100mg, 7 µmol) was dissolved in 0.1 M borate buffer 
pH 7.5 at a concentration of 20 mg/ml. Succinimidyloxycarbonyl-α-methyl-α-(2-
pyridyldithio)toluene (SMPT; Pierce, Rockford, IL, USA; 5.4 mg, 14 µmol) was dissolved 
in 0.1 ml of acetonitrile and added drop-wise to the lysozyme solution and stirred for 30 
minutes. Then, captopril (3.3 mg, 15.4 µmol; Sigma-Aldrich) dissolved in 0.1 ml of 
absolute ethanol was added drop-wise and further stirred for 2 hours. The conjugate was 
purified by cation exchange chromatography using HiTrap™ SP XL columns (Amersham 
Biosciences AB, Uppsala, Sweden) and then dialyzed against water at 4°C. The purified 
conjugate was lyophilized and stored at -20°C. The captopril content was estimated by high 
performance liquid chromatography (HPLC; Waters, Milford, MA, USA) (14). The degree 
of captopril substitution in conjugate was found to be 1.1 mole of captopril per mole of 
lysozyme. No free captopril was found in the final preparation. 




All animal experiments were approved by Animal Ethics Committee of the University 
of Groningen and licensed under numbers 3094. Upon arrival, male Wistar rats (Harlan, 
Zeist, The Netherlands, 250-275 g) were housed in a temperature-controlled room with a 12 
hour light/dark cycle and offered ad libitum intake of tap water and standard rat chow 
(HopeFarm Inc., Woerden, The Netherlands). To induce nephrosis, a single intravenous 
injection of adriamycin (2 mg/kg; Adriblastina R.T.U., 2 mg/ml, Pharmacia and Upjohn, 
Woerden, The Netherlands) was administered via the dorsal penile vein under isoflurane 
anesthesia. For 6 weeks, the development of nephrosis was monitored once weekly on the 
basis of 24-hour protein excretion in urine, collected in metabolism cages. Proteinuria was 
determined using the biuret assay for total protein in urine (15). After 6 weeks, the rats 
were stratified by ranking them in an ascending order based on proteinuria and distributed 
equally over the two groups of subcutaneous or intravenous administration.  The average 
proteinuria was found to be approximately 450 mg/24hrs per treatment group.  
Gamma camera imaging of renal lysozyme uptake in healthy and proteinuric rats 
To assess the absorption rate from the site of injection and the renal uptake profile, rats 
were injected subcutaneously or intravenously with 2MBq 123I-TC-lysozyme combined 
with/without 100 or 500 mg/kg (n=4 per group) unlabeled lysozyme. Gamma camera 
imaging was conducted under isoflurane anesthesia (2% isoflurane in 2:1 O2/N2O, 1 l/min) 
on a low energy collimator at 0, 3, 6, 12, and 24 hours following injections, according to a 
previously described protocol by (12). Body temperature was monitored and maintained at 
37°C with a heat pad and a lamp. Time course of radioactivity in the kidneys and whole 
body was recorded by a gamma camera in 1 minute frames for 15 minutes and plotted after 
analysis of the respective “regions of interest”. After correction for counting efficiency, the 
total body radioactivity was set at 100% and used to express the renal uptake of tracer as % 
of the injected dose. 
Pharmacokinetics of captopril-lysozyme 
In this study, the rats were kept on low salt diet (0.05% NaCl, HopeFarm Inc., 
Woerden, The Netherlands) for one week before the administration of captopril-lysozyme 
conjugate. A single dose of captopril-lysozyme (equivalent to 1mg/kg captopril and 62 
mg/kg lysozyme) dissolved in 5% glucose at a concentration of 66 mg/ml was administered 
subcutaneously at the dorsal side of the neck region or intravenously in the penile vein. 
Rats (n=4 at each time-point except at t=0, n=7) from each group were sacrificed at 
different time-points (0, 1, 2, 4, 6, 12 and 24 hours) following injections. Blood samples 
were taken in heparinised tubes from abdominal aorta and kidneys were isolated after 
gently flushing the organs with saline. Plasma samples and kidneys were snap-frozen into 
liquid nitrogen. Urine samples were collected using metabolic cages and combined with the 




urine collected from urinary bladder after sacrificing the animals. Kidneys were weighed, 
homogenized (1:9 w/v) in ice-cold potassium phosphate buffer (pH 7.5) using an Ultra 
Turrax T25 homogenizer (IKA, Stauffen, Germany) and then stored at -80°C. ACE activity 
was determined in kidney homogenates and plasma samples by a method of Hip-His-Leu 
conversion to His-Leu as described elsewhere (16). Total captopril (captopril-SH analysis 
after reduction of disulfide adducts) concentrations were estimated in all the samples by 
HPLC as described previously (14). In brief, samples were treated with the reducing agent 
0.1% tributylphosphine for 20 min to reduce the dithio (–S-S-) bond between the thiol 
group of captopril and other thiol-containing molecules such as the linker used in the 
captopril-lysozyme conjugate. The formed captopril was separated by HPLC and detected 
by on-line post-column derivatization with o-phthaldialdehyde (OPA), as measured by 
fluorescence of the captopril-OPA adduct. In urine samples, the relative amounts of 
captopril-lysozyme by adding methanol (3:1 % v/v) and non-conjugate bound captopril 
were also measured by precipitating intact captopril-lysozyme, followed by total captopril 
analysis in the supernatant and precipitate as described above.  
In another study, rats (n=3) were injected with free captopril (1 mg/kg dissolved in 1 
ml of 5% glucose) via the subcutaneous route. Rats were placed in metabolic cages and 
sacrificed at 2 hours after administration of the drug. Urine samples were collected and 
analyzed for total captopril levels as mentioned above.  
Pharmacokinetics and statistical calculations 
The statistical analyses were performed using Student’s t test with p<0.05 as the 
minimal level of significance unless indicated otherwise. Sigmastat Version 1 software was 
used to analyse the statistical parameters. Results are presented as mean ± SEM. 
Pharmacokinetic analysis of the plasma captopril concentrations was performed using the 
Multifit program (Department of Pharmacokinetics and Drug Delivery, University of 
Groningen, The Netherlands). The pharmacokinetic parameters for subcutaneous 
administration were calculated by performing simultaneous analysis of the data derived 
from plasma captopril concentrations-time curve of intravenous and subcutaneous 
administrations. The two- compartment model and first-order kinetics were used to analyze 
this data. A log-normal distribution of the plasma concentration measurement errors was 
assumed, and log-transformed concentration data were used in the fitting procedure. The 
correctness of the latter assumption was tested by visual inspection of the graphs of the 
residuals plotted against time and against concentration. Goodness-of-fit was evaluated 
from visual inspection of the measured and calculated data points and of the residuals 
plotted against time and against concentration. The choice between one- and two-
compartment model was based on the lowest value of the Akaike's Information Criterion 
(AIC). 
Renal targeting using subcutaneous captopril-lysozyme 
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RESULTS 
Gamma camera imaging 
The external counting of 123I was performed using a gamma camera to study the 
absorption profile of lysozyme from the subcutaneous injection site, and the time course 
and total extent of renal uptake of lysozyme after a single subcutaneous or intravenous 
injection of radiolabeled lysozyme. This technique clearly demonstrated that lysozyme was 
gradually and almost completely absorbed from the site of injection in 24 hours. Both after 
subcutaneous and intravenous administration, lysozyme accumulated in the kidneys, as 
illustrated in Fig. 1. These pictures Fig. 1 (A to E) demonstrate that the subcutaneously 
administered lysozyme accumulated continuously in the kidneys resulting in a gradual 
shifting of the radioactivity from the site of injection into 2 hot-spots at the renal locations. 
In case of intravenous administration, 123I-TC-lysozyme was rapidly and primarily 
deposited into the kidneys within 15 minutes as shown in Fig. 1 (F).  
 
From the gamma camera data, we quantified the cumulative renal uptake of 123I-TC-
lysozyme at the time points 0, 3, 6, 12 and 24 hours (Fig. 2, solid lines). Approximately 
90% of the dose of 123I-TC-lysozyme accumulated in the kidneys within 15 minutes after 
intravenous administration. A similar extent of renal accumulation was found after 
subcutaneous administration, but now the maximum renal content was reached only after 
12 hours. In addition, we investigated the influence of total lysozyme dose on the renal 
uptake of radiolabeled lysozyme. Renal uptake of 123I-TC-lysozyme was decreased 
gradually and significantly with increasing dose of unlabeled lysozyme after intravenous 
administration. However, this was statistically significant at the highest dose in the case of 
subcutaneous administration (Table 1). Of note, the values of renal uptake of 123I-TC-
lysozyme were found to be significantly (p<0.01) higher at the dose of 500 mg/kg after 
subcutaneous administration compared to that of intravenous administration. Similar 
experiments were conducted in adriamycin-induced nephrotic rats to observe the effect of 
proteinuria on the renal uptake of radiolabeled lysozyme. We found that the renal 
Figure 1. Gamma camera images of the 
body distribution of lysozyme (indicated by 
123I) after injection of 2 MBq 123I-tyramine-
cellobiose-lysozyme in the healthy rat. (A-E) 
At 0, 3, 6, 12 and 24 hours after 
subcutaneous injection; (F) At 15 minutes 
after intravenous injection. 




accumulation of 123I-TC-lysozyme was reduced at the pathological state by 30% (p<0.05) 
both after intravenous and subcutaneous administration in comparison to healthy rats (Fig. 
2, dotted lines). No hot-spots except the kidneys were detected by the gamma-camera, 
while the radioactivity excreted in the urine during the 24h period was increased (data not 
shown). 
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Table 1 Cumulative accumulation of lysozyme in kidneys (indicated by 123I) within 24 hours 
following subcutaneous or intravenous injections of 2 MBq of 123I-TC-lysozyme combined with 
different doses of unlabeled lysozyme in healthy and adriamycin-nephrotic rats.   
Healthy rats Adriamycin-nephrotic rats Dose of unlabeled 
lysozyme (mg/kg) subcutaneous intravenous  subcutaneous intravenous 
0 89 ± 4.4 88 ± 1.9  59 ± 7.9 61 ± 9 
100 75 ± 4.7 61 ± 3.6 ***  44 ± 7.8 34 ± 5.9 * 
500 63 ± 3.5 ** 35 ± 5.7 † , ***  26 ± 6.5 * 9 ± 7.8 ** 
Data represent the mean ± SEM for n=4 in all cases. The extent of lysozyme accumulation was 
compared between subcutaneous and intravenous dose for healthy and diseased animals († p<0.01) 
and between tracer dose of 123I-TC-lysozyme alone and tracer dose combined with 100 or 500 mg/kg 
unlabeled lysozyme (* p<0.05, ** p<0.01 and *** p<0.001). 
Similar to healthy rats, the dose-dependent decrease in renal uptake was also found in 
the proteinuric rats; the renal uptake of 123I-TC-lysozyme was clearly lower at higher doses 
of unlabeled lysozyme (Table 1). Yet the subcutaneous administration displayed a better 
renal uptake profile, since uptake of lysozyme in the kidneys was higher with all the three 
tested doses, compared to intravenous injection. 
Figure 2. Time profile of cumulative renal 
uptake of lysozyme (indicated by 123I) after 
single subcutaneous (closed symbols) and 
intravenous (open symbols) injection of 2 
 MBq 123I-tyramine-cellobiose-lysozyme in 
healthy rats (solid lines) and adriamycin-
induced proteinuric rats (dotted lines). Data 
represent the mean ± SEM for n=4 in both 
administrations. 
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Pharmacokinetics of captopril-lysozyme 
After determining the renal uptake of the carrier lysozyme, we compared the 
pharmacokinetics of the drug-lysozyme conjugate captopril-lysozyme after intravenous and 
subcutaneous administration in healthy rats. For this purpose, we determined captopril 
concentrations after reduction of disulfide bonds, thus analyzing the total concentration of 
captopril that can be regenerated from the captopril-lysozyme conjugate together with 
captopril-SH and captopril disulfide metabolites already formed in vivo. Since captopril 
disulfides are interchanged readily in vivo to free captopril-SH, all of these species of 
captopril can become pharmacologically active and are considered as the total sum of 
potentially active drug. We will therefore refer to these concentrations as total captopril 
concentrations. Fig. 3 shows the plasma levels of total captopril at various time points after 
a single subcutaneous or intravenous injection of the conjugate. The pharmacokinetic 
parameters derived from these plasma disappearance curves are shown in Table 2. To 
calculate pharmacokinetic parameters, one-compartment and two-compartment models 
were tested for the best-fit according to AIC. The two-compartment model (AIC -22.7) 
fitted our data significantly better than first-compartment model (AIC 8.0). 
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 The renal levels of captopril after subcutaneous injection gradually increased until 6 
hours indicative of sustained absorption from the injection site, whereas after intravenous 
injection they reached a maximum already after 1 hour and subsequently decreased 
gradually (Fig. 4). Captopril concentrations in the kidneys following subcutaneous 
administration were significantly higher at 6, 12 and 24 hours in comparison to the 
intravenous administration. In addition, to compare the efficiency of captopril-lysozyme 
accumulation in the kidneys, we calculated the renal AUC from 0 till 24 hrs (AUC0-24) from 
the renal captopril concentration-time curve of subcutaneous or intravenous administration. 
Figure 3. Total captopril concentrations 
(captopril-SH concentrations after reduction 
of disulfides) in plasma at different time-
points after single subcutaneous (closed 
symbols) and intravenous (open symbols) 
injection of captopril-lysozyme (equivalent 
to 1 mg/kg captopril) in healthy rats. The 
continuous and dotted lines show the 
pharmacokinetic data-fit for intravenous and 
subcutaneous administration, respectively. 
Data represent the mean ± SEM for n=4 in 
both administrations. 




We found that the renal AUC0-24 after subcutaneous administration (242.8 ± 8.93 µg.h/g) 
was significantly higher than after intravenous administration (166.11 ± 7.29 µg.h/g). 
Table 2. Pharmacokinetic parameters (two-compartment model) derived from plasma captopril 
concentration-time curves after a single dose (equivalent to 1 mg/kg of captopril) of captopril-
lysozyme. 
Parameters units values (mean ± SE) 
Ka /h 0.45 ± 0.06 
F  0.71 ± 0.07 
Vss ml/kg 477 ± 89 
CL ml/kg/h 150 ± 14 
t1/2 α h 0.46 ± 0.12 
t1/2 β h 3.32 ± 0.23 
Ka: absorption rate constant; F: bioavailability; Vss: volume of distribution at steady state level; CL: 
plasma clearance; t1/2 α: absorption half life; t1/2 α: first compartment elimination half life; t1/2 β: 
terminal elimination half life (second compartment).  
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 In accordance with the gamma camera studies with lysozyme, this experiment 
demonstrated that subcutaneous administration of the captopril-lysozyme conjugate 
resulted in a slow but sustained release from the site of injection and a concomitant 
accumulation in the kidneys in time.  
Figure 4. Total captopril concentrations 
(captopril-SH concentrations after reduction 
of disulfides) in kidneys at different time-
points after single subcutaneous (closed 
symbols) and intravenous (open symbols) 
injection of captopril-lysozyme (equivalent 
to 1 mg/kg captopril) in healthy rats. Data 
represent the mean ± SEM for n=4 in both 
administrations. 
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In urine samples, total and non-protein-bound captopril were measured and captopril-
lysozyme excretion levels were calculated from those data. The protein bound captopril 
(captopril-lysozyme conjugate) in urine at different time points shows that the conjugate 
was excreted in significantly higher amounts after intravenous injection than after 
subcutaneous injection (Fig. 5A). In addition, the constant levels of the conjugate in urine 
after both administration routes demonstrate that there was no further direct excretion of the 
conjugate in the urine after 4 hours. Urine excretion of low-molecular weight captopril (free 
captopril plus captopril disulfide) after intravenous or subcutaneous injection was not 
significantly different except at the time point 6 hour after dosing (Fig. 5B). Moreover, this 
figure shows that subcutaneously administered free captopril was rapidly eliminated from 
the body.  Total captopril levels after administering free captopril was significantly higher 
than after captopril-lysozyme intravenously or subcutaneously at all time points.     
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Figure 5. Urine excretion of intact captopril-lysozyme conjugate (A) and unbound captopril 
(captopril-SH and captopril-S-S-captopril) (B) at different time-points after single subcutaneous (fine 
crossed bars) and intravenous (striped bars) injection of captopril-lysozyme (equivalent to 1 mg/kg 
captopril) in healthy rats. Data represent the mean ± SEM for n=4 in both administrations of the 
conjugate. Differences between subcutaneous and intravenous administration of captopril-lysozyme 
are presented as *p<0.05 and **p<0.01. The filled bar at 2 hour (B) shows the urinary excretion of 
captopril after administering 1 mg/kg free captopril subcutaneously in rats (n=3). At all time points, 
subcutaneously administered free captopril excretion is significantly (#p<0.05) higher than the 
captopril excretion (lysozyme bound and unbound) after subcutaneous or intravenous administration 
of the conjugate. 
We measured the renal and plasma ACE activities at chosen time points to determine 
whether the subcutaneously administered captopril-lysozyme would effectuate a similar 




renal-selective profile as the intravenously administered conjugate. As shown in Fig. 6A, 
the plasma ACE activity was not significantly reduced at any time point after subcutaneous 
or intravenous administration. On the other hand, the renal ACE activity was significantly 
inhibited until 12 hours and subsequently increased to normal after intravenous 
administration. Similarly, following subcutaneous administration renal ACE activity was 
also inhibited significantly until 12 hours after injection (Fig. 6B). Although the decline 
was more gradual as compared to intravenous injection. The difference between 
subcutaneous and intravenous of the renal specific drug was only significant at t=1h.  
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Figure 6. Plasma (A) and renal (B) ACE activity after administering a single subcutaneous (closed 
symbols) and intravenous (open symbols) injection of captopril-lysozyme (equivalent to 1 mg/kg 
captopril) in healthy rats. One unit (U) of ACE activity presents nmol His-Leu/min/ml. Data represent 
the mean ± SEM for n=4 in both administrations. The control values of renal ACE activity (55.82 ± 
4.75 U/g; n=7) and plasma ACE activity (50.3 ± 2.0 U/ml; n=7) are shown as a dotted line. Plasma 
ACE activities were not inhibited significantly in both treatment groups. Renal ACE activities were 
inhibited significantly after captopril-lysozyme subcutaneously (4-12h) and intravenously (1-12h). At 
1h, renal ACE activity differed significantly between subcutaneous and intravenous administration of 
captopril-lyzoyme (*p<0.05). 
Discussion 
Many drug-targeting preparations, for instance the drug-protein conjugate presented in 
this study, are macromolecular constructs which have to be administered parenterally. 
Commonly, these types of therapeutics are administered via intravenous administration. 
When aiming for a chronic treatment protocol however, even in laboratory animal studies, 
repeated intravenous injections are not convenient and may lead to adverse effects. 
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Subcutaneous administration is in principle an attractive alternative route of administration. 
Data from the present study suggest that drug targeting preparations can be administered 
subcutaneously, resulting in sustained and complete absorption in the target organ. In 
addition, the sustained release of lysozyme after subcutaneous administration restricts the 
dose-dependent and proteinuria-dependent loss of the carrier protein in the urine. The 
subcutaneous administration of captopril-lysozyme conjugate also leads to a sustained 
release of the intact conjugate from the site of injection which results in a more prolonged 
residence time in kidneys compared to intravenous administration.  
LMWPs are reabsorbed in the kidneys via the megalin/gp 330 receptor that is 
expressed specifically on the brush-border of proximal tubular cells (17). In addition, renal 
disease will damage the glomerulus leading to filtration of plasma proteins, which 
subsequently are also reabsorbed by these receptors (18). High concentrations of lysozyme 
or plasma proteins in the pre-urine may saturate the megalin receptors and reduce the 
efficiency of the reabsorption process (19). Indeed, we observed this phenomenon when we 
administered different doses of lysozyme in healthy and proteinuric rats. Strikingly, this 
less efficient renal uptake was much less apparent after subcutaneous administration. From 
this result, it can be inferred that the slow release from the subcutaneous injection site 
reduces the levels of lysozyme in the kidneys, and consequently the degree of saturation or 
competition due to high dose or plasma proteins is lower. We therefore conclude that the 
lysozyme carrier can deliver drugs to the kidney even at pathological conditions and that 
the renal delivery is more efficient when using the subcutaneous route of administration.        
Interestingly, the subcutaneous route resulted in higher levels of captopril in the 
kidneys for a prolonged period of time as compared to the intravenous route. In addition, 
we found that less conjugate was excreted directly in the urine, confirming our hypothesis 
that the renal tubular reabsorption process is more efficient after subcutaneous injection of 
captopril-lysozyme. This higher renal reabsorption of the conjugate after subcutaneous 
administration is possibly due to the prevention of the saturation of receptors-mediated 
uptake process in contrast to intravenous administration. The urine data of the unbound 
captopril (Fig 5B) show that both after subcutaneous and intravenous injection of captopril-
lysozyme, the released captopril was excreted continuously until 24 hours in the urine. This 
result indicates that the conjugate accumulates and stays in the kidneys after internalization 
in the tubular cells until the release of captopril from the conjugate. In contrast, 
subcutaneous administration of non-targeted free captopril resulted in a rapid excretion of 
captopril in the urine. Thus, one of the major improvements in captopril disposition after 
administration of the conjugate is that the drug is available during a prolonged period, 
which may improve its local effects.  
One of the concerns raised when discussing the subcutaneous administration of a drug-
LMWP conjugate is the risk that a premature cleavage of the conjugate may occur at the 
site of injection as well as in the lymphatic fluid that drains the product into the general 
circulation. As discussed above, this would result in a rapid excretion of free captopril in 




the urine. Since we only observed minor amounts of such captopril products during the first 
hours of the experiment, we conclude that the captopril-lysozyme conjugate is accumulated 
intactly within the kidney after subcutaneous administration. This result was corroborated 
by our results on plasma ACE activity, which showed no significant inhibitions until 24 
hours after injection of the captopril-lysozyme conjugate. The present data therefore show 
that the conjugate remained stable at the site of injection as well as in systemic circulation, 
causing no decline in plasma ACE activity.  
Within the kidneys, however, the renal ACE activity was reduced gradually and 
remained significantly inhibited until 12 hours after subcutaneous administration, which 
reflects the release of the active captopril from the conjugate after tubular uptake in the 
kidneys. Renal ACE activity was inhibited more during initial hours after intravenous 
administration of captopril-lysozyme. Obviously, intravenous injections will result in 
higher initial renal concentrations of the conjugate immediately after administration, while 
the subcutaneous route will result in lower levels at initial time points but sustained higher 
levels are reached at later time points. This sustained uptake and release may be quite 
relevant since free captopril is eliminated rapidly from the kidneys (6).  
The present study with captopril-lysozyme resulted in approximately 40-50% of renal 
ACE inhibitions after subcutaneous administration during the period of 4 to 12 hours. Zoja 
et al (2002) have shown the significant improvement of renal functions in rats with passive 
Heymann nephritis after achieving roughly 50% renal ACE inhibition during a long-term 
treatment with an ACE inhibitor (20). The observed pharmacological effect in this study 
after administration of captopril-lysozyme is therefore sufficient to reverse or retard kidney 
damage and proteinuria. Moreover, multiple dosing or higher doses of the conjugate may 
provide a more pronounced effect. Our data show that subcutaneous administration, which 
would be more convenient for multiple dosing, can be applied for this type of drug 
targeting preparations.  
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High sodium intake blunts the renoprotective efficacy of ACE inhibitors (ACEi). We 
investigated whether targeting the drug to the kidney may attenuate the inferior response to 
ACEi under a high sodium condition. The ACEi captopril was coupled to the low molecular 
weight protein (LMWP) lysozyme, yielding captopril-lysozyme conjugates that accumulate 
specifically in the proximal tubular cells of the kidneys. We compared the antiproteinuric 
efficacy of captopril to that of the captopril-lysozyme conjugate in adriamycin induced 
proteinuric rats fed with a high sodium diet. Rats with adriamycin (single injection 2mg/kg) 
induced proteinuria were put on a high sodium diet (HS; 3% NaCl). When stable 
proteinuria developed at 5.5 weeks, animals were assigned to the following subcutaneous 
treatments: (1) vehicle (n=7); (2) lysozyme (equivalent to the amount in conjugate) (n=7); 
(3) captopril (5mg/kg/24h) (n=8); (4) captopril-lysozyme conjugate (captopril content 
equivalent to 1mg captopril/kg/24h) (n=7). Blood pressure and proteinuria were monitored. 
After ten days of treatment the rats were sacrificed and kidneys and plasma were taken out. 
After injection with adriamycin at t=0, stable proteinuria developed amounting 547 ± 79 
mg/24h at week 5.5. Subsequently, after 7 and 9 days of treatment, no reduction of in 
proteinuria was observed in the captopril treated group. In contrast, a significant reduction 
in proteinuria amounting 35 ± 4% (day 7) and 25 ± 2% (day 9) was observed in the 
captopril-lysozyme conjugate group (p<0.05 compared to captopril group). In contrast, 
blood pressure was reduced in the captopril treated group by 13.9 ± 2.9 mmHg, while in the 
captopril-lysozyme treated group an increase of 7.9 ± 3.3 mmHg was found. The renal ACE 
activity was lowered with 30% in the captopril as well as in the captopril-lysozyme 
conjugate treated group compared with control. Further, the ratio of kidney over plasma 
levels of captopril doubled almost as a consequence of coupling to lysozyme. In proteinuric 
rats fed with a high sodium diet, captopril induced a reduction in blood pressure without an 
effect on proteinuria. In contrast, renal targeting of a 5 times lower dose of the ACEi with 
the captopril-lysozyme conjugate reduced the proteinuria without reducing blood pressure. 
Therefore, renal targeting of ACEi may be a promising strategy to optimize the therapy 
response of ACEi. 
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Introduction 
Angiotensin Converting Enzyme inhibitors (ACEi) are a frequently used therapy for 
patients with hypertension. Apart from their antihypertensive effect, ACEi also display 
cardiovascular and renoprotective effects, both in human and experimental renal diseases 
(1,2). These renoprotective effects can be monitored well by studying the antiproteinuric 
effect of the drug. Unfortunately, ACEi treatment does show side effects such as cough, 
hypotension (3) and hyperkalemia (4), and only a limited number of patients show an 
optimal antiproteinuric and renoprotective response. This non response can (partly) be 
overcome by several manners amongst which the dosing and the dietary sodium intake are 
important. Increasing the dose of the ACEi will increase the antiproteinuric efficacy. 
However this may go at the expense of side effects. The efficacy of ACEi can also be 
enhanced by lowering the dietary sodium intake (5-8). However, compliance with a strict 
dietary sodium restriction is difficult for many patients in western cultures.   
We have previously found that renal selective drug targeting offers a way to gain high 
drug concentrations in the kidneys. For this purpose, we synthesized a conjugate of the 
ACEi captopril with the low-molecular-weight-protein lysozyme which was accumulated in 
the kidney paralleled by an increased renal ACE inhibition in comparison with systemically 
applied captopril (9,10). 
To investigate whether the response to ACEi under high sodium condition may be 
enhanced by targeting the drug to the kidney, we studied the effect of captopril-lysozyme 
conjugate on adriamycin induced proteinuria in rats fed with a high sodium diet, and 
compared that to the efficacy of the untargeted ACEi. 
Materials and Methods 
Synthesis and characterization of captopril-lysozyme 
The process of synthesis and characterization of captopril-lysozyme is described 
elsewhere (11). Briefly, lysozyme (8.3 g, 0.58 mmol) was dissolved in 0.1 M borate buffer 
pH 7.5 at a concentration of 20 mg.mL-1. Succinimidyloxycarbonyl-α-methyl-α-(2-
pyridyldithio)toluene (SMPT; Pierce, Rockford, IL, USA; 450 mg, 1.17 mmol) was 
dissolved in 8.3 mL of acetonitrile and added drop-wise to the lysozyme solution and 
stirred for 30 minutes. Then, captopril (277 mg, 1.29 mmol; Sigma-Aldrich) solution in 8.3 
mL of absolute ethanol was added drop-wise and further stirred for 2 hours. The 
purification of the conjugate was done by using cation exchange fast protein liquid 
chromatography (HiTrap™ SP XL, Amersham Biosciences AB, Uppsala, Sweden). 
Afterwards the conjugate was dialyzed extensively against water at 4ºC. The purified 
conjugate was lyophilized and stored at -20°C. The estimation of the amount of captopril in 
the conjugate was done by high performance liquid chromatography (HPLC; Waters, 
Milford, MA, USA) (12). The degree of substitution in captopril-lysozyme conjugate was 




found to be 1.14 mol of captopril per mol of lysozyme. No free captopril was found in the 
final preparation. 
Experimental animals 
Animal experiments were conducted in accordance with the National Institutes of 
Health Guidelines for the Care and Use of Laboratory Animals. The Animal Experimental 
Committee approved all protocols. Male Wistar rats (310 – 325 g; n=29) were housed 
under standard conditions with free access to food and drinking water. 
Experimental procedure 
After one week of adaptation, baseline 24 hour urine samples were collected in 
metabolic cages. Rats were injected with adriamycin (2 mg/kg; Adriblastina R.T.U., 2 
mg/ml) in the tail vein under anesthesia with isoflurane 3% in N2O/O2 (2:1) to induce 
proteinuria. After three weeks the animals were put on a high sodium diet (3.0% NaCl) 
(Hope Farms, Woerden, The Netherlands). From that time onwards, 24h-urine was 
collected in metabolic cages weekly. In addition, systolic blood pressure was measured 
weekly using tail-cuff plethysmography (IITC Life Science, Woodland Hills, CA) in awake 
restrained animals. Animals with proteinuria less than 80 mg/24h were excluded from the 
experiment. After stratification for proteinuria, from t=5.5 weeks onwards the animals were 
given the following treatments by once daily subcutaneous injections for 10 days (all 
dissolved in 5% glucose):  (1) vehicle (5% glucose; n=7); (2) lysozyme (76 mg/kg/24h, 
Sigma-Aldrich, St. Louis, MO, USA; n=7); (3) captopril (5mg/kg/24h, Sigma-Aldrich; 
n=8); (4) captopril-lysozyme conjugate (equivalent to 1mg/kg/24h captopril and 76 
mg/kg/24h lysozyme; n=7). After 1, 4, 7 and 9 days of treatment proteinuria was measured. 
After 3, 6 and 9 days of treatment blood pressure was measured at 30 (n=2) or 60 (n=2), 
120 (n=2) and 240 (n=2) minutes after the last injection. Animals were sacrificed after 10 
days of treatment at 60 (n=2 or 3) or 240 (n=5) minutes after the last injection. Laparotomy 
was performed under anesthesia with isoflurane 3% in N2O/O2 (2:1) and a blood sample 
was taken from the abdominal aorta. Kidneys were flushed with saline, removed and 
weighed. Kidney samples were homogenized using turrax homogenizer for the estimation 
of captopril amount and ACE-activity.   
Analytical procedures 
Urine samples were analysed using colorimetric assays for total protein with 
molybdate red. Captopril concentrations were measured in plasma and kidney homogenate 
by HPLC as described previously (13). ACE activity was measured in plasma and kidney  
homogenate at 60 or 240 minutes after the final injection as described previously (14). 
Calculations and statistical analysis 
Data of the captopril and captopril-lysozyme treated groups are corrected with data of 
their respective controls, vehicle glucose and lysozyme treated animals.  All data are 
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presented as mean ± S.E.M. Differences in mean values between groups were compared 
using one-way analysis of variance (ANOVA) and a Bonferroni t-test to identify the groups 
that were different. In all tests, p<0.05 was considered statistically significant. 
Results  
All animals completed the study and no differences in growth curves were observed 
between the groups (data not shown).  
Proteinuria 
After injection with adriamycin, a stable proteinuria developed amounting 547 ± 79 
mg/24h at 5.5 weeks after induction of renal disease. Upon start of treatment with captopril 
and captopril-lysozyme hardly any effect on proteinuria was found after one and four days 
of treatment (figure 1). After 7 days of treatment a slightly lowering of proteinuria was 
observed in the captopril group (-9 ± 10 %), although this was not significant, while after 9 
days of the treatment the decrease in proteinuria in the captopril group was completely 
blunted. In the captopril-lysozyme conjugate treated group a decrease in proteinuria of -35 
± 4 % (7 days) and -25 ± 2 % (9 days) was found. The reduction in proteinuria was 
significant at both time points compared to captopril (p<0.05). Further, in the lysozyme 
treated group a slight increase in proteinuria was noticed at day 7 and 9 (6 ± 13 % and 12 ± 
8 %, respectively). 
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Figure 1. Antiproteinuric effect of therapy in % of proteinuria before start of the treatment. Filled 
triangles: lysozyme (equivalent amount as in captopril-lysozyme conjugate); filled rounds: captopril 
(5mg/kg/24h); open rounds: captopril-lysozyme conjugate (amount corresponding to 1 mg 
captopril/kg/24 h). Data is mean ± S.E.M. *p<0.05 represents the significant difference between 
captopril and captopril-lysozyme treated groups.  
 





The mean of the systolic blood pressure (SBP) measured at 3 and 5 days before 
treatment was considered as baseline measurement. After the onset of the treatment, SBP 
was measured after 2, 5 and 8 days, at 30, 60, 120 and 240 minutes after the injection in 
separate rats. As no differences were observed between these time points (data not shown) 
the data were pooled. Baseline SBP was compared to the average of the three 
measurements after the start of the treatments. SBP was significantly reduced in the 
captopril group compared to control (-13.9 ± 2.9 mmHg) (figure 2). In contrast, the animals 
in the captopril-lysozyme conjugate group showed a trend to an increase in SBP compared 
to control (7.9 ± 3.3 mmHg). Accordingly, SBP was significantly decreased in captopril 
treated animals compared to the captopril-lysozyme conjugate treated group.  The animals 
in the lysozyme group showed a reduction in SBP (-11.5 ± 3.4 %), although this was not 
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Figure 2. Effect of therapy on Systolic Blood Pressure (SBP) in delta SBP (mmHg). Black bars: 
lysozyme (equivalent amount as in captopril-lysozyme conjugate); white bars: captopril 
(5mg/kg/24h); gray bars: captropril-lysozyme conjugate (amount corresponding to 1mg 
captopril/kg/24h). Data in mean ± S.E.M., * significant difference (p<0.05), # significant difference 
between treatment and control (p<0.05).  
ACE activity 
To obtain insight in the efficacy of renal targeting, ACE activity was measured in 
kidneys collected 60 and 240 minutes after the final injection (table 1). After 60 minutes the 
ACE activity seemed inhibited to a larger extend in de captopril group than in the captopril-
lysozyme group, although the difference is not significant. In contrast, after 240 minutes 
renal ACE activity was reduced to a similar extent in the captopril treated group as well as 
in the captopril-lysozyme conjugate treated group compared to control.  
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Table 1. ACE activity in the kidneys. 
 
Time point 
after last dose glucose lysozyme captopril 
captopril- 
lysozyme 
60 min 35.5 ± 6.2 (n=2) 48.7 ±16.6 (n=2) 16.2 ± 3.7 (n=3) 24.3 ±10.6 (n=2) Renal ACE 
activity (nmol 
HisLeu/g/min) 240 min 30.8 ± 5.2 (n=5) 35.2 ± 5.6 (n=5) 25.2 ± 3.1 (n=5) 26.0 ± 3.9 (n=5) 
Data represents mean ± S.E.M. 
Captopril levels 
To further investigate renal delivery of captopril, total captopril levels were determined 
in plasma and kidneys 60 and 240 minutes after the final injection (table 2). Sixty minutes 
after the last dose renal captopril levels did not differ between the captopril group and the 
captopril-lysozyme group. However, after 240 minutes there was a significantly higher 
amount found in the captopril-lysozyme group compared to the captopril group (Table 2).  
Table 2. Total captopril concentration in kidneys and plasma. 
 
Time point 
After last dose captopril captopril-lysozyme 
60 min 11.7 ± 3.7 (n=3) 
8.1 ± 0.9 
(n=2) Total captopril 
concentration in kidneys 
(µg/g) 240 min 2.4 ± 0.6# (n=5) 
10.0 ± 1.2* 
(n=5) 
60 min 2.5 ± 0.5 (n=3) 
1.1 ± 0.3* 
(n=2) Total captopril 
concentration in kidneys 
(µg/g) 240 min 
0.32 ± 0.03# 
(n=5) 
0.7 ± 0.07 
(n=5) 
Data in mean ± S.E.M., *p<0.05 represents the significance difference between captopril and 
captopril-lysozyme treated groups at the same time point, # p<0.05 represents the significance 
difference between the time points for one treatment. 
In contrast to the kidneys, the plasma levels of captopril 60 minutes after the final dose 
were significantly lower in the captopril-lysozyme group compared tot the captopril group. 
After 240 minutes a significant reduction of captopril levels was found in the captopril 
group while those in the captopril-lysozyme group remained at a similar level as observed 
at 60 min. Thus, the percentage of captopril levels in plasma compared to the levels in the 
kidney 240 minutes after the final dosing is about halved in the captopril-lysozyme 
conjugate group (7.2%) compared to the captopril group (17.3%). Moreover, the percentage 




of free plasma captopril was significantly higher in the captopril group compared to the 
captopril-lysozyme group at 240 minutes (60 minutes: 30.0 ± 6.1% and 18.3 ± 1.6 %, 240 
minutes and 39.4 ± 4.4% and 21.3 ± 0.8%, respectively). Thus, coupling to lysozyme 
resulted in an about 50% reduction of the percentage of free captopril in plasma.  
Discussion 
The aim of the present study was to investigate whether an inferior response to ACEi 
under high sodium condition may be attenuated by targeting the drug to the kidney. 
Therefore, we studied the effect of captopril-lysozyme conjugate on adriamycin induced 
proteinuria in rats fed with a high sodium diet. In proteinuric rats fed with a high sodium 
diet, captopril-lysozyme conjugate significantly reduced the proteinuria without affecting 
blood pressure. In contrast, captopril treated animals displayed the opposite effect, i.e. a 
reduction in blood pressure without any effect on proteinuria. Although captopril-lysozyme 
conjugate was administered in a dose five times lowers than captopril, even higher captopril 
levels were found in the kidneys. These results demonstrate the working profile of the 
captopril-lysozyme conjugate to be renoselective up to an extent that anti-proteinuric 
effects were observed, without any effect on blood pressure in nephrotic rats on high 
sodium diet. 
In a previous study employing single injection in healthy animals, it was shown that 
subcutaneous injection is an adequate route of administration to deliver captopril-lysozyme 
conjugate (15), as the conjugate was almost completely absorbed from the injection site, 
remained stable and displayed a prolonged residence time in the kidneys. Furthermore, the 
single subcutaneous dose of captopril-lysozyme conjugate produced a moderate but 
sustained inhibition of the renal ACE during the 24-hour observation period, with no effects 
on plasma ACE. In the present study we extended these findings to chronic subcutaneous 
administration in nephrotic animals. The levels of total captopril that were measured in the 
current study are in good agreement with those obtained from previous pharmacokinetic 
data after single s.c. injection (15). Further, our data demonstrate a substantial decrease in 
the percentage free captopril in plasma by coupling of the drug to lysozyme. Previously, it 
has been observed that the conjugate does not inhibit plasma ACE (16). Therefore, it is 
conceivable that the absence of a blood pressure reduction in the captopril-lysozyme 
conjugate group is attributable to the lack of inhibition of non-renal ACE. Although, when 
blood pressure is measured by tail cuff, this implies that no gross changes were observed. 
Because of this method, minor changes in blood pressure effect may have been unnoticed. 
The advantage of targeting captopril over normal dosing is clearly demonstrated by the 
observation that higher levels of total renal captopril are reached, even following a 5 times 
lower dose of targeted captopril compared to the parent drug.  
Similar to the earlier single dose study with captopril-lysozyme conjugate (15), the 
present study with a ten-day treatment period shows a moderate inhibition of renal ACE 
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activity albeit non-significant (Table 1). Accordingly, our data demonstrate an effective 
targeting of captopril to the kidney of nephrotic animals by conjugating the drug to 
lysozyme. Therefore it is likely that the antiproteinuric effect observed in the captopril-
lysozyme conjugate group results from the selective distribution of captopril to the kidneys. 
The higher renal levels of total captopril found following the administration of 
captopril-lysozyme conjugate compared to administration of captopril were accompanied 
by an antiproteinuric effect in captopril-lysozyme conjugate treated animals. However, 
increased renal levels of captopril in the conjugate group did not result in a higher 
inhibition of renal ACE activity at the time points measured, compared to captopril treated 
animals. There may be several explanations for the discrepancy between effects on ACE 
activity and on proteinuria. First, the antiproteinuric effect represents the effectiveness of 
the drug during a 24 h period, while ACE activity was measured at specific time points. As 
conjugation of captopril to lysozyme apparently prolongs the half-life in renal tissue, renal 
ACE activity may simply be inhibited for a longer period of time due to conjugation. 
Secondly, drug levels measured in the captopril-lysozyme conjugate group represent total 
captopril levels, i.e. both conjugated and unconjugated drug. The thiol group of captopril is 
conjugated with lysozyme, however this group is essential for the ACE inhibitor action of 
captopril (17). So, before the coupled captopril can be active, it must be uncoupled in the 
kidney, probably by reduced glutathione (18). Kok et al. found that the majority of an 
intravenous dose of captopril-lysozyme conjugate was accumulated in the kidney in the 
first hour, while the relative amount of free captopril rose during 3 hours after injection to 
21% of the total captopril concentration. This feature of the captopril-lysozyme conjugate 
may explain the discrepancy between the total renal captopril concentration measured and 
the renal ACE activity measured. Thirdly, distribution of the drug within the kidney may 
differ when administered as captopril-lysozyme conjugate. Following glomerular secretion 
captopril-lysozyme conjugate is selectively taken up by tubular cells by receptor mediated 
endocytosis (19). The majority of ACE in the kidney is localized in the brush border of the 
proximal and distal tubular cells of the cortex and in the glomeruli (20,21). In overt 
proteinuria, ACE and angiotensinogen are both up regulated in the proximal renal tubules 
(22). As noticed before, captopril-lysozyme conjugate is selectively reabsorbed in the 
tubular cells and uncoupled by intracellular gluthatione. Therefore, the captopril released 
from the conjugate at the level of tubular cells may be responsible for the antiproteinuric 
effect observed in the captopril-lysozyme conjugate group. It could be, that ACE present in 
other cells than the tubular cells, such as in the endothelial cells, is not inhibited in the 
captopril-lysozyme group, while it is in the captopril group. Therefore, the total ACE 
inhibition would be lower in the captopril-lysozyme group, while tubular ACE is inhibited 
to the same extent.  
The antiproteinuric effect of ACEi develops slowly (23), and usually takes five weeks 
of treatment to reach its maximal effect. In the present study, we treated the animals with 
captopril-lysozyme conjugate for 9 days. However, it is likely that after 9 days of treatment 
the maximal antiproteinuric effect is not reached yet, indicating the need for future research 




in which the efficacy of long-term treatment with captopril-lysozyme conjugate is 
investigated.   
The results of previous clinical studies and animal experiments showed that an increase 
in sodium intake blunts the antiproteinuric effect of ACEi (24-27). As sodium intake itself 
has no influence on proteinuria in adriamycin induced nephrosis (28), the efficacy of 
captopril-lysozyme conjugate in animals fed a high sodium diet is likely the result of 
improved pharmacokinetic or dynamic properties of the drug. The most obvious 
explanation would be a change in kinetic parameters of captopril because of coupling to 
lysozyme, in view of the prolonged residence time in the kidney. However, in the present 
study we cannot exclude a different pharmacodynamic profile of the drug.  
In this study we demonstrate that drug targeting provides a feasible method to 
chronically treat nephrosis. Targeting of captopril to the kidney has some important 
benefits: it is devoid of reduction of blood pressure and it has an antiproteinuric effect, even 
in conditions of high sodium load. In general, blood pressure reduction is sought in therapy 
of proteinuric renal disease. In this perspective, conjugation of the ACEi does not seem to 
have any advantage, as the blood pressure reduction is lost. Recent evidence suggests that 
the anti-proteinuric effect of the systemic administration of ACEi is enhanced by dose 
increase or combination with ARB (29). In these situations, reduction of blood pressure 
may become limiting to obtain an optimal antiproteinuric effect. Then, conjugation of ACEi 
to lysozyme may be employed to allow renal titration of ACEi in the face of limitations of 
systemic application because of side-effects such as hypotension.  
Because of the chemical limitations of ACE inhibitors with more potent antiproteinuric 
efficacy, captopril had to be used in the present drug targeting approach. In spite of this, the 
conjugate displayed an antiproteinuric effect at a very low dose. Nevertheless, future 
research may/will need to disclose strategies to couple more potent ACEi to a small protein 
carrier, as to avoid administration of large amounts of lysozyme.  
Conclusions 
Our results show that in adriamycin nephrotic rats fed a high sodium diet, the 
subcutaneous injection with captopril-lysozyme conjugate induced an antiproteinuric effect 
without reduction of blood pressure. In contrast, a five time higher dose of subcutaneously 
administered captopril did not display an antiproteinuric effect and did have a systemic 
effect in reducing blood pressure. ACEi-lysozyme conjugate provides a valuable tool to 
further study the way to enhance efficacy and improve on response variability of RAS 
intervention for renoprotection. 
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Approximately 80% of the kidney is composed of tubular cells which secret and 
reabsorb substances to and from the urine. Activated tubular cells play a pivotal role in the 
etiology of renal fibrosis. During renal injury, these activated tubular cells participate in the 
initiation of fibrogenic processes which eventually may lead to tubulointerstitial fibrosis 
and end stage renal disease (ESRD). Current therapies such as angiotensin converting 
enzyme inhibitors, angiotensin II receptor type-1 antagonists and statins do not suffice for 
the treatment of renal fibrosis. However, in recent years, better understanding of disease 
mechanisms led to the development of new drug entities that intervene in the signal 
transduction pathways involved in the disease pathogenesis. This review discusses possible 
new drugs directed to intracellular signal transduction pathways such as mitogen−activated 
protein kinases (p38, ERK and JNK), growth factors receptor tyrosine kinases (TGF-β and 
PDGF), Rho kinase, and nuclear transcription factors that are activated during disease. In 
addition to kinase inhibitors, novel approaches such as renal selective drug targeting, 
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Introduction 
There is a tremendous increase in number of patients world-wide with end stage renal 
diseases (ESRD). Recent data show that the incidence of ESRD in European countries has 
increased to about 135 cases per million per year, albeit below the rates in the USA (336 
per million per year) (1). In most of the developed countries, there is an expected increase 
in the annual incidence rate of the diseases of 5 to 8%. In relation to this, an increase in the 
annual expenditure is expected from US$9 billion (1995) to US$28 billion by 2010 (costs 
in the USA) (1,2). ESRD are the consequences of diabetic nephropathy, chronic 
glomerulonephritis, tubulointerstitial fibrosis and hypertensive nephrosclerosis. The largely 
increased knowledge about the mechanisms of interstitial fibrosis and renal function loss 
has elicited novel approaches to treat these renal diseases (3). In general, tubulointerstitial 
fibrosis is considered as a common endpoint of several pathological events in the kidney. 
The tubulointerstitial injury may be initiated by primary renal diseases or may be instigated 
by secondary processes of progressive glomerular diseases (4). Present research topics are 
focused on the understanding of the molecular mechanisms involved in the initiation and 
progression of these diseases. In this frame work, many new potential drug candidates, 
particularly those affecting signaling cascades have been recently tested in preclinical 
studies. Such compounds have not advanced into the clinic yet. However, they are seen as 
potentially important and complimentary to antihypertensive approaches such as 
angiotensin converting enzyme (ACE) inhibitors and angiotensin II type-1 receptor 
blockers (ARBs) that are commonly advocated for the treatment of renal fibrosis (5,6). In 
this review, we will briefly discuss the pathophysiological pathways involved in the 
initiation of tubulointerstitial fibrosis and we will particularly focus on the various novel 
therapeutic strategies, including signal transduction interventions and advanced 
technologies involving macromolecular therapeutics in the field of drug delivery as well as 
gene and antisense concepts.  
Pathophysiologic mechanisms leading to tubulointerstitial 
fibrosis 
Excessive urinary excretion of proteins (proteinuria) is a hallmark of renal injury. After 
an initial renal insult, either immunologic or non-immunologic, distinct molecules such as 
albumin, transferrin, immunoglobulins, complement factors, growth factors, angiotensin-II 
(Ang II), cytokines and high glucose filter through the glomerulus and subsequently interact 
with renal tubular cells (7), as described in Fig. 1. These molecules activate tubular cells via 
diverse signaling cascades. In addition, hypoxia, oxidative stress, and many other factors 
which are induced during pathological conditions stimulate pro-inflammatory and 
profibrotic signaling pathways in tubular cells. Table 1 summarizes the effect of these 
activating factors on renal tubular cells in vitro and related pathways involved in the 
cellular response. 




Table 1. Activation of renal tubular cells against various stimuli in vitro. 
Stimuli Signal/pathway Response References 
    
Increase in transglutaminase activity Increase in ECM (195) 
Activation of ERK and p38 MAPK Induces of TGF-β1 expression, 
hypertrophy 
(196,197) 
Activation of p38 MAPK Enhances angiotensinogen gene 
expression 
(198) 
Activation of smad2/3 TGF-β1 production (early) 
Increase collagen-1 exp. (late) 
(199) 
High glucose 
Polyol pathway dependent Fibronectin accumulation (200) 
    
Hemin Hemeoxygenase-1 dependent activation 
of p21 
Inhibit cell growth, provoke cell cycle 
arrest 
(201) 
    
Low O2 plus 
high CO2 
- Apoptosis (202) 
    
Phosphatidylinositol 3-kinase (PI3K) 
dependent 
Production of HIF-1α and VEGF (203) Hypoxia 
Via activation of NF-kB Induces synthesis of ICAM-1 (204) 
    
Partly TGF-β1 dependent Fibronectin production (205) Thrombin 
 MCP-1 and TGF-β1 secretion (206) 
    
Oleate-
complexed rHSA 
Protein kinase C (PKC) activation Fibronectin secretion (207) 
    
PKC and tyrosine kinase dependent Increase in NF-kB and TNF-α specific 
mRNA expression 
(208) 
Via p44/42 (ERK) MAPK pathway 
activation 
Causes cell proliferation (209) 
NF-kB activation 
PKC and NAD(P)H oxidase dependent 
Increase in H2O2 and ROS production 




Via p44/42 (ERK) MAPK pathway 
activation 




    
Insulin Post-transcriptional pathway Increase in the production of TGF-β1 
and expression of type-IV collagen 
(212) 
    
Transferrin  Increase in expression of complement 
C3 
(213) 
    
Activation of smad2/3 Transdifferentiation of the cells into 
myofibroblasts 
Induces α-smooth muscle actin, 
collagens expression and loss of 
e−cadherin 
(214-216) 
 Release preformed bFGF (217) 
TGF-β1 
Mediated via PKC Induces VEGF expression (218) 
    
Activation of p38 and ERK MAPK IL-6 production (219) TNF-α 
 Increase in IL-8 expression (220) 
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Stimuli Signal/pathway Response References 
Activation of ERK, p38 and P27kip1 Cellular hypertrophy (221,222) Angiotensin−II 
Partly by TGF-β1 activation Induces collagen α3(IV) expression (223,224) 
    
 Increase in IL-8 expression (220) IL-1β 
TGF-β1 dependent Enhances α-smooth muscle actin and 
fibronectin expression 
(225) 
    
 Increase in IL-8 expression (220) LPS 
NF-kB dependent Induce MCP-1 expression (226) 
    




 Stimulates TGF-β expression by 
overgenerating intracellular ROS 
(228) 
    
CD40 ligands  Increase complement C3 expression (229) 
    
CTGF  Increase in TGF-β1 and α-smooth 
muscle actin expression while decrease 
in collagen-IV 
(230) 
    
HIV-1 gp120 Phosphorylation of p38 MAPK apoptosis (231) 




 Stimulate TGF-β1 synthesis (232) 
 
Filtered albumin acts on tubular cells through unknown mechanisms and, among other 
effects, generates reactive oxygen species which in turn activate the transcription factor 
nuclear factor-κB (NF-κB) within tubular cells. Activation of this pathway leads to the 
production of various chemokines and cytokines such as monocyte chemoattractant protein-
1 (MCP-1), regulated upon activation normal T-cell expressed and secreted (RANTES) and 
transforming growth factor-β (TGF-β) (8-10). Chemoattractants such as MCP-1 and 
RANTES in turn facilitate the infiltration of monocytes and neutrophils from the systemic 
circulation into tubulointerstitial space that surround the activated resident cells. These 
infiltrated macrophages augment the fibrogenic response of interstitial fibroblasts by 
generating various profibrotic factors, including TGF-β, tumor necrotic factor-α (TNF-α), 
and endothelin-1, which are instrumental in the synthesis of extracellular matrix (ECM). 
Macrophages are also involved in the production of inhibitors of matrix degrading 
proteases such as tissue inhibitor of metalloproteinase-1 (TIMP-1) and plasminogen 
activator inhibitor-1 (PAI-1) (11,12). Other factors, for instance TGF-β1, either secreted 
from resident tubular cells or filtered through glomeruli, bind to TGF-β type-II receptors 
present on tubular epithelial cells and interstitial fibroblasts. This also initiates several 
fibrotic events such as transformation of fibroblasts into myofibroblasts (3), production of 
inhibitors of matrix degrading enzymes, transdifferentiation of tubular cells into fibroblasts 
(epithelial mesenchymal transformation), and further chemotaxis of inflammatory cells. 
Interstitial myofibroblasts produce ECM proteins including collagens and fibronectin as 




essential components of the renal scar tissue. The production of the ECM within the tissue 
should be seen as a dynamic and tightly regulated process. For instance, parallel to the 
increased production of ECM components, matrix metalloproteinases (MMPs) are activated 
from their latent forms that degrade ECM proteins. Plasmin which is produced from its 
precursor plasminogen also degrades ECM proteins and also facilitates the activation of 
MMPs. In turn, these matrix degrading MMPs and plasmin are inhibited by TIMP-1 and 
PAI-1 which are produced by activated macrophages (12). So, activated tubulointerstitial 
cells stimulate a matrix producing system, a matrix degrading system and inhibitor 
pathways that control both systems, at the same time. Eventually, it is the imbalance 
between the producing mechanism and the degradation of ECM that leads to progressive 
tubulointerstitial fibrosis. Therapeutic approaches may aim at preventing the activation of 
tubulointerstitial cells by preventing proteinuria, hypertension or tissue damage, or may aim 
at an intervention of the subsequent events. As outlined above, this is a very complex 
enterprise.  
 
Figure 1. Mechanisms of tubulointerstitial fibrosis. Proteinuria, cytokines or hypoxia generated 
during renal injury activate proximal tubular cells and in turn, tubular cells produce growth factors, 
chemokines and adhesion molecules. Chemoattractants such as MCP-1 and RANTES attract 
monocytes from systemic circulation. These infiltrated macrophages are activated by cytokines and 
produce subsequently several profibrotic factors which further stimulate fibroblast cells. TGF-β 
produced by tubular cells or macrophages activated different cell types, leading to fibrogenesis. TGF-
β−activated renal epithelial tubular cells undergo epithelial mesenchymal transdifferentiation (EMT) 
and transform into myofibroblasts. Myofibroblasts produce extracellular matrix (ECM) proteins 
including fibronectin and collagens in the interstitial space which eventually cause tubulointerstitial 
fibrosis. 
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Current Therapies 
Angiotensin-II and its blockers 
Ang II is a well known vasoconstrictor peptide and also considered as a renal growth 
factor which participates in many intracellular signaling mechanisms that regulate cell 
growth and synthesis or degradation of ECM (13). The role of Ang II in the pathogenesis of 
renal fibrosis has been well established as suggested by the following studies. In proteinuric 
rats, an increase in ACE activity and local Ang II generation primarily in proximal tubular 
cells was associated with the induction of tubulointerstitial lesions (14). In addition, 
infusion of Ang II in rats resulted in tubulointerstitial injury, with tubular atrophy and 
dilation, cast formation, infiltration of monocytes, and mild interstitial fibrosis with 
increased type IV collagen deposition (15). Stimulation of Angiotensin II type-1 receptors 
led to the activation of several intracellular signaling cascades such as protein kinase C, 
tyrosine kinases, mitogen-activated protein kinases (p38, ERK and JNK) and their 
downstream nuclear transcription factors, activator protein-1 and NF-κB (Fig. 2) (16). Ang 
II has also been reported to directly induce TGF-β production in renal tubular cells and 
fibroblasts. Moreover, blockade of Ang II by administering ACE inhibitor or ARBs 
reduced TGF-β expression and ameliorated tubulointerstitial fibrosis in different 
experimental animal models such as unilateral ureteral obstruction (UUO) model, Heymann 
Nephritis model, cyclosporin nephropathy, etc. (17).  
ACE inhibitors and ARBs are generally prescribed as antihypertensive agents that can 
interfere with Ang II−induced vasoconstriction. Recent clinical trials data demonstrated that 
both classes of compounds reduced serum creatinine levels, blood pressure and proteinuria 
in patients with hypertension and primary renal disease (proteinuria >1.5 g/24h) (18). In 
these studies, ARBs provided a superior renoprotection compared with ACE inhibitors and 
the combination of ARBs and ACE inhibitors resulted even in additive ameliorative effects. 
Other studies also reported similar benefits of high-dose combination therapies such as 
valsartan with benazepril, losartan with lisinopril, and irbesartan with enalapril or 
fosinopril, in patients with diabetic and non-diabetic renal diseases (19). Unfortunately, 
these therapies only retard the progression of chronic renal diseases and do not prevent or 
reverse the renal function loss, indicating the need for additional therapeutic approaches.   
Statins 
Statins are the competitive inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG CoA) 
reductase which regulates cholesterol biosynthesis in liver and other organs. Statins (e.g. 
lovastatin or pravastatin) are generally prescribed for the treatment of 
hypercholesterolemia. Apart from the cholesterol-lowering effect, statins exhibit 
“pleiotropic” effects such as anti-inflammatory effects, anti-thrombotic and anti-angiogenic 
effects, anti-hypertrophic effects, and plaque modifying effects (20-22). There is increasing 
evidence for an ameliorative effect of statins in renal diseases (23,24). Many in vitro studies 
have demonstrated that statins modulate a variety of intracellular signaling pathways 




involved in cell proliferation and inflammatory responses in mesengial and renal tubular 
cells (25-28). Furthermore, preclinical studies in different experimental disease models 
showed that treatment with statins inhibited glomerular and interstitial recruitment of 
macrophages and neutrophils, independent of their cholesterol−lowering effects (29-31). 
Also, in ischemia-reperfusion renal injury models, treatment with statins substantially 
improved the renal functions (32,33). These potential cholesterol-independent effects of 
statins are due to the inhibition of an early step in the cholesterol synthesis pathway: statins 
inhibit the synthesis of isoprenoids such as farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate that are important posttranscriptional lipid attachments for intracellular 
signaling molecules Rho GTPases (34). The role of the Rho pathway in renal fibrosis will 
be described in a later section of this review. Several combination approaches such as 
statins plus an ACE inhibitor, and even statins and ACE inhibitors and then combined with 
ARB have been tested in renal fibrosis models and resulted in synergistic effects (35,36).  
Clinical studies have also illustrated that long-term treatment with cerivastatin and 
pravastatin significantly reduced proteinuria in patients with IgA nephropathy and non-IgA 
nephropathy (37,38). In contrast, a recent study showed that fluvastatin treatment did not 
improve renal parameters, despite a positive effect on lipid parameters (39). 
A few studies have demonstrated the therapeutic effects of Ang II blocking agents and 
statins on renal diseases in clinics. However, clinical studies with an apparent therapeutic 
effect on preventing end-stage renal failure have not been reported.  
New Therapeutic Approaches 
Signaling cascade modifiers 
In recent years, the understanding of signal transduction cascades that play a role in the 
pathogenesis of renal diseases has increased and many potent signal transduction modifiers 
have become available. The studies presently available to date have been performed in 
experimental animal models for renal fibrosis and, no clinical data are available yet. Table 
2 summarizes the studies carried out with different signal inhibitors in renal disease animal 
models. They represented an emerging research topic and may provide new leads for 
antifibrotic drugs. 
Mitogen− activated protein kinase and their inhibitors  
Four different subgroups of MAPK have been described which include (1) p38 MAPK, 
(2) extracellular signal-regulated kinases (ERKs), (3) c-jun N-terminal or stress-activated 
protein kinase (JNK/SAPK), and (4) ERK5. These MAPKs are activated by their specific 
upstream activators MAPK kinase (MKK) and a further activator MAPK kinase kinase 
(MKKK). For instance, p38 is activated by MKK3 and MKK6, and ERK1/2 is activated by 
both MAPK/ERK kinase (MEK)1 and MEK2 whereas JNKs are activated by MKK4 and 
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MKK7 (40). The role of MAPKs in renal fibrosis will be described here in more detail and 
several studies will be discussed.  
P38 MAPK and its inhibitors  
The p38 kinase is a ser/thr kinase and is activated by phosphorylation on Thr and Tyr 
residues in a Thr-Gly-Tyr motif by dual specific MKKs (41). There are four different p38 
isoforms: p38α, p38β, p38γ and p38δ. P38α plays an important role in inflammation and is 
involved in the expression of IL-1β and TNF-α whereas the role of other isoforms is not 
well understood yet (42). Various stimuli, such as growth factors (Ang II, TGF-β), 
cytokines (IL-1β, TNF-α), stress factors (LPS, osmotic stress) and high glucose activate 
p38 in tubular and mesengial cells (Table 1, Fig. 2). The p38 pathway regulates the 
production of various proinflammatory genes (e.g. MCP-1, IL-1β, TNF-α and IL-6), and is 
involved in the expression of extracellular matrix components, intracellular enzymes and 
adhesion molecules. P38 is also associated with cell hypertrophy and cell differentiation 
(43). In vivo studies reveal that activation of p38, among other factors, is responsible for 
renal damage after hemorrhagic shock, unilateral ureteral obstruction, and ischemia injury 
in rats (44-46). Activation (phosphorylation) of p38 was also detected in tubular cells, 
glomerular endothelial cells and macrophages during tubulointerstitial injury (45,47). 
Moreover, in acute and chronic glomerulonephritis, the activation of p38 suggests an 
important role of p38 MAPK in the regulation of acute and chronic inflammation (48). 
P38 MAPK inhibitors have been the most widely studied among all MAPK inhibitors, 
since p38 is activated by many important stimuli that play a role in renal disease, as 
described in Table 1. P38 regulates the production of TNF-α and IL-1 and, therefore, p38 
inhibitors are supposed to interfere with inflammatory and immunoresponsive diseases 
(49). Archetypal p38 inhibitors are the derivatives of pyridinyl-imidazole such as SB-
202190 and SB-203580. In recent years many new compounds have been developed, e.g. 
L-167307, AMG-548, BIRB-796, VX-745 and acyclic urea analogs (42,50). Fig. 3 depicts 
the chemical structure of some of these p38 inhibitors. All the above mentioned compounds 
competitively bind to the ATP−binding pocket of p38 kinase (51,52) and inhibit the 
phosphorylation of p38 and/or downstream transcription factors. The effect of many more 
p38 inhibitors for the treatment of renal inflammation and fibrosis has been studied in 
different animal models. Furuichi et al showed that treatment of renal ischemic mice with 
the p38 inhibitor FR167653 inhibited cell infiltration into the outer medulla and attenuated 
the extent of acute tubular necrosis (53). In addition, it decreased TNF−α, IL−1β, RANTES 
and MCP−1 gene expressions in ischemic kidneys. FR167653 has also been reported to 
reduce renal inflammation after burn injury (54). In both studies, FR167653 inhibited the 
phosphorylation of p38 in kidneys. In acute inflammatory renal injury either induced by 
cisplatin or in the anti-GBM glomerulonephritis model, p38 inhibitors significantly 
improved the renal functions (55,56). In the UUO rat model for renal fibrosis, blockade of 
p38α using its specific inhibitor NPC31169 markedly reduced ECM production (45). These 




studies provide sufficient evidence that p38 inhibitors may be a valuable asset during the 
treatment of renal fibrosis.  
Table 2.  Overview of signal transduction modifiers evaluated in animal models for renal fibrosis. 
Category Compound Dose Disease model References 
     
P38 MAPK 
inhibitors 
FR167653 32 mg/kg/d, s.c. renal ischemia-reperfusion mice 
model 
(53) 
  10 mg/kg/d, s.c. Renal failure with HRP−induced 
burn injury 
(54) 
     
 NPC31169 40 mg/kg b.i.d., 
gavage 
anti-GBM glomerulonephritis rat 
model 
(55) 
  40 mg/kg b.i.d., 
gavage 
UUO rat model (45) 
     
 SKF-86002  cisplatin-induced acute renal 
injury in mice 
(56) 
     
ERK inhibitors U0126 10 mg/kg, i.v. cisplatin-induced renal injury in 
mice 
(63) 
     
JNK inhibitor CC-401 100 mg/kg, 
b.i.d., gavage 
UUO rat model (64) 
     
Rho-ROCK 
inhibitors 
Y-27632 40 mg/kg/d, 
p.o. 
UUO mice model (71) 
  100 µg/kg, i.p. Ischemia-reperfusion-induced 
acute renal failure in rats 
(74) 
     
 Fasudil 10 mg/kg, i.p. UUO rat model (75) 
  30 mg/kg/d, 
p.o. 
Glomerulosclerosis in Dahl salt-
sensitive rats 
(76) 
  3 mg/kg/d, i.p. subtotally nephrectomized 
spontaneously hypertensive rats 
(77) 





  200 mg/kg/d, 
p.o. 
Passive Heymann nephritis rat 
model 
(141) 
     
 Dehydroxymethyl-
epoxyquinomicin 
8 mg/kg/d, i.p. UUO rat model (143) 





UUO rat model (153) 
     
TGF-β receptor 
kinase inhibitor 
SB-525334 10 mg/kg/d, 
p.o. 
PAN-induced renal fibrosis (105) 
     
PDGF receptor 
kinase inhibitor 
AG1295 12 mg/kg/d, i.p. UUO rat model (130) 
     
 STI571 (Gleevec) 50 mg/kg/d, i.p. anti-Thy 1.1 glomerulonephritis (132) 
s.c., subcutaneously; i.p., intraperitoneally; p.o., orally; 
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Several p38 inhibitors such as PS540446 (Pharmacopeia), Ro3201195 (Roche) and 
8565533 (GlaxoSmithKline) are currently in clinical Phase I for the treatment of 
rheumatoid arthritis. Moreover, TAK-715 (Takeda) has advanced into clinical Phase II 
trials (57).  
ERK and its inhibitors  
ERK is a ser/thr kinase and is generally activated by both receptor tyrosine kinases and 
G-protein coupled receptors. ERK1 (p44) and ERK2 (p42) are activated by phosphorylation 
at the TEY motif by MEK1 and MEK2 which are in turn activated by the Ras/Raf pathway 
as depicted in Fig. 2 (40). In kidneys, a large number of stimuli including albumin, high 
glucose, angiotensin−II and cytokines, can activate the ERK pathway in tubular cells. These 
factors are strongly associated with the induction of renal diseases. Recent studies have 
demonstrated that ERK is activated during tubulointerstitial fibrosis induced by UUO or 
puromycin aminonucleoside (PAN) administration in animals (47,58). In addition, 
activation of the ERK pathway in the kidney has been correlated with increased cell 
proliferation, histologic lesions and renal dysfunction in human glomerulopathies (59). 
More evidence for activation of the ERK pathway has been reported during renal 
ischemia−reperfusion injury, in stroke-prone spontaneously hypertensive rats, in 
aldosterone/salt induced hypertensive rats and in Dahl salt-sensitive rat models (60-62). 
Several potent MEK inhibitors such as U0126 (Fig. 2), PD98059, L-783277, RWJ-
68354 have been developed to block ERK activity and attained to the preclinical 
development. Other MEK inhibitors CI-1040 and ARRY-142886 have reached phase-I 
stages of clinical trials in cancer patients (57). Jo et al showed that pretreatment of mice 
with the MEK inhibitor U0126 decreased ERK1/2 phosphorylation, improved renal 
functions and reduced TNF-α expression, apoptosis and leukocyte infiltration in the 
kidneys (63). This suggests that inhibition of ERK pathway can be a future approach for the 
treatment of renal disease.  
JNK and its inhibitors 
JNK pathway, also known as the stress activated protein kinase (SAPK) pathway, is 
generally activated by hypertonicity, heat shock and proinflammatory cytokines (Fig. 2). 
Members of the JNK pathway include JNK1 (or p46) and JNK2 (or p54) and brain specific 
JNK3 (p49) (40). MKK activates JNKs at their TPY motifs by dual phosphorylation. JNKs 
have been reported to play a role in inflammation, apoptosis and tumor formation. 
Activation of JNK in kidney disorders is found in mesengial and proximal tubular cells at 
an early stage of renal injury in PAN-induced renal disease (47). In addition, the JNK 
pathway has also been reported to be activated in podocytes, endothelial cells, macrophages 
and myofibroblasts in the crescent glomerulonephritis model (48). Treatment with the JNK 
inhibitor CC-401 in the UUO rat model reduced JNK phosphorylation which was 
associated with a reduced tubulointerstitial volume (64). In addition, a significant reduction 




in alpha-smooth muscle actin and collagen-IV immunostaining and gene expression of 
TGF-β and CTGF was found after administration of CC-401.  
The above mentioned studies reveal that p38, ERK and JNK pathways play a crucial 
role in the regulation of progression of renal diseases and those MAPK inhibitors may 
provide potential therapies for the treatment of renal fibrosis.  
Rho-ROCK system and its inhibitors 
Rho GTPases belong to the Ras superfamily of GTP−binding proteins. At least ten 
different Rho GTPases have been identified; Rho (A-E, and G), Rac and Cdc42 were 
studied most extensively. These GTPases switch between GTP-bound (active) and GDP-
bound (inactive) conformations. Active (GTP-bound) Rho interacts with effector molecules 
such as Rho−kinases (ROCK-I and ROCK-II), mDia, Rhophilin, Rhotekin, and protein 
kinase N which initiate downstream signaling cascade (65). An important role for Rho in 
the etiology of renal diseases has been acknowledged recently (66). Several profibrogenic 
growth factors such as Ang II, lysophosphatidic acid, TGF-β, PDGF, and endothelin-I have 
been reported to activate Rho-dependent pathways (67-70). The activation of the Rho-
ROCK system is shown in Fig. 2. Activation of human renal fibroblasts with TGF-β caused 
induction of connective tissue growth factor (CTGF), which is a profibrotic factor and this 
effect was abrogated by RhoA specific inhibitors (68). Inhibition of Rho-ROCK system 
also suppressed migration of macrophages but could not inhibit proliferation of renal 
fibroblasts (71). Epithelial mesenchymal transdifferentiation, a key process in 
tubulointerstitial fibrosis, was blocked by Rho/Rho kinase pathway inhibition in human 
renal tubular cells (72). These studies demonstrate that Rho signaling may play a crucial 
role in the pathogenesis of renal fibrosis.  
Y-27632 and fasudil are specific inhibitors of ROCK (chemical structures are shown in 
Fig. 3). Y-27632 inhibits ROCK by binding to the catalytic site with 10-20 fold higher 
affinity towards ROCK-I/II in comparison to other Rho kinases. It is metabolized rapidly in 
vivo and does not cause major side effects even at higher doses (73). In the UUO model of 
renal fibrosis, specific inhibition of ROCK with Y-27632 decreased smooth muscle actin, 
TGF-β and collagen expression, macrophage infiltration and interstitial fibrosis (71). 
Treatment with Y-27632 at a low dose of 100µg/kg/d i.p. for 2 weeks prevented the 
development of ischemia/reperfusion-induced acute renal failure (74), supporting a pivotal 
role of ROCK in this process.  
Fasudil (or HA-1077) inhibits ROCK by binding to its catalytic site. It is metabolized 
rapidly to its active metabolite hydroxyfasudil which inhibits Rho-kinase with a Ki similar 
to the parent compound (73). Fasudil inhibited monocyte and macrophages infiltration and 
interstitial fibrosis in UUO rat model (75). Treatment with fasudil in Dahl salt-sensitive rats 
improved renal functions and attenuated glomerulosclerosis by reducing TGF-β and 
collagen expression (76). In subtotally nephrectomized spontaneously hypertensive rats, 
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fasudil inhibited tubular injury by upregulating p27 kip1 and subsequently inhibited cell 
proliferation and macrophage recruitment (77). 
Transforming growth factor-β and its inhibitors. 
The TGF-β superfamily includes three TGF-β isoforms (TGF-β1, -β2, and β-3), 
activins, inhibins, and bone morphogenic protein (BMP). TGF-β is considered a 
multifunctional cytokine that can regulate cell proliferation, differentiation, immune 
response, apoptosis and extracellular matrix deposition (78,79). Most of the intracellular 
signaling through TGF-β is mediated via Smad pathways which are 
activated/phosphorylated by TGF-β type I receptors (ALK5, ALK1 and ALK8). However, 
also Smad-independent pathways such as MAPK, NF-kB or PI3 kinase/AKT pathways are 
activated by TGF-β (80-82) as illustrated in Fig. 2. TGF-β signaling is considered to be a 
key regulator of the extracellular matrix deposition during renal fibrosis. TGF-β expression 
can be produced by different cell types within the kidney depending on the type of renal 
injury. TGF-β, in turn, can stimulate mesangial cells, interstitial fibroblasts, and tubular 
epithelial cells in vitro to undergo myofibroblastic activation or transition and to become 
ECM producing fibrogenic cells (83). Following UUO in animals, TGF-β is increased 
significantly in proximal tubules, thick ascending limbs of Henle, and distal convoluted 
tubules, whereas its expression in glomeruli and collecting ducts was constant (84,85). It is 
likely that TGF-β is also produced by macrophages since a strong correlation has been 
found between TGF-β and numbers of macrophages (86). In PAN, gentamycin and 
adriamycin nephritis models, TGF-β expression also increases significantly in the renal 
cortex demonstrating the apparent role of TGF-β in renal fibrosis (87-89).  
In patients with glomerulonephritis and in experimental tubulointerstitial fibrosis 
models like unilateral ureteral obstruction, apoptosis in tubular epithelial cells produces 
tubular atrophy (90,91). In these studies, a correlation between TGF-β1 expression and 
apoptosis in tubular cells was observed, implicating the proapoptotic role of this growth 
factor in renal diseases. Studies in a TGF-β1 transgenic model of glomerulosclerosis have 
indicated that TGF-β1 causes apoptosis in podocytes and in glomerular endothelial cells 
(92,93). A recent study has reported elevated levels of plasma TGF-β in patients with mild 
to moderate ureteral obstruction (94). In addition, a substantial correlation was found 
between glomerular TGF-β1 expression levels and severity of glomerulosclerosis (95).  
For many years, therapeutic approaches aiming at a TGF−β blockade have been 
pursued in order to prevent the progression of renal fibrosis. These include antisense 
oligonucleotide of TGF−β, neutralizing anti-TGF-β antibody and blockade of TGF-β 
activation by decorin or soluble TGF-β receptor (83). Other indirect approaches have been 
used to inhibit TGF−β signaling like the use of Ang II receptor antagonists or antisense 
inhibition of CTGF in animal renal fibrosis models (96-99). A more direct inhibition of 
TGF−β signaling can be effectuated via inhibition of the TGF−β type I receptor kinase, also 




known as the Activin Receptor Like Kinase (ALK5). ALK5 phosphorylates Smad 2 and 3, 
which mediate profibrotic effects of TGF−β1 for instance tubular dedifferentiation and the 
deposition of ECM. The inhibitors of ALK5 belong to dihydropyrroloimidazole and 
tiarylimidazole analogues which interact with the ATP-binding site of ALK5 (100,101). 
 
Figure 2. Different signaling pathways involved in the tubulointerstitial fibrosis. 
The p38 inhibitor SB203580 also inhibited the ALK5 phosphorylation of Smad3 due to 
the similarities between the ATP-binding pocket of ALK5 and serine/threonine kinase p38  
(101). Recently, the potent and specific ALK5 inhibitor SB-431542 was developed which 
had no effect on any other signaling pathway but clearly inhibited TGF-β1-induced 
procollagen-1αI expression in renal epithelial cells (100,102,103). Procollagen-1αI is an 
important marker for increased ECM deposition, so SB-43154 may be quite relevant. 
Thereafter, another pyridinyl imidazole compound SB-505124 was developed which 
inhibited ALK4-, ALK5-, and ALK7-dependent activation of Smad2 and Smad3 selectively 
(104). This compound blocked the effects of TGF-β in prostrate epithelial cells and 
hepatoma cells (104). In the same series of compounds, SB-525334 was found to be 
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effective for the treatment of renal progressive diseases. SB-525334 inhibited TGF-β 
induced phosphorylation of Smad2 and Smad3 and expression of PAI-1 and procollagen-
1αI in renal epithelial carcinoma cells (105). In this study, treatment with SB-525334 
during acute PAN-induced renal fibrosis in rats reduced the fibrotic markers procollagen-
1αI and -1αIII significantly. Recently, A-83-01 was found to be more potent in the 
inhibition of ALK5 than SB-431542, and also inhibited the epithelial-to-mesenchymal 
transition induced by TGF-β (106). SD-208, a selective and novel 2,4-disubstituted 
pteridine derivative blocked TGF-β−induced PAI-1 expression in vitro and retarded the 
progression of established lung fibrosis in rats (107). The new ALK5 inhibitor GW6604 
was shown to inhibit the process of liver fibrosis (108). In vitro, GW6604 inhibited the 
expression of liver fibrosis markers in hepatocytes and in vivo reduced collagen expression 
and matrix deposition in dimethylnitrosamine−induced liver fibrosis model. These studies 
reveal that ALK5 inhibitors are effective in vivo and can be the new potential therapeutics 
for renal fibrosis. 
Platelet derived growth factor (PDGF) and its inhibitors 
PDGF is a potent growth factor for mesenchymal cell types such as myofibroblasts. 
The PDGF family is composed of PDGF−A, −B, −C and –D, which form either the 
homodimers or heterodimers PDGF−AA, −AB, −BB, −CC, and −DD. These isoforms exert 
their cellular effect by binding to the structurally similar tyrosine kinase receptors −α and –
β. These receptors, in turn, dimerize when the dimeric PDGF binds and create either 
homodimers or heterodimers of the receptors in three combinations PDGFR−αα, −αβ and 
−ββ. PDGF−AA, −AB, −BB and −CC can induce αα receptor homodimers, PDGF−AB, 
−BB can induce αβ form and PDGF−BB and −DD can induce ββ receptor form (109,110). 
PDGFs play pivotal roles in wound healing, regulation of interstitial fluid pressure and 
embryonic development. In addition, they participate in malignancies, atherosclerosis and 
fibrotic diseases (109,111). The role of PDGF in various human and animal renal diseases 
has been confirmed by the increased expression of PDGF and PDGF receptors in renal 
tissue. The induced expression of PDGF and its receptor was found in patients with IgA 
nephropathy and other human proliferative glomerulonephritis (112-114). PDGF-BB has 
been recognized as a potent mitogen and chemoattractant for renal mesengial cells and also 
induces ECM deposition, which leads to glomerulosclerosis (111). Iida et al found a 
marked increase in PDGF−A and −B and PDGFR-β mRNA expression in glomeruli in the 
mesengial proliferative nephritis model in rats (115). The important role of PDGF in 
tubulointerstitial fibrosis was demonstrated when administration of PDGF-BB in rats 
substantially increased tubulointerstitial cell proliferation and expressions of alpha-smooth 
muscle actin and collagens (116). In human diabetic nephropathy, gene expression levels of 
PDGF−A and −B were found to be several fold increased and immunohistochemistry 
showed that PDGF−A was present at both glomeruli and proximal tubular cells whereas 
PDGF−B was localized in the areas of peritubular, interstitial and periglomerular fibrosis 




(117). The functions of the new members of the PDGF family, PDGF-C and PDGF-D have 
been also reported recently in renal diseases (118,119). PDGF-C is constitutively expressed 
in parietal Bowman’s capsule, tubular epithelial cells and arterial endothelial cells and 
upregulated in podocytes and interstitial cells after renal injury (118). PDGF-D was found 
to be normally expressed in vascular smooth muscle and mesengial cells but not in other 
interstitial cells. However, PDGF-D was highly expressed in interstitial cells, mainly in 
myofibroblasts and other fibrotic areas in the UUO mice model as well as in mesengial 
cells in the anti-Thy 1.1 glomerulonephritis model (119,120).  
Inhibition of PDGF−mediated processes using different approaches has been employed 
for the treatment of fibrosis. However there is little evidence for an effective treatment of 
renal fibrosis (121-123). Pirfenidone, an antifibrotic drug, reduced lung fibrosis probably 
by inhibiting the production of PDGF−A and −B isoforms by lung macrophages (121). 
Application of soluble PDGF-β receptor to influence proliferative hepatic stellate cells 
caused inhibition of their proliferation and, even more important, its intravenous 
administration to the bile duct ligated animals significantly reduced the expression of 
collagen and alpha-smooth muscle actin (123). Trapidil, an antagonist of the PDGF 
receptor, reduced mesengial cell proliferation induced by different growth factors in vitro 
and in vivo in anti-thymocyte serum−induced glomerulonephritis model in rats (124,125). 
Treatment with trapidil reduced the nephrotoxicity of gentamicin in rats (126). In contrast, 
administration of trapidil in renal ischemic rats worsened the renal damage probably by 
inhibiting the tubular repair process after acute tubular injury (127), induced by PDGF. 
A variety of chemical compounds have been developed as selective PDGFR kinase 
inhibitors and applied for the treatment of fibrosis. Chemical structures of some of these 
inhibitors are shown in Fig. 3. Quinoxalines such as AG1295, AG1296, AGL 2033 and 
AGL 2043 have been reported to be highly potent and selective towards PDGFR (128). 
They bind to the ATP binding site of the tyrosine kinases. All these inhibitors contain an 
aryl group that interacts with a lipophilic pocket near the ATP binding site, not available to 
ATP. This extra binding is probably essential for the potency of these inhibitors and seems 
to be an important factor in their selectivity (128). These compounds were proven to reduce 
fibrosis in animal models. In a rat model of pulmonary fibrosis, administration of AG1296 
reduced the number of proliferative epithelial and mesenchymal cells by 50% (122). In 
vitro, AG1295 treatment effectively decreased PDGF-BB−induced proliferation of hepatic 
stellate cells and also inhibited autophosphorylation of PDGFR-β, PDGF-BB−induced 
activation of MAPK isoforms and tyrosine phosphorylation of PI3-kinase, PLC-γ and p21 
ras guanosine triphosphate-activating protein in these cells (129). Interestingly, treatment 
with AG1295 substantially reduced interstitial fibrosis in the rat UUO model by reducing 
the tubulointerstitial area, ECM deposition and number of macrophages (130).  
Another category of PDGFR tyrosine kinase inhibitors are phenylaminopyramidines, 
represented by STI571/ imatinib/Gleevec which also blocks Bcr-Abl kinase, indicating its 
different mode of binding as compared to the other compounds (131). Clinical use of 
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Gleevec has been approved so far only for secluded cases of chronic myelomonocyatic 
leukemia and dermatofibrosarcoma protuberans with very good response (131). Gleevec 
reduced PDGF−stimulated mesengial cells proliferation in vitro and the number of alpha-
smooth muscle actin positive mesengial cells as well as glomerular collagen deposition in 
animals with anti-Thy 1.1 glomerulonephritis (132). In a recent study, treatment with three 
distinct PDGFR tyrosine kinase inhibitors SU9518, SU11657 or Gleevec markedly 
attenuated the development of irradiation−induced pulmonary fibrosis in mice (133). Upon 
irradiation, up-regulated expression of PDGF (A-D) isoforms led to phosphorylation of 
PDGF receptors and this was highly inhibited by these inhibitors.   
Nuclear factor (NF)-κB signaling and its inhibitors 
NF-κB comprises a family of transcription factors that play a crucial role in the 
regulation of innate and adaptive immunity. The NF-κB family is composed of five 
members p65 (RelA), RelB, c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2). They exist 
as homo− and hetero−dimers bound to IκB family proteins in unstimulated cells. Upon 
activation, IκB proteins are phosphorylated by IκB kinases, IKKα and IKKβ, and 
ubiquitinated and degraded in proteasomes. NF-κB pathway can be activated by distinct 
signal transduction cascades such as TNF-α, IL-1, LPS or stress−mediated cascades (Fig. 
2). Degradation of IκB allows NF-κB to translocate from cytoplasm into the nucleus where 
it binds to DNA to regulate the production of various cytokines, chemokines, stress 
response proteins and anti-apoptotic proteins (134,135). For further details on signaling of 
NF-κB we recommend to read a recent review by Hayden and Ghosh (136).   
NF-κB is a main mediator of genes that regulate cell proliferation and apoptosis which 
makes NF-κB an important participant in the pathogenesis of cancer (135,137). NF-κB is 
also associated with the pathogenesis of chronic inflammatory diseases such as asthma, 
rheumatoid arthritis and inflammatory bowel disease, since it regulates the expression of 
proinflammatory cytokines, chemokines and adhesion molecules. The pathogenic 
significance of NF-κB pathway in renal fibrosis has been identified in recent years. The 
following studies provided strong evidence for the involvement of NF-κB activation in 
various experimental animal models for renal diseases. Sakurai et al showed that induction 
of glomerulonephritis with nephrotoxic serum in rats caused NF-κB activation in glomeruli 
which was increased from day 3 to5 and persisted until day 14 (138). In 
adriamycin−induced tubulointerstitial injury, the activity of NF-κB (p50/65, p50/c-Rel) was 
increased in the renal cortex from day 7 and reached a maximum on day 28. This pattern 
was inhibited by chronic treatment with a specific NF-κB inhibitor (139). Garre et al 
showed the activation of NF-kB in proximal tubular cells in vivo in protein over-load renal 
fibrosis model and in vitro models in relation to Ang II and endothelin-1 in 
tubulointerstitial injury (140). Furthermore, in passive Heymann nephritis, NF-κB 
activation predominantly occurred in podocytes and correlated with the existence of 
proteinuria (141). 



































































Figure 3. Chemical structures of various kinase inhibitors as referred in the text. 
In many other animal models for tubulointerstitial fibrosis and glomerulonephritis, 
activation of NF-κB was found to be localized in tubular and glomerular cells, respectively 
(142-145). Sakai et al identified NF-κB−positive cells in patients with crescentic 
glomerulonephritis which were mainly present in crescentic lesions, tubular epithelial cells, 
and interstitial mononuclear infiltrates (146). Recently the same research group established 
the activation NF-κB as the p65−positive nuclei were found in kidneys of patients with 
diabetic nephropathy. These NF-κB (p65) positive cells were identified as mesengial cells, 
endothelial cells, podocytes, tubular cells, and mononuclear infiltrates in the interstitium 
(147). In both studies, they demonstrated that NF-κB activation was associated with the 
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phosphorylation of p38 MAP kinase in glomerular cells during glomerulonephritis and in 
tubulointerstitial cells during diabetic nephropathy.  
NF-κB inhibition has drawn much attention in the field of drug development since it 
regulates various crucial pathophysiologic pathways. A wide range of NF-κB inhibitors 
have been developed during the last decade and, moreover, plenty of existing compounds 
have been identified as NF-κB inhibitors (for further details see review by Aggarwal et al) 
(148). In this review we will focus on those studies in which NF-κB inhibitors have been 
tested in renal fibrosis models. As an example, pyrrolidine dithiocarbamate (PDTC) has 
been examined in various renal disease models for its efficacy. Treatment with PDTC 
inhibited NF-κB activity and reduced tubular cells atrophy, interstitial volume, ED-1 
infiltration and cortical lipid peroxidation without any effect on proteinuria in 
adriamycin−induced tubulointerstitial injury in rats (139). In the Passive Heymann nephritis 
rat model, PDTC markedly decreased MMP-9 mRNA levels in glomeruli and it also 
reduced the proteinuria (141). Moreover, in other renal disease models such as 
FK506−induced nephropathy and gentamicin−induced tubulointerstitial injury, PDTC 
treatment attenuated the disease in both cases (142,149). Glucocorticoids such as 
prednisolone and dexamethasone have also been reported to inhibit NF-κB activity in 
nephrotoxic serum−induced glomerulonephritis in rats and in rat mesengial cells in vitro, 
respectively (150,151). It has been suggested that glucocorticoids inhibit the NF-κB activity 
by increasing the levels of IκB resulting in cytoplasmic retention of p65 and/or by 
inhibiting NF-κB DNA binding (135). Lopez-Franco et al showed that treatment with 
different NF-κB inhibitors such as gliotoxin (a fungal metabolite) or parthenolide (a plant 
extract), significantly reduced proteinuria and glomerular damage in anti-Thy 1.1 rat model 
and anti-mesengial cell nephritis in mice, respectively (145). Miyajima et al evaluated a 
novel NF-κB inhibitor dehydroxymethyl-epoxyquinomicin (DHMEQ) in the UUO rat 
model and found a substantial reduction in apoptosis and proliferation of tubular cells, 
which was associated with reduced interstitial fibrosis (143). They showed that DHMEQ 
inhibited NF-κB activity by preventing p65 translocation to nuclei which had also been 
described by others (152). Since IκB is degraded in proteasomes enabling translocation of 
NF-κB to the nucleus, inhibition of this degradation is a relevant approach to inhibit NF-κB 
activity. Administration of the proteasome inhibitor N-benzyloxy-carbonyl-Ile-Glu(o-t-Bu)-
Ala-Leucinal, to UUO rats decreased inflammation and attenuated the development of 
fibrosis by reducing MCP-1 gene expression, macrophages influx and gene expression of 
pro-fibrogenic molecules (153). These studies verify that if NF-κB activity is inhibited, 
significant reduction of renal disease is achieved in several cases.  
Renal drug targeting 
Many reasons can be portrayed to perform renal drug targeting. Various compounds 
used for the treatment of renal fibrosis do not sufficiently reach the kidneys to achieve 
therapeutic levels at tolerable doses. Even though compounds may reach the kidneys, they 




might not enter the specific target cell aimed at due to suboptimal intra-renal transport. As a 
consequence, high doses are needed to achieve therapeutic levels in the kidneys which in 
turn cause extra-renal side effects. Additionally, pathological conditions and rapid (local) 
metabolism of the drugs can limit the renal distribution and/or accumulation of drugs at the 
target site. To deliver therapeutic amounts of drugs and to avoid interactions with non-
target organs, renal targeting therefore may be an interesting approach.  
Renal specific delivery of drugs can be achieved by carriers that are filtered in the 
glomerulus and reabsorbed from the urine by receptor-mediated endocytosis in the 
proximal tubule as shown in Fig. 4. Alternatively, carrier groups can be attached that 
facilitate uptake via receptors at the basolateral membrane of proximal tubular cells, thus 
not requiring the filtration of the compound into the urine (154,155). Low molecular weight 
proteins (LMWPs) and low molecular weight polymers belong to the first category of 
carriers, and are suitable for renal targeting for various reasons. First, when the size of these 
macromolecules allows glomerular filtration, they accumulate rapidly in the proximal 
tubular cells where, in principle, they can release free drug intracellularly. Of note, the 
filtration and subsequent accumulation of carriers may depend on the charge since 
negatively charged carriers are repelled by the glomerular basement membrane. This is 
important since charge and other physiochemical properties of the carrier can be modified 
after coupling the drugs to the carrier. Only a few studies have reported the renal delivery 
of drugs using polymers (156). In contrast, lysozyme has extensively been employed to 
deliver various drugs to the kidneys. Franssen et al described various drug-LMWP 
conjugates with different linkages between drug and protein (157). It has been established 
that drug-lysozyme conjugates are internalized by proximal tubular cells via the megalin 
receptor through an endocytosic mechanism. Inside the lysosomes, the protein carrier is 
degraded by proteolytical enzymes and the drug is released either enzymatically or by 
pH−sensitive linkage degradation. The released drug may produce its pharmacological 
effect inside the target cell but may also diffuse outside the cell and produce its action at the 
cell surface or in other cell types. In the latter case, the tubulointerstitial cell serves as a 
slow release depot for drugs within the kidneys. 
The anti-inflammatory drug naproxen and the ACE inhibitor captopril have been 
targeted to the kidneys by coupling them to lysozyme using amide and disulfide linkages, 
respectively (158,159). These drug-lysozyme conjugates produced renal−specific effects 
after intravenous administration. Moreover, captopril-lysozyme conjugate could be 
administered through the subcutaneous route which provided a slow and prolonged 
accumulation of the conjugate in kidneys (160). Prolonged treatment of this captopril 
conjugate exhibited a significant reduction in proteinuria without affecting systolic blood 
pressure in adriamycin−induced nephrotic animals (161). Using the same renal carrier 
system, we have recently delivered the p38 MAPK inhibitor SB202190 to the kidneys 
(162). The SB202190-lysozyme efficiently accumulated in the kidneys and the drug was 
released from its carrier during a prolonged period of time, which is preferred for a chronic 
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drug effect. At present, we are investigating the antifibrotic effects of this conjugate, and 
drug-lysozyme conjugates with other kinase inhibitors are under development. This 
approach will allow local intervention in kinase pathways involved in the development of 
renal fibrosis, without the risk of side effects outside the kidneys. Many of the MAPkinase, 
ERK, JNK or other signaling inhibitors require local high concentrations within/around the 
target cells but distribute poorly to the kidneys. As a consequence, they may benefit greatly 
from renal targeting. 
Gene therapy 
In the contest of therapeutics for renal diseases, gene therapy has also shared its 
contribution. For renal gene therapy, several techniques such as viral, nonviral, and cellular 
vectors have been used both in vivo and ex vivo (163). Ideally, an efficient and selective 
gene delivery is needed to achieve therapeutic effects in kidneys and avoid interaction with 
other organs.  
Wolf et al demonstrated that kallikrein adenoviral gene delivery in rats with 5/6 
nephrectomy−induced fibrosis reduced the occurrence of glomerular sclerotic lesions, 
tubular damage, and interstitial inflammation in kidneys (164). Kallikrein cleaves 
kininogen substrate into kinin which plays a pivotal role in cardiovascular function. 
Furthermore, kallikrein gene therapy substantially decreased DOCA−salt induced 
proteinuria, glomerulosclerosis, tubular dilation, and luminal protein casts which resulted in 
a reduction of renal fibrosis (165). Adenovirus−mediated delivery of a vasodilator gene, 
adrenomedullin, attenuated renal damage in hypertensive dahl salt-sensitive rats and 
Goldblatt hypertensive rats (166,167). Adenoviral gene delivery has also been employed to 
deliver the entire soluble extradomain of the TGF-β type II receptor (fused with IgG) into 
the kidneys of rats with anti-GBM nephritis in order to block the action of TGF-β (168). To 
affect the TGF-β signaling, non-viral transfection techniques have also been used. A 
doxycycline-regulated Smad7 gene was delivered by renal arterial injection in rats with 
UUO or 5/6 nephrectomy using an ultrasound-microbubble (Optison)-mediated system. 
This inhibited tubulointerstitial fibrosis in terms of reduced myofibroblasts accumulation 
and collagen expression (169,170).  
Since HGF displayed beneficial effects in renal fibrosis, gene delivery of HGF via 
systemic administration of naked plasmid vector was also tested. This treatment 
ameliorated renal fibrosis induced by UUO or streptozotocin−induced diabetic nephropathy 
in mice (171,172). Gene delivery of HGF was performed by various methods such as 
liposomes containing hemagglutinating virus of Japan (HVJ liposome) and by 
electroporation of plasmid vector encoding HGF (173,174). In these studies, gene therapy 
of HGF prevented the tubulointerstitial fibrosis induced by either UUO or cyclosporine. In 
another approach, intrarenal injection of the naked plasmid 7ND, encoding for an N-
terminal deletion mutant of the human MCP-1 gene, significantly reduced macrophage 
infiltration, tubular damage, and gene expression of TGF-β1 and MCP-1 in the protein-




overload renal injury model (175). In the UUO mice model, gene delivery of 7ND 
produced beneficial effects on renal fibrosis (176). 
 
Figure 4. Schematic presentation of drug delivery and gene delivery to the kidneys. 
Yokoi et al demonstrated that administration of CTGF antisense oligonucleotide by 
hydrodynamic-based gene transfer technique in rats with UUO attenuated the induction of 
fibronectin, ED-A and collagen 1α(I) gene expression as well as collagen deposition in the 
interstitial fibrotic area (177). Short synthetic interfering RNA duplexes (siRNAs) can 
selectively silence the expression of a complementary gene in mammalian cells. Recently 
this technique has been applied in different animal models of renal disease. siRNA 
molecular targeting against TGF-β1 were administered via the renal artery followed by 
electroporation in anti-Thy 1.1−induced glomerulonephritis in rats (178). This treatment 
significantly suppressed TGF-β1 mRNA and protein expression, thereby inhibiting the 
deposition of ECM. In another study, a plasmid DNA expressing siRNA against TGF-β 
receptor was injected into the kidney via the ureter and then UUO was performed. This 
Novel therapeutic targets for the treatment of renal fibrosis 
 57 
resulted in reduced TGF-βR levels and alpha smooth muscle actin and collagen expression 
in the renal cortex (179).     
There are many examples of renal gene delivery that have not been discussed here. 
These studies reveal that gene therapy using viral and non-viral approaches can be the 
future therapeutic interventions for renal diseases. At present, safety issues related to these 
techniques are major hurdles that need to be resolved before one can adopt these techniques 
in patients.  
Other therapeutic interventions  
Recently identified biological therapeutics includes Interleukin-10 (IL-10), bone 
morphogenetic protein-7 (BMP-7), hepatocyte growth factor, and transglutaminase 
inhibitors. IL-10 is an immunomodulatory cytokine produced by monocytes/macrophages, 
B cells, and T cells. IL-10 acts as an endogenous immunosuppressive and anti-
inflammatory factor during inflammation. Administration of IL-10 to mice with 
glomerulonephritis induced by anti-GBM globulins prevented the decline in renal function 
and markedly diminished glomerular T cell and macrophage accumulation (180). Further 
studies confirmed that IL-10 administration attenuated glomerulonephritis induced by either 
anti-GBM or anti-Thy 1.1 antibody (181,182). A recent study showed that treatment with 
another interleukin (IL-11) reduced glomerular NF-κB activity markedly, caused a 
reduction in glomerular macrophage infiltration, fibrin deposition and albuminuria in 
nephrotoxic serum induced glomerulonephritis in mice (183). BMPs are ligands for ALK 
receptors and phosphorylate Smad-1, -5 and -8. BMP-7 has been found to be reduced 
during acute renal injury in an ischemia mouse model (184,185). The therapeutic potential 
of BMP-7 has been recently reviewed (186). Briefly, administration of recombinant BMP-7 
in the UUO model inhibited interstitial inflammation, fibrogenesis, apoptosis and tubular 
atrophy (187,188). Similarly, treatment with recombinant BMP-7 improved renal functions 
and reduced interstitial fibrosis in two genetic mouse models (189). 
HGF is an endogenous peptide, composed of a 69 KDa α-chain and a 34 KDa beta-
chain and antagonizes the effects of TGF-β. HGF binds to its specific tyrosine kinase 
receptor c-met, thereby stimulating cell proliferation and differentiation and also cell 
migration and tumorigenesis. Liu has described the therapeutic effects of HGF in renal 
fibrosis in detail (190). In short, administration of recombinant HGF into UUO mice 
substantially suppressed the progression of renal interstitial fibrosis with a decrease in renal 
alpha-smooth muscle actin expression, total collagen content, interstitial matrix components 
such as fibronectin, and renal expression of TGF-β1 and its type I receptor (191). 
Moreover, in the rat remnant kidney model, a continuous infusion of HGF prevented 
tubulointerstitial fibrosis and collagen deposition which was associated with increased 
tubular expression of MMP-9 (192).  




Stabilization of the ECM has been considered as an important mechanism to prevent 
the progression of renal fibrosis. Tissue transglutaminase is a calcium-dependent enzyme 
that contributes to the stabilization of ECM proteins by forming γ-glutamyl-lysine cross-
links. In subtotal nephrectomy and diabetic nephropathy animal models, activation of tissue 
transglutaminase was found within tubular cells and glomeruli (193,194). An highly 
specific site−directed inhibitor of tissue transglutaminase (1,3-dimethyl-
2[(oxopropyl)thio]imidazolium) inhibited the glucose-induced deposition of ECM proteins 
in renal tubular epithelial cells in vitro (195). If further evidence for in vivo effectiveness 
can be obtained, transglutaminase inhibitors can open a future direction for the treatment of 
renal fibrosis.   
Conclusions  
Tubulointerstitial fibrosis is a complex process involving various factors associated 
with diverse intracellular signaling cascades. Therefore, signal transduction therapies are 
currently taking the attention as future therapeutic interventions complementary to the 
current therapies. Yet, efficacies of these therapies have been definitely verified only in 
experimental animal models of renal fibrosis. Most of the clinical studies performed at 
present with the candidate compounds have been carried out for rheumatoid arthritis, cancer 
and other diseases but not yet for renal fibrosis. This invites further clinical evaluation of 
the particular concepts in which long term toxicity aspects will be included. In view of the 
multiple and complex mechanisms underlying chronic renal diseases, the question should 
be addressed if combination therapies are rather necessary to cope with the multifactorial 
pathological process. Classical treatment schemes may be combined with the novel 
approaches mentioned in the present review. New experimental therapies may reveal 
whether the strategy to inhibit one of the signal transduction pathways outlined in this 
review will provide an effective therapy for this chronic disease. It remains to be 
established whether interference in this complete system of signal amplification provides 
powerful tools to treat this disease, creates serious adverse effects due to the ubiquitous 
presence of the signal pathways or that redundancy within the system leads to a dampening 
of all the pharmacological effects of drugs. In any case, new opportunities and questions 
emerge to resolve the complexity of renal fibrosis.  
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We have developed a sensitive and reproducible high performance liquid 
chromatography (HPLC)-UV method for the quantification of the p38 MAPkinase inhibitor 
SB202190 in serum, kidney homogenates and urine samples. Liquid-liquid extraction of 
SB202190 from the samples was performed using diethylether after adding a derivative of 
SB202190 as internal standard (I.S.). Chromatography was carried out using a C8 reversed-
phase column with an isocratic mobile phase consisting of acetonitrile-water-trifluoroacetic 
acid (30:70:0.1v/v/v, pH 2.0). Both drug and I.S. were measured at 350 nm and eluted at 
5.0 and 10.6 minutes, respectively. Peak-height ratios of the drug and the I.S. were used for 
the quantification of SB202190 from the different matrixes. The limit of quantitation of 
SB202190 in serum, kidney and urine were 0.25 µg/ml, 1 µg/g and 1 µg/ml, respectively. 
The average recoveries were 74%, 75% and 92% in serum, kidney and urine, respectively. 
The intra-day and inter-day precision (%CV) and accuracy (%bias) were below 15% for all 
concentrations. The method was successfully applied for a pharmacokinetic study of 
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Introduction 
In recent years, p38 mitogen activated protein kinase (p38 MAPK) has been 
investigated extensively and found to play a pivotal role in the etiology of various 
inflammatory diseases such as septic shock, arthritis and other joint diseases (1,2,3). 
Several p38 MAPK inhibitors have been developed and are currently being tested as anti-
inflammatory therapeutics (3). In addition, the use of these inhibitors has recently been 
proposed for the treatment of end-stage organ diseases such as renal fibrosis (4). 
SB202190 (4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole, 
Figure 1) is a well known selective p38 MAPK inhibitor which is often used in various 
studies to display the role of p38 MAPK pathway (5-8). We have recently developed a 
renal-specific delivery formulation of SB202190 to treat renal fibrosis. To study the 
pharmacokinetics of SB202190 in different biological samples, we now report a sensitive, 
accurate and reproducible method. A C8 reversed-phase column was used for 
chromatographic separations and the drug was detected specifically by UV measurement at 
350 nm. Since the drug levels can be quite low and variable in different samples, we used a 
liquid-liquid extraction method to isolate the drug from serum, kidney homogenate and 
urine samples. In order to correct for variation in the extraction, we spiked our samples with 
a pyridinyl imidazole compound that has similar chemical properties as SB202190. We also 









Figure 1. Chemical structure of SB202190. 
Experimental  
Materials 
SB202190 was purchased from L.C. Laboratories (Woburn, MA, USA) and the purity 
was at least 99%. The SB202190 related compound was used as an internal standard 
(VI7004D) was kindly gifted by Prof. György Kéri (Semmelweiss University, Budapest, 
Hungary). Acetonitrile (HPLC grade) was purchased from Biosolve, Valkenswaard, The 
Netherlands. Diethylether was purchased from Boom B.V., Meppel, The Netherlands. All 




other chemicals were of analytical-reagent grade. Water was purified to ultra-pure water of 
18.2 MΩ resistance by Arium 611 (Sartorius AG, Goettingen, Germany).  
Drug–free serum, urine and kidneys were obtained from healthy male Wistar rats (250-
300g) provided by Harlan (The Netherlands).  
Instrumental 
HPLC analyses were performed using chromatographic system consisting of a Waters 
510 HPLC pump, a column oven set at 40°C and a Waters 715 Ultra WISP autoinjector 
(Waters Inc., Milford, MA, USA) in combination with a Spectroflow 757 UV detector 
(Kratos, Kanagawa, Japan). Separations were achieved with a C8 reversed-phase column 
(250 x 4.6 mm i.d., 5µm particle size) purchased from Thermo-Hypersil Keystone 
(Bellefonte, PA, USA), preceded by a C18 guardPak precolumn (Waters). The mobile phase 
consisted of acetonitrile-water-trifluoroacetic acid (30:70:0.1, v/v/v; pH 2.0) at a flow rate 
of 1 ml/min. The effluents were monitored at 350 nm.  
Preparation of stocks, calibration standards and quality control samples 
The standard solutions of SB202190 and internal standard (100 µg/ml) were prepared 
in methanol and kept at 4°C with light protection. Fresh working standards (10-20 µg/ml) 
were prepared by diluting the main standards in water.  
Calibrations standards were prepared by adding different concentrations of the working 
standards in drug-free serum, kidney homogenate (1:3 w/v) and urine. Serum and kidney 
homogenate standards were prepared at concentrations of 0.25, 0.5, 1, 2, 3, and 5 µg/ml and 
1, 2, 4, 8, 12 and 20 µg/g of tissue, respectively. Urine calibration standards were prepared 
at concentrations of 1, 2.5, 5, 10, 15 and 20 µg/ml. Four pools of quality control (QC) 
samples were prepared by spiking the biological matrixes at the concentrations of 0.25, 1, 2 
and 5 µg/ml (serum) 1, 4, 8 and 20 µg/g (kidney homogenate) and  1, 5, 10, and 20 µg/ml 
(urine). 
Sample preparations 
Analysis of SB202190 in serum samples 
A 100 µl aliquot of serum was spiked with 25 µl of the I.S. solution in water (20 
µg/ml) in a glass tube and vortexed for 30 s. Subsequently, 2 ml of diethylether was added 
and the sample was vortexed for another 2 min. The mixture was centrifuged at 900 g for 5 
min at ambient temperature and the aqueous layer was frozen in liquid nitrogen. The upper 
organic layer was transferred to another borosilicate glass tube and evaporated completely 
at 50°C. The extraction procedure was repeated twice and the total residue was 
reconstituted in 100 µl of mobile phase. A 25 µl of the reconstituted sample was injected 
into the HPLC system. The sensitivity of the detector was 0.02 AUFS. 
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Analysis of SB202190 in kidney homogenate 
Kidney homogenate was prepared in 0.1 M phosphate buffer saline (pH 7.2) in 1:3 w/v 
using an ultra-turrax-T25 apparatus (20,000 rpm, 1 min). To 200 µl of homogenate, 50 µl 
of the I.S. solution in water (20 µg/ml) was added in a glass tube and vortexed for 30 s. The 
extraction was performed by adding 2 ml of diethylether and vortexing for 2 min. The 
mixture was centrifuged at 900 g for 5 min and the aqueous layer was frozen in liquid 
nitrogen. The upper organic layer was transferred to another borosilicate glass tube and 
evaporated completely at 50°C. The extraction procedure was repeated twice and the total 
residue was reconstituted in 200 µl of mobile phase. A 25 µl of the reconstituted sample 
was injected into the HPLC system. The kidney homogenate samples were estimated at the 
sensitivity of 0.02 AUFS . 
 Analysis of SB202190 in urine 
100 µl of urine was spiked with 100 µl of the I.S. solution in phosphate buffer saline 
(20 µg/ml) in a glass tube and vortexed for 30 s. Subsequently, 2 ml of diethylether was 
added and the sample was vortexed for 2 min. The mixture was centrifuged at 900 g for 5 
min at ambient temperature and the aqueous layer was frozen in liquid nitrogen. The upper 
organic layer was transferred to another borosilicate glass tube and evaporated completely 
at 50°C. The extraction procedure was repeated twice and the total residue was 
reconstituted in 100 µl of mobile phase. A 25 µl of the reconstituted sample was injected 
into the HPLC system. Urine samples were estimated at 0.1 AUFS.   
Assay Validation 
Validation of this method was performed in compliance with the current FDA 
guidelines for biological method validation [9]. 
Quantifications 
To quantify the concentration of SB202190 in QC or unknown samples, peak-height 
ratios of SB202190 to that of the I.S. were calculated and related to standard curves of 
SB202190 in drug-free matrix. Lower limits of detection (LLOD) and quantitation (LLOQ) 
were determined from signal-to-noise ratios. The LLOD is defined as the lowest 
concentration level resulting to a signal-to-noise ratio of 3:1, while the signal-to-noise ratio 
should be 10:1 for the LLOQ.  
 Recovery 
The recoveries of SB202190 from serum, kidney homogenate and urine were 
determined for different standard concentrations by spiking the drug into the corresponding 
blank sample. The percentage recovery was calculated by comparing the peak-heights of 
extracted samples with samples in which the compound was spiked directly in mobile 
phase. Recoveries at four QC concentration levels for serum, kidney homogenate and urine 
were examined at least five times for each sample type. 




 Linearity, precision and accuracy 
For the construction of calibration curves in serum, kidney homogenate and urine, 6 
different calibration standards of SB202190 were prepared and processed as mentioned 
above. Six different calibration curves were constructed in serum and kidney homogenate 
and four different calibration curves in urine. To evaluate precision, at least 5 QC samples 
of four different concentrations, to represent the entire range of the standard curve, from 
each type of biological matrix were processed and injected on a single day (intra-day) and 
at different days (inter-day). The variability was expressed as the coefficient of variation 
(%CV) which should be ≤15% at all the concentrations except lower-limit of quantitation 
(LLOQ) whose value should not be more than 20%. Accuracy of the method is established 
from the same QC samples. Accuracy is expressed as % bias which should be within limits 
of ±15% at all concentrations.  
 Stability studies 
The stabilities of SB202190 and I.S. standards (5 µg/ml in methanol) at room 
temperature were determined by placing the solutions at the bench up to 24 h. The freeze-
thaw stability and long-term stability studies were performed on SB202190 in serum, 
kidney homogenates and urine. Three freeze-thaw cycles (for 72 h period at -80°C to room 
temperature) were performed in QC of serum (0.25 and 5 µg/ml), kidney homogenates (1 
and 20 µg/g) and urine (1 and 20 µg/ml). Samples were allowed to freeze at -80°C for 24 h 
and then removed from freezer to thaw them at room temperature under normal light. 
Samples were again frozen at -80°C. This cycle was repeated another 2 times and then 
samples were estimated for SB202190 after last thaw. To evaluate the long-term stability, at 
least three QC of serum (0.25 and 5 µg/ml), kidney homogenates (1 and 20 µg/g) and urine 
(1 and 20 µg/ml) were prepared and stored at -80°C for 3 weeks. The samples were 
estimated for SB202190 at the end of the 3 weeks.  
Pharmacokinetics of SB202190 
The animal experiments were approved by the Animal Ethics Committee of the 
University of Groningen and licensed under number D4266A. In brief, male Wistar rats 
(n=3; 280-300 g) were anesthesized with hypnorm/valium (Janssen-Cilag Ltd., Saunderton, 
UK) and equipped with a cannula in the carotid artery for blood sampling. The animals 
remained under anesthesia during the course of the pharmacokinetic study. An intravenous 
bolus dose of SB202190 (5 mg/kg) was injected through the penile vein. SB202190 was 
dissolved in 20% hydroxypropyl β-cyclodextrin solution (pH 3.0) at the concentration of 
2.5 mg/ml using 5% DMSO. Blood samples (500 µl) were collected from the cannulated 
carotid artery at 2, 15, 30, 60, 120 and 240 min after injection. Kidneys and urine (from 
urinary bladder) were collected at 240 min after sacrificing the animals. Serum was 
obtained by allowing the blood samples to stand for 1 hour on ice, after which the samples 
were centrifuged at 13,000 rpm for 5 min. Kidneys were homogenized in 0.1 M phosphate 
buffer saline (pH 7.2) in 1:3 w/v using ultra-turrax-T25 apparatus (20,000 rpm, 1 min). All 
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the samples were stored at -80°C until analysis of SB202190, as described above. 
Pharmacokinetic analysis of SB202190 concentrations in serum was performed using the 
Multifit program (Department of Pharmacokinetics and Drug Delivery, University of 
Groningen, The Netherlands). Goodness-of-fit was evaluated from visual inspection of the 
measured and calculated data points and of the residuals plotted against time and against 
concentration. The choice between one- and two-compartment models was based on the 
lowest value of the Akaike's Information Criterion (AIC). 
Results and Discussion 
Method Development 
In the present study, we have developed a straightforward and accurate HPLC method 
to detect SB202190 in serum, kidney homogenates and urine. The extracted samples of 
SB202190 along with the I.S. were successfully separated on a C8 analytical column. We 
tested several mobile phases at different pHs and found acetonitrile:water:trifluoroacetic 
acid (30:70:0.1 v/v/v; pH 2.0) as an appropriate mobile phase for the separation of the 
compounds within a run-time of 15 minutes. Both SB202190 and the I.S. were detected at 
350 nm in the acidic conditions of the eluent, which allowed the straightforward detection 
of these compounds in the reconstituted extracts from the biological matrixes. Typical 
HPLC chromatograms of SB202190 after extraction from spiked serum, kidney 
homogenate and urine are shown in Figure 2A-C, respectively. No interfering peaks of 
endogenous compounds were found at the retention times of SB202190 and the I.S.  
 Method Validation 
The average recoveries of SB202190 after the extraction procedure ranged from 74% 
from serum (0.25-5 µg/ml) and 75% from kidney homogenates (1-20 µg/g of tissue) to 92% 
from urine (1-20 µg/ml). In addition, the % recoveries of the I.S. in these matrixes were 
also found to be comparable with SB202190 (Table 1). A linear relationship was found 
between peak heights and drug concentrations within the ranges of 0.25 to 5 µg/ml for 
serum, 1 to 20 µg/g of tissue for kidney homogenate and 1 to 20 µg/ml for urine. The mean 
(±S.D.) regression equation for calibration curves in serum was (0.000221 ± 0.000011)C + 
(-0.0113 ± 0.0242), r2 = 0.9931 ± 0.0042. The mean (±S.D.) regression equations for 
calibration curves in kidney homogenates and urine were (0.0575 ± 0.00703)C + (0.00067 
± 0.0153), r2 = 0.9957 ± 0.0028 and (0.0749 ± 0.00363)C + (0.0144 ± 0.0187), r2 = 0.9988 
± 0.0019, respectively. The coefficient of variations of slope for SB202190 in serum, 
kidney homogenates and urine were found to be <15% which indicates a high precision of 
the assay. 
 The intra-day and inter-day variability of the assay for serum, kidney homogenates, 
urine are listed in Table 2, 3 and 4, respectively. Our data demonstrate that the method is 
reliable and reproducible since both %CV and %bias were below 15% for all estimated 
concentrations. In serum samples, a higher variation was observed in %CV at the higher 




concentrations. Similarly, the data of SB202190 extraction from serum in Table 1 show 
highest variability. The possible cause of the variation can be the less efficient extraction of 
SB202190 from the serum than from other samples. The variation might be reduced by 
adjusting the pH or diluting the samples with buffer to improve the extraction efficiency. 
The LLOD and LLOQ of SB202190 were found to be 0.1 and 0.25 µg/ml in serum, 0.4 and 
1 µg/g in kidneys and 0.5 and 1 µg/ml in urine, respectively. 
                 
     
Table 1 Recoveries of SB202190 and the I.S. from serum, kidney and urine samples after spiking the 
samples with several concentrations of the drug.  
Compound Serum Kidney Urine 
 µg/ml 
Recovery (%), 
mean ± S.D. 
(n = 6) 
µg/g 
Recovery (%), 
mean ± S.D. 
(n = 5) 
µg/ml 
Recovery (%), 
mean ± S.D. 
(n = 6) 
SB 202190 0.25 74.3 ± 15.6 1 76.67 ± 9.1 1 105 ± 8.6 
 1 77.1 ± 5.1 4 71.54 ± 5.1 5 88.1 ± 1.6 
 2 72.9 ± 14.9 8 80 ± 3.7 10 86.8 ± 2.9 
 5 71.4 ± 14.2 20 70 ± 4.2 20 86.5 ± 1.8 
       
I.S. 5 72.6 ± 9.5 20 83.3 ± 3.1 (n = 6) 20 101.7 ± 2.5 
Figure 2. Typical HPLC chromatograms of 
SB202190 after extraction from spiked rat 
serum (A), kidney homogenate (B) and urine 
(C). Upper lines in each figure represent 
spiked samples, while blank samples are 
shown at the bottom. Peaks of SB202190 
and the internal standard are indicated by SB 
and I.S., respectively. 
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Table 2 Intra-day and Inter-day precision and accuracy of SB202190 measurements in rat serum. 
Concentrations 
(µg/ml) Intra-day   Inter-day   
 
Mean ± S.D. 





Mean ± S.D. 





             0.25 (LLOQ) 0.25 ± 0.03 13.8 −0.30 0.27 ± 0.04 14.51 8.00 
1 1.06 ± 0.09 8.35 6.08 1.00 ± 0.10 9.61 −0.29 
2 1.90 ± 0.14 7.61 −5.08 2.09 ± 0.24 11.45 4.56 
5 4.50 ± 0.47 10.43 −9.92 4.73 ± 0.27 5.64 −5.36 
Table 3 Intra-day and Inter-day precision and accuracy of SB202190 measurements in kidney 
homogenates (per gram tissue). 
Concentrations 
(µg/g) 
Intra-day   Inter-day   
 Mean ± S.D. 




 (% bias) 
Mean ± S.D. 





              1 (LLOQ) 1.09 ± 0.08 7.74 9.21 1.11 ± 0.14 12.45 11.39 
4 4.08 ± 0.29 7.10 1.94 4.32 ± 0.29 6.64 7.95 
8 8.22 ± 0.27 3.23 2.77 8.51 ± 0.45 5.25 6.40 
20 19.89 ± 0.88 4.43 −0.53 19.85 ± 1.54 7.74 −0.75 
Table 4 Intra-day and Inter-day precision and accuracy of SB202190 in rat urine samples. 
Concentrations 
(µg/ml) Intra-day   Inter-day   
 
Mean ± S.D. 





Mean ± S.D. 





             1 (LLOQ) 1.05 ± 0.08 7.34 5.40 0.92 ± 0.07 7.79 −8.13 
5 4.77 ± 0.20 4.15 −4.54 4.99 ± 0.17 3.41 −0.13 
10 9.20 ± 0.23 2.51 −7.99 9.90 ± 0.41 4.18 −1.01 
20 18.69 ± 0.55 2.94 −6.56 19.39 ± 0.57 2.95 −3.06 
Stability studies 
The standards of SB202190 and I.S. were found be stable at room temperature since 
the % recoveries were 109% and 107%, respectively after 24 h. SB202190 was also found 
to be stable in serum and urine after three consecutive freeze-thaw cycles since the %CV 
and %bias were below ± 15% at both lower and higher concentrations (Table 5). However, 
we found rather lower recovery of SB202190 in kidney homogenate at 20 µg/g but there 
was no significant change after a single thaw. Therefore it is recommended that the kidney 
homogenate samples containing SB202190 should be stored in aliquots to avoid multiple 
freezing and thawing. After a long-term stability study, we found SB202190 was stable in 
all the matrices since the %CV and %bias were below ±15% for higher concentrations and 
below ±20% for lower concentrations (Table 5).  




Table 5 Stability of SB202190 in serum, kidney and urine after three freeze-thaw cycles of 24 h each 
and long-term storage.  
 µg/ml or µg/g Mean ± S.D. % CV % Bias 
Long-term 
stability     
 Serum (n = 3) 0.25 0.29 ± 0.01 4.49 16.2 
 5 4.89 ± 0.3 6.13 −2.14 
     
 Kidney (n = 3) 1 1.14 ± 0.19 17.6 11.4 
 20 18.6 ± 0.52 2.80 −7.12 
     
 Urine (n = 4) 1 1.0 ± 0.15 14.7 0.22 
 20 20.8 ± 1.41 6.78 3.92 
     
Three freeze–
thaw cycles     
 Serum (n = 3) 0.25 0.25 ± 0.02 9.62 −1.88 
 5 4.89 ± 0.48 9.76 2.29 
     
 Kidney (n = 4) 1 1.11 ± 0.17 15.2 10.9 
 20 16.9 ± 0.48 2.86 −15.3 
     
 Urine (n = 3) 1 0.96 ± 0.08 8.15 −4.22 
 20 18.0 ± 0.64 3.56 −9.97 
Pharmacokinetic study of SB202190 in rats 
We applied the method for a pharmacokinetic study in which SB202190 was 
administered to healthy rats. A representative chromatogram of SB202190 in serum of one 
of the animals is shown in Figure 3. After a single intravenous bolus injection of 5 mg/kg of 
SB202190, we monitored the drug concentrations in serum until 240 min after 
administration (Figure 4). One-compartment and two-compartment models were tested for 
the best-fit according to AIC. The calculated pharmacokinetic parameters are listed in Table 
6. Our experiments show that SB202190 is distributed rapidly over a large initial volume of 
distribution of 2002 ± 292 ml/kg and after which 50% of the compound is eliminated in 
approximately 50 min. These data are in good agreement with the pharmacokinetics study 
of SB203580, a p38 MAPK inhibitor which has a similar structure as SB202190 (9).  
 
Figure 3.  HPLC chromatogram of 
SB202190 (SB) and the internal standard 
(I.S.) obtained from the extracts of the serum 
collected from a rat at 15 min after the 
intravenous injection of SB202190 (5 
mg/kg). Internal standard (5 µg/ml) was 
added in the samples before extraction. 
Bioanalysis and Pharmacokineitcs of the p38 inhibitor SB202190 
 83 
We also monitored SB202190 concentration in kidneys and urine after sacrificing the 
animals, i.e. at 240 min after the administration of the compound. Drug levels in kidney and 
urine samples were found to be below LLOQ, while one rat had minor amounts of 
SB202190 in the urine, corresponding to less than 0.3% of the injected dose. These results 
indicate that SB202190 is not eliminated via the renal route. Most likely, this type of 
compounds is eliminated via the liver, either by metabolism or excretion into the bile.  
Table 6 Pharmacokinetic parameters (two-compartment model) derived from serum concentration-
time curves after a single intravenous dose of 5 mg/kg of SB202190 in rats. 
Parameters Values (mean ± S.E.) 
Vss (ml/kg) 4343 ± 400 
CL (ml/kg/min) 72.2 ± 4.2 
AUC(0−∞) (min µg/ml) 69.2 ± 4.0 
t1/2 α (min) 4.3 ± 1.7 
t1/2 β (min) 48.3 ± 6.8 
MRT (min) 60.1 ± 6.7 
Time (min)





















In future studies, we will investigate whether SB202190 can be delivered to the 
kidneys for the purpose of treating renal fibrosis. The present pharmacokinetic study with 
non-targeted SB202190 suggests that such a delivery strategy is required to achieve 
adequate renal concentrations of this drug. We have previously shown that the low 
molecular weight protein lysozyme can be applied as renal-specific drug carrier (10, 11), 
and we will employ this drug targeting approach for SB202190 using SB202190-lysozyme 
conjugates.  
Figure 4. Serum concentration- time 
disappearance curve of SB202190 in rats. 
Filled circles and the line depict the serum 
levels and the fitted pharmacokinetic data of 
SB202190, respectively. Data represent the 
mean ± standard deviation. 
Vss: volume of distribution at steady state 
level; CL: plasma clearance; AUC(0-∞): 
area under the curve from zero to infinity; 
t1/2 α: distribution half life; t1/2 β: 
elimination half life; MRT: mean residence 
time 





The present HPLC method provides a new simple, reproducible and validated assay for 
the determination of SB202190 in serum, kidney homogenate and urine. This HPLC 
method will help in performing future experiments with renal delivered SB202190. 
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During renal injury, activation of p38 MAPkinase in proximal tubular cells plays an 
important role in the inflammatory events that eventually lead to renal fibrosis. We 
hypothesized that local inhibition of p38 within these cells may be an interesting approach 
for the treatment of renal fibrosis. To effectuate this, we developed a renal specific 
conjugate of the p38 inhibitor SB202190 and the carrier lysozyme. First, we demonstrated 
that SB202190 inhibited the expression of albumin−induced proinflammatory (MCP-1) and 
TGF-β1−induced profibrotic (procollagen−Iα1) genes over 50% in renal tubular cells 
(NRK-52E). Next, we conjugated SB202190 via a carbamate linkage to lysozyme. 
However, this conjugate rapidly released the drug upon incubation in serum. We therefore 
applied a new platinum(II) based linker approach, so-called Universal Linkage System 
(ULS™), which forms a coordinative bond with SB202190. SB202190-ULS-lysozyme 
remained stable in serum but released the drug in kidney homogenates. SB202190-ULS-
lysozyme accumulated efficiently in renal tubular cells and provided a local drug reservoir 
during a period of 3 days after a single i.v. injection. Treatment with SB202190-ULS-
lysozyme inhibited TGF-β1-induced gene expression for procollagen-Iα1 by 64% in HK-2 
cells. Lastly, we evaluated the efficacy of a single dose of the conjugate in the unilateral 
renal ischemia-reperfusion rat model. A reduction of intrarenal p38 phosphorylation and 
alpha-smooth muscle actin protein expression was observed 4 days after the ischemia-
reperfusion injury. In conclusion, we have developed a novel strategy for local delivery of 
the p38 MAPkinase inhibitor SB202190 which may be of use in the treatment of renal 
fibrosis. 
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Introduction 
Efficient treatment of renal fibrosis is one of the major challenges in the field of 
nephrology as there is a trend of a continuously increasing number of patients each year 
world wide (1). Current therapies such as inhibition of renin-angiotensin system 
components have yet not been able to prevent end-stage renal diseases, and therefore more 
specific approaches are required. It has been described that renal tubular cells play a pivotal 
role in the initiation of inflammatory processes leading to interstitial fibrosis (2). During a 
renal insult, tubular cells are activated by various stimuli such as filtered proteins, cytokines 
or hypoxia, upon which they produce several proinflammatory chemotactic factors (MCP-1 
and RANTES) and profibrotic factors (TGF-β1) (3-6). These factors further activate tubular 
cells, macrophages and fibroblasts. P38 mitogen−activated protein kinase (MAPK) plays a 
crucial role in the activation of tubular cells and in the secretion of various cytokines from 
tubular cells (7). Therefore, blockade of p38 in tubular cells may be valuable for the 
treatment of renal injuries. The beneficial role of p38 inhibitors has been demonstrated for 
the treatment of renal injuries (8,9). However, tubular cell−specific effects were not 
delineated and relatively high doses were required to achieve a therapeutic effect. 
Moreover, several clinical trials showed that p38 inhibitors exerted various side effects in 
other organs, such as immunosuppression, as reviewed (10). Such a systemic 
immunosuppressive effect of a drug against renal fibrosis is unfavorable. We therefore 
hypothesized that renal specific drug delivery can greatly improve the therapeutic profile of 
p38 MAPkinase inhibitors for renal disorders.   
Target-cell specific drug delivery is an attractive approach to investigate the cell-
specific effects of drugs, as it can avoid interactions with non-targeted cells in other organs 
and thereby decrease side-effects. Furthermore, drug delivery can augment local drugs 
levels at the target site, thereby improving therapeutic efficacy. We have gathered unique 
expertise in delivering the drugs to the kidneys using the low molecular weight protein 
lysozyme (LZM) as drug carrier (11). We now propose to utilize drug-LZM conjugates for 
the delivery of antifibrotic kinase inhibitors. Recently, we evaluated the pharmacokinetics 
of the well-known p38 inhibitor SB202190 (4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-
pyridyl)1H-imidazole) and demonstrated that it distributed poorly to the kidneys (12). This 
result underscored the need for drug delivery of this type of hydrophobic compounds to 
achieve appropriate drug levels in the kidney, which predominantly accumulates 
hydrophilic compounds.  
Although SB202190 has been used extensively as model compound for p38 inhibition, 
only a few studies report its use in renal tubular cells, e.g. after activating them with 
angiotensin II and insulin (13,14). In these studies, SB202190 reduced angiotensin II-
induced apoptosis in tubular cells but did not alter the effect of insulin in these cells. In the 
present study, we therefore first evaluated the effect of SB202190 on fibrotic signaling 
cascades in renal tubular cells. Furthermore, we conjugated SB202190 to LZM via two 




different strategies: we conjugated the drug via a carbamate linkage which appeared 
suitable for the hydroxyl group of SB202190 and we employed a new platinum-based 
linkage system called Universal Linkage System (ULS™) to couple the drug via a 
coordinative bond at its pyridinyl group. The latter coupling strategy offers advantages with 
respect to the synthesis and stability of the constructs. Since platinum compounds are 
known to produce nephrotoxicity (15,16), we investigated the SB202190-ULS-LZM 
conjugate (further referred to as SB-ULS-LZM) for cytotoxicity in renal tubular cells in cell 
cultures and in vivo. In addition, we investigated the drug release profile of the SB-LZM 
conjugates in vitro and evaluated the pharmacokinetics of SB-ULS-LZM in normal rats. 
Lastly, we tested the capability of SB-ULS-LZM to interfere with fibrotic signaling events 
in human renal tubular cells in vitro and in the unilateral ischemia-reperfusion renal injury 
model in vivo in rats.  
Materials and Methods 
Cells and Animals 
NRK-52E (normal rat kidney) cells were kindly provided by Prof. Russel, University 
of Nijmegen, The Netherlands. Cells were cultured in DMEM medium (BioWhittaker, 
Verviers, Belgium) supplemented with 5% fetal calf serum (FCS, BioWhittaker), 4 mM L-
glutamine, penicillin (50 units/ml) and streptomycin (50 ng/ml). Human kidney tubular 
cells (HK-2) were obtained from ATCC (Manassas, VA) and grown in RPMI-1640 medium 
supplemented with 10% FCS, 2 mM L-glutamine, penicillin (100 units/ml) and 
streptomycin (100 ng/ml). Human recombinant TGF-β1 was purchased from Roche 
Diagnostics, Mannheim, Germany.  
All experimental protocols for animal studies were approved by the Animal Ethics 
Committee of the University of Groningen. Normal male Wistar rats (220-240 g) were 
obtained from Harlan (Zeist, The Netherlands). 
Determination of mRNA expression 
After the treatments (as described in the legends of the figures), cells were harvested 
using lysis buffer and total RNA was isolated from the cells using Stratagene Microkit 
(Stratagene, La Jolla, CA). RNA content was measured by a nanodrop UV-detector 
(NanoDrop Technologies, Wilmington, DE). cDNA was synthesized from the similar 
amount of RNA using the Superscript III first strand synthesis kit (Invitrogen, Carlsbad, 
CA). Gene expression levels for the following genes were measured by quantitative real-
time RT-PCR (Applied Biosystems., Foster City, CA). The primers for rat species were 
obtained from Sigma-Genosys (Haverhill, UK) as follows: monocyte chemoattractant 
protein-1 (MCP-1; 5'-TCCTCCACCACTATGCAGGT-3' and 5'-
TTCCTTATTGGGGTCAGCAC-3', 255 bp), tissue inhibitor of metalloproteinase-1 
(TIMP-1; 5′-GAGAGCCTCTGTGGATATGT-3′ and 5′-CAGCCAGCACTATAGGTCTT-
3′, 334 bp), procollagen-Iα1 (5′-AGCCTGAGCCAGCAGATTGA-3′ and 5′-
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CCAGGTTGCAGCCTTGGTTA-3′, 145 bp) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH; 5′-CGCTGGTGCTGAGTATGTCG-3′ and 5′-
CTGTGGTCATGAGCCCTTCC-3′, 179 bp). The Taqman primers for Human species 
were obtained from Applied Biosystems (Assay−On−Demand). 
For NRK-52E cells, SYBR® Green PCR Master Mix (Applied Biosystems, 
Warrington, UK) was used as a fluorescent probe for real-time RT-PCR. For each sample, 1 
µl of cDNA was mixed with 0.4 µl of each gene-specific primer (50 µM), 0.8 µl DMSO, 
8.4 µl water and 10 µl SYBR Green PCR Master Mix. For HK-2 cells, qPCR™ Mastermix 
Plus (Eurogentec, Seraing, Belgium) was used as a fluorescent probe for real-time RT-PCR. 
For each sample, 1.25 µl of cDNA was mixed with 0.5 µl of each gene-specific primer, 4.5 
µl water and 5 µl qPCR™ Mastermix Plus. The cDNA amplification was performed until 
40 cycles. Finally, the threshold cycle number (Ct) was calculated for each gene and 
relative gene expressions were calculated after normalizing for the expression of the control 
gene GAPDH. 
Synthesis of SB-carbamate-LZM 
SB201290 (3 µmol, L.C. Laboratories, Woburn, MA)) was reacted with N-
succinimidyl-N-boc-ethylenediamine (NSED, 90 µmol, Sigma, St. Louis, MO) in 
dichloromethane in the presence of tributylamine (60 µmol) with stirring for 24 hours at 
room temperature. After completion of the reaction, as demonstrated by thin layer 
chromatography (silica plates, ethylacetate: acetone, 1:1 v/v) the intermediate product was 
purified on preparative silica TLC and characterized by electronspray ionization mass 
spectrometry (ESI-MS) and HPLC analysis. The boc−group was removed by incubating 
with 10 % trifluoroacetic acid for 1 h. Following evaporation of the acid under reduced 
pressure, the deprotected amine (3 µmol) was then reacted with 
γ−maleimidobutyryloxysuccinimide ester (GMBS, 2.7 µmol, Sigma) in dimethylformamide 
(DMF) and dichloromethane (1:1) for 1 h in the presence of tributylamine (42 µmol). The 
product was evaluated by ESI-MS and HPLC analysis. Total amount of SB202190-
carbamate product was calculated by estimating SB202190 with HPLC analysis by 
detaching it in strong basic condition.   
To introduce thiol groups that can be reacted with the maleimidyl group of the 
SB202190-carbamate adduct, egg-white LZM (1.4 µmol, Sigma) was modified with N-
Succinimidyl-S-acetylthioacetate (2.1 µmol, Sigma) in 0.1 M PBS for 1 h. The product was 
dialysed against phosphate buffered saline (PBS, pH 7.4) for 24 h and the purified product 
was treated with 0.1 M hydroxylamine and ethylenediaminetetraacetic acid mixture to 
deprotect the thiol group.  The SB202190-carbamate product (2.8 µmol) dissolved in DMF 
was slowly added to the solution of LZM−SH (1.4 µmol) in PBS (pH 7.4) and reacted for 2 
hours at room temperature. The final product was dialyzed against water, filtered with 0.2 
µm syringe filter, lyophilized and stored at -20°C. The conjugate was characterized by ESI-
MS analysis for the whole conjugate and by HPLC analysis for SB202190, as described 




earlier (12). For this latter analysis, the coupled drug was released by incubating with 0.5 M 
NaOH at 37°C for 24 h.  
Synthesis of SB-ULS-LZM 
Synthesis of SB202190-ULS  
SB202190 was coupled with ULS in 1:1 molar ratio. Cis-[Pt(ethylenediamine)nitrate-
chloride] (ULS; 5.2 µmol) was added to SB202190 (5.4 µmol, 10 mg/ml in DMF) and 
heated at 37oC for 3 h. The reaction mixture then was evaporated to dryness under reduced 
pressure, affording a pale yellow solid (yield 92%) that was analyzed by HPLC, 1HNMR 
and ESI-MS, These analyses confirmed the 1:1 coupling ratio of drug and linker.  
1H NMR of free SB202190 (CD3OD): δH 6.88 (d, J = 8.74 Hz, 2H, F(CHCH)2), 7.17 
(m, 2H, N(CHCH)2), 7.50 (m, 4H, (CHCH)2OH), 7.82 (d, J = 8.68 Hz, 2H, F(CHCH)2), 
8.41 (m, 2H, N(CHCH)2) ppm.   
1H NMR of SB202190-[Pt(ethylenediamine)dichloride] (CD3OD): δH 2.59 (m, 4H, 
H2N(CH2)2NH2), 5.58 (s, 2H, NH2), 5.91 (s, 2H, NH2), 6.89 (d, J = 8.75 Hz, 2H, 
F(CHCH)2), 7.22 (m, 2H, N(CHCH)2), 7.53 (m, 4H, (CHCH)2OH), 7.82 (d, J = 8.73 Hz, 
2H, F(CHCH)2), 8.52 (m, 2H, N(CHCH)2) ppm.   
MS (ESI+) m/z: 622 [M+H]+, 585 [M-Cl--H+]+. 
Synthesis of SB-ULS-LZM 
Drug-ULS adducts react readily with thiol groups of methionine and cysteine residues 
at 37°C, as has been demonstrated with albumin carrier proteins (17). Pilot experiment 
showed that LZM did not react readily with fluorescein-ULS (data not shown), presumably 
because the methionine residues and disulfide bridges are buried in the core of the protein. 
We therefore introduced additional methionine residues onto the protein surface by 
chemical derivatization of lysyl residues. Boc-L-methionine hydroxysuccinimide ester 
(0.84 µmol, Fluka, Germany) was dissolved in dimethyl sulfoxide and added to LZM (0.7 
µmol, 10 mg/ml in 0.1 M sodium bicarbonate buffer, pH 8.5). The mixture was stirred for 1 
h at room temperature. The product was dialyzed against water for 48 h, filtered through 
0.2-µm membrane filter, lyophilized and characterized by ESI-MS analysis. Methionine-
LZM was further reacted with SB202190-ULS to obtain the final SB-ULS-LZM conjugate. 
SB202190-ULS (2.1 µmol) in DMF was added to methionine-LZM (0.7 µmol) dissolved in 
ULS labeling buffer (20 mM tricine/NaNO3 buffer pH 8.5). The mixture was reacted at 
37°C for 24 h, after which the product was dialyzed against water for 48 h, filtered, 
lyophilized and stored at -20°C. ESI-MS and HPLC analysis of the coupled SB202190 
were performed to confirm the composition of the SB-ULS-LZM conjugate. The 
conjugated drug was determined after releasing the drug from the SB-ULS-LZM conjugate 
by competitive displacement with an excess of thiocyanate, which is an excellent ligand for 
platinum-coordination. In brief, appropriate aliquots of the conjugate (0.2 mg/ml in PBS) 
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were incubated with 0.5 M potassium thiocyanate in PBS at 80°C for 24. The released 
SB202190 was estimated by HPLC as described before (12). Free drug levels in the 
preparation were also investigated by HPLC analysis of freshly prepared appropriate 
dilutions of the conjugate in PBS.  
Stability of the conjugates 
Drug–free serum and kidneys were obtained from healthy male Wistar rats. Kidney 
homogenates were prepared in PBS (pH 7.4) or sodium acetate buffer (pH 5.0) in 1:3 w/v 
using an Ultra-Turrax-T25 apparatus (IKA, Stauffen, Germany) at the highest speed. All 
matrices were kept on ice before incubation with the conjugate. SB-carbamate-LZM was 
incubated with PBS, serum and kidney homogenates (pH 7.4 and pH 5.0) whereas SB-
ULS-LZM was incubated in the conditions listed above and in 0.1 M sodium acetate buffer 
(pH 5.0), 5mM glutathione (GSH) in PBS, and kidney homogenates at pH 7.4 and pH 5.0. 
Incubations were performed at 37°C and 100 µl aliquots were taken at 2, 6 and 24 h, after 
which they were processed immediately for HPLC analysis of SB202190.  
Assessment of the toxicity of ULS conjugates 
We determined the platinum-related cellular toxicity of the SB-ULS adduct and its 
lysozyme conjugate in the renal tubular cell line NRK-52E. Cells were seeded at 104 
cells/well in 96-well plates in culture medium (200 µl). After 24 h of incubation, medium 
was replaced by medium containing different dilutions of cisplatin or the ULS−containing 
compounds. Plates were incubated for 24 h, after which cell viability was assessed by 
Alamar Blue assay (Serotec, Oxford, UK).  
Pharmacokinetics of SB-ULS-LZM 
Rats (n=11) were injected with a single dose of the SB-ULS-LZM conjugate (16 mg/kg 
equivalent to 376 µg/kg of SB202190, dissolved in 5% glucose) that was administered 
intravenously through the penile vein under inhalation anesthesia. Animals were placed 
back into metabolic cages to collect urine, which was combined with urine collected from 
the urinary bladder after sacrificing the animals. At each indicated time point except 24 h 
(n=2), a single animal was sacrificed. This procedure was chosen to characterize the 
pharmacokinetics of the compounds, allowing multicompartmental curve-fitting (see 
below). At 5, 15 min, and 1, 2, 6, 12, 24, 36, 48 and 72 h, animals were anesthetized and 
blood samples were collected by heart puncture and kidneys were isolated after gently 
flushing the organs with saline. Kidneys were weighed and half of the kidney was 
homogenized (1:3 w/v, PBS) which was stored at -80°C. Released drug amounts were 
estimated by HPLC analysis after extraction as described above. To estimate total drug 
(bound plus released), samples were treated with potassium thiocyanate to release 
SB202190 from the ULS linker as described above and then subjected to HPLC analysis. 
Anti-LZM immunohistochemical staining was performed on frozen kidney sections to 
detect the renal uptake of the conjugate.  




In vivo toxicity of ULS after administration of SB-ULS-LZM was assessed in the same 
animals as used for the pharmacokinetic study, and compared to untreated animals (n=4) 
and to the animals treated with a dose of cisplatin (3 mg/kg, i.v., n=4) for 24 h. This dose of 
cisplatin is 8-fold higher than the amount of platinum in the SB-ULS-LZM conjugate. To 
examine the effect on the renal function, serum and urine creatinine levels were determined 
to calculate creatinine clearance. In case of SB-ULS-LZM treated animals, creatinine 
clearance at 24, 32, 48 and 72 h was calculated from serum and urine samples collected at 
the latest 24 h before sacrificing the animals. To calculate proteinuria for the SB-ULS-LZM 
group, the mean of the urinary protein levels at different days was taken. TUNEL staining 
and Masson staining were performed on kidney cryostat sections to examine the number of 
apoptotic cells and changes in renal morphology. In addition, we determined the platinum 
levels in kidneys using Inductively Coupled Plasma−Atomic Absorption Spectrometry 
(ICP-AAS) after digestion of the tissue in concentrated nitric acid for 24 h at room 
temperature and heating at 70°C until the formation of clear solution.  
Efficacy of SB-ULS-LZM in unilateral ischemia-reperfusion (I/R) rats  
The pharmacological efficacy of SB-ULS-LZM was evaluated in the unilateral 
ischemia-reperfusion (I/R) rat model. At 2 h prior to the ischemia procedure, rats were 
injected with SB-ULS-LZM (32 mg/kg of conjugate, equivalent to 752 µg/kg SB202190; 
n=6), vehicle (5% glucose; n=6), or free SB202190 (800 µg/kg; n=3). SB-ULS-LZM was 
dissolved in 5 % glucose whereas SB202190 was dissolved in 20 % hydroxypropyl-β-
cyclodextrin solution with 5 % DMSO as described earlier (12). Compounds were 
administered intravenously via the penis vein as described above. Animals were allowed to 
recover and placed back into the cages until the induction of renal ischemia. Rats were 
operated and the renal artery and vein were clamped under microscope to stop renal blood 
flow. After 45 min, clamps were removed and reperfusion of the kidney was observed 
before closing of the wound. Sham-operated animals (n=3) received the same surgical 
procedure except ischemia, were included as a control group. After 4 days, animals were 
sacrificed and blood samples were collected from the abdominal aorta. Kidneys were 
isolated after gently flushing the organs with saline and preserved in 4 % formalin for 
preparation of paraffin−embedded sections, or frozen in icecold isopentane for preparation 
of cryosections.  
Histological and Immunohistochemical analyses  
Kidney cryostat sections were used for immunohistochemical detection of LZM, α-
SMA, TUNEL positive cells and for Masson staining. Cryostat sections of 4-µm thickness 
were fixed with acetone and incubated with rabbit anti-LZM polyclonal IgG (dilution 
1:500, Chemicon, Temecula, CA) or anti-α-SMA monoclonal IgG (dilution 1:500, Sigma) 
for 1 h at room temperature. After washing with PBS, sections were incubated with 
hydrogen peroxide (0.07 % in PBS) to inactivate endogenous peroxidase activity and 
subsequently incubated with goat anti-rabbit or rabbit anti-mouse horseradish peroxide 
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conjugated antibodies (dilution 1:50, Dako, Denmark) for 20 min. Peroxidase activity was 
visualized with 3-amino-9-ethylcarbazole as red color. Sections were counter-stained with 
hematoxylin and mounted with Kaiser’s glycerin gelatin solution. TUNEL staining 
(TUNEL Pod Kit, Roche Diagnostics) was performed according to the supplier’s protocol. 
Positively stained cells were counted in 10 different fields (magnification, 200×) of kidney 
cortex region using NIH Image J software. Masson staining was performed according to 
standard protocols. 
Anti-p-p38 immunohistochemical staining was performed on 3-µm thick 
paraffin−embedded sections. Sections were deparaffinized in xylene and rehydrated in 
alcohol and distilled water. To retrieve antigen, sections were boiled in 10 mM citrate 
buffer pH 6.0 for 10 min in microwave and cooled down. Then, sections were incubated 
with 3 % hydrogen peroxide for 10 min. After washing in distilled water, sections were 
blocked with 1% BSA for 1 h and incubated with rabbit anti-p-p38 monoclonal IgG 
(Dilution 1:100, Cell signaling, Danvers, MA) overnight at 4°C. After washing 3 times with 
Tris−buffered saline (pH 7.6), section were incubated with secondary goat-anti-rabbit 
antibody and subsequently with rabbit-anti-goat hydrogen peroxidase, Dako, Denmark, 
each for 20 min. Finally, staining was developed with 3,3'diaminobenzidine 
tetrahydrochloride (DAB).  
Semi-quantification of α-SMA and p-p38 immunohistochemical staining was 
performed by two independent observer in a double-blind manner. Each section was scored 
as following: −, negative; −/+, faint staining; +, occasional positive; ++, strong; +++, 
abundant staining.  
Statistical analysis 
The statistical analyses were performed using Student’s t-test with p<0.05 as the 
minimal level of significance. Results are presented as mean ± standard error of the mean. 
Pharmacokinetic analysis of the plasma SB202190 concentrations was performed using the 
Multifit program (Department of Pharmacokinetics and Drug Delivery, University of 
Groningen, The Netherlands).  
Results 
Effect of SB202190 on fibrotic signaling in renal tubular cells 
To investigate the effect of SB202190 on pro-inflammatory and pro-fibrotic signaling 
cascades in renal tubular cells, we activated NRK-52E cells with either bovine serum 
albumin (BSA, 30 mg/ml) or TGF-β1 (10 ng/ml). Albumin stimulated the gene expression 
of the inflammation marker MCP-1 over 30-fold, which in turn could be reduced by 55% 
after p38 inhibition (Fig. 1A). Furthermore, BSA enhanced the gene-expressions of TIMP-1 
significantly, while procollagen−Iα1 was not elevated significantly (Fig. 1B-C). Treatment 
with SB202190 reduced the expression of these genes to levels below basal expression, as 




was also observed for non-activated cells that were treated with the drug. Similarly TGF-β1 
also induced the gene expression of procollagen−Iα1 and TIMP-1 significantly in 24 h and, 
treatment with SB202190 inhibited the gene expression of all the genes significantly (Fig. 
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Figure 1. Effects of SB202190 on albumin or TGF-β1 induced gene expressions of MCP-1 (A), 
procollagen-Iα1 (B) and TIMP-1 (C) in NRK-52E cells. Cells were grown to 80% confluency in 12-
well plates and then deprived from serum for 24 h. Thereafter the cells were preincubated for 2 h with 
SB202190 (10 µM) and then activated with either BSA (30 mg/ml) or TGF-β1 (10 ng/ml) for 24 h. 
After that, cells were harvested for RNA isolation. The mRNA expressions were determined by 
quantitative RT-PCR. Data represent the mean ± SEM for at least 3 independent experiments. 
Differences versus control are presented as †p<0.05, ††p<0.01 and †††p<0.001. Other differences are 
*p<0.05, **p<0.01, ***p<0.001. 
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Synthesis and characterization of SB202190-LZM conjugates 
SB-carbamate-LZM conjugate (Fig. 2A) 
SB202190 was converted to SB202190-NSED with an overall yield of 88% after 
purification, as estimated by HPLC analysis. Next, SB202190-NSED was reacted with 
GMBS and provided the SB202190-carbamate linker adduct at 90% yield. SB202190-
carbamate was reacted to thiol-modified LZM which produced a SB-carbamate-LZM 
conjugate with an average drug/carrier ratio of 0.7:1, as characterized by mass spectrometry 
of the whole conjugate and by HPLC analysis of the coupled drug.  
SB-ULS-LZM conjugate (Fig. 2B) 
SB202190 was efficiently coupled with ULS yielding the drug-ULS 1:1 adduct at an 
overall yield of 92%. The identity of the product was confirmed by HPLC, 1HNMR and 
ESI-MS. 1H NMR and Pt-NMR studies indicated that SB202190 was coordinated to ULS at 
the pyridinyl nitrogen of the drug. The resulting methionine-LZM carrier was 
straightforwardly converted in the SB-ULS-LZM product by incubating with drug-ULS 
overnight. The final product was characterized by mass spectrometry of the whole 
conjugate and by HPLC analysis of the coupled drug, confirming 1:1 drug to protein 
coupling.  
In an ideal drug delivery conjugate, the drug-carrier linkage should be stable during 
storage and in the systemic circulation in order to reach the target cells intactly. In addition, 
the linkage should display an appropriate drug−release profile once the conjugate has been 
accumulated in target cells, to provide the pharmacologically active compound. Fig. 3A and 
3B show the drug−release profile of the SB-carbamate-LZM and SB-ULS-LZM conjugates, 
respectively. A clear difference was observed in the stability of the two types of conjugates. 
SB-carbamate-LZM was unstable in PBS and even more unstable in serum whereas SB-
ULS-LZM conjugate remained stable in both media. In kidney homogenate, the target 
tissue of the constructs, both conjugates displayed gradual release of the drug at pH 7.4, but 
at pH 5.0 only SB-ULS-LZM did release the drug (Fig. 3A and 3B). Since the constructs 
are taken up via endocytosis and drug release should occur in lysosomes (pH 5.0) this is 
quite relevant. In vivo, endogenous compounds such as GSH can bind to platinum and 
thereby displace the drug. We found that SB-ULS-LZM released the drug maximally at 2 h 
after incubating with GSH and no further release occurred until 24 h. Based on the release 
profile in serum and kidney homogenates, we decided to pursue our study with SB-ULS-
LZM.  
Toxicity of platinum containing compounds in tubular cells 
The effect of ULS on viability of renal tubular epithelial cells (NRK-52E) was 
compared with an equimolar concentration of the well-known cytostatic drug cisplatin. 
ULS showed no effect on the viability of the cells at the concentration of 100 µM, whereas 
cisplatin caused a significant reduction of the number of viable cells (Fig. 4A). We also 




tested the drug-ULS and drug-ULS-LZM constructs and found them non-toxic in 






































































































Figure 2. Synthesis scheme of SB-carbamate-LZM (A) and SB-ULS-LZM conjugates (B). Large 
filled circles represent LZM. NSED, N-succinimidyl-N-boc-ethylenediamine; TFA, trifluoroacetic 
acid; GMBS, γ−maleimidobutyryloxysuccinimide ester; SATA, N-Succinimidyl-S-acetylthioacetate; 
ULS, Universal Linkage System. 
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Figure 3. Release of SB202190 from SB-carbamate-LZM (A) and SB-ULS-LZM (B) in different 
conditions. The experiment was performed in triplicate, mean ± SEM. 
Pharmacokinetics of SB-ULS-LZM conjugate 
In prior studies with other drug-LZM conjugates, we observed a rapid renal 
accumulation of these products after intravenous administration (18).  We used this 
knowledge to design a protocol for the pharmacokinetic studies with SB-ULS-LZM that 
allowed optimal estimation of the pharmacokinetic parameters. In such a so-called optimal 
sampling protocol, the data are fitted to a non-linear multi-compartment model (Multifit 
program). The serum-disappearance curve of SB-ULS-LZM, which followed a two-
compartment pharmacokinetic model, is shown in Fig. 5. Since we sacrificed the individual 
animals at different time points rather than at fixed moments in time, calculated parameters 
are less prone to extrapolation and are consequently more reliable (Table 1). Only 
carrier−bound SB202190 was detected in the serum, while free drug was absent at all time 
points. From this result, we concluded that the conjugate remained stable in the serum. 
Furthermore, in accordance to other drug-LZM conjugates, SB-ULS-LZM accumulated 
efficiently in the kidneys within 1 h following the intravenous injection (Fig. 6A). The 
accumulation of the conjugate in proximal tubular cells was confirmed by anti-LZM 
immunohistochemical staining on kidney sections (Fig. 6C-D). In parallel with the 
accumulation of ULS-bound drug, we observed continuous levels of free SB202190 in the 
kidneys at all time points starting from 1 h after dosing until the last sampling point, 3 days 
after injection (Fig. 6A). Prior studies in our group had demonstrated that free SB202190 
does not accumulate in the kidneys upon intravenous administration (12). Therefore, the 
presence of free drug in the kidneys predominantly reflects the continuous local release of 
SB202190 from the conjugate within the kidneys.  




Apart from serum and kidneys, we analyzed liver samples for the presence of the 
conjugate. Although bound drug was detectable in liver homogenates, no free drug was 
detected (data not shown). Furthermore, we investigated the excretion of the drug into the 
urine that was collected during the experimental period in metabolic cages. We observed a 
prolonged and continuous excretion of both free SB20190 and linker−bound drug which 
corresponded to the continuous release profile in the kidneys (Fig. 7).  
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Figure 4. Comparison of cellular toxicity of different platinum containing compounds on renal 
tubular cells (NRK-52E). Cells were incubated for 24h with indicated  compounds, after which cell 
viability was determined by the Alamar blue assay. Concentrations tested corresponded to 10 and 100 
µM platinum, or were equivalent to the amount of drug (SB202190) or protein (LZM). Data represent 
the mean ± SEM for 3 independent experiments. **p<0.01. 
Time (h)




















Nephrotoxicity is one of the most prominent side-effects of cisplatin treatment, and is 
mostly associated with acute toxicity to renal tubular cells (19). Thus, administration of a 
platinum-containing compound that efficiently accumulates in the proximal tubule may 
induce unwanted nephrotoxicity. We therefore closely examined the animals during the 
pharmacokinetic study and observed no apparent discomfort up to 72h. Furthermore, we 
Figure 5. Serum disappearance curve of SB-
ULS-LZM. Symbols represent the % dose of 
SB202190 at each time point; the continuous 
line represents the pharmacokinetic data-fit 
curve (two-compartment model). 
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determined renal function and other parameters to determine platinum−related toxicities 
(Table 2). Creatinine clearance remained normal in animals receiving vehicle or conjugate 
while an increase in urinary protein levels was found with SB-ULS-LZM in comparison to 
untreated rats. However, the observed value of the conjugate−treated group was well within 
normal limits. Second, we detected tubular damage by TUNEL staining on kidney sections, 
which clearly demonstrated that cisplatin-treated animals had higher apoptotic tubular cells 
as compared to untreated rats. In contrast, SB-ULS-LZM−treated rats showed no increase 
in the number of apoptotic cells, despite the comparable levels of platinum in the kidneys of 
cisplatin and SB-ULS-LZM−treated groups. Morphological analysis of kidney sections 
using Masson staining showed no renal damage by SB-ULS-LZM treatment in comparison 
to control animals (Fig. 6E-G). Nephrotoxicity by cisplatin treatment was furthermore 
associated with a loss of body weight, while SB-ULS-LZM treated rats showed a constant 
body weight during the experiment for 3 days. From these results, we concluded that the 
pharmacological and toxicological behavior of the linker ULS is quite different from those 
of the cytostatic agent cisplatin.  
Table 1 Pharmacokinetic parameters (two-compartment model) derived from serum concentration-
time curves after a single intravenous dose of 16 mg/kg (equivalent to 376 µg/kg SB202190) of SB-
ULS-LZM in rats. 
Parameters units 
Values 
(mean ± SE) 
V1 ml/kg 101 ± 18 
CLini ml/kg/h 149 ± 28 
CL ml/kg/h 24.0 ± 1.5 
AUC(0-∞) h.µg/ml 15.6 ± 1.0 
t1/2 α h 0.41 ± 0.1 
t1/2 β h 18.7 ± 1.8 
V1, volume of central compartment; CLini, sum of elimination and distribution clearance from central 
compartment; CL, Total serum clearance; AUC(0-∞), area under the curve from zero to infinity; t1/2 α, 
distribution half life; t1/2 β, elimination half life 
Effect of SB-ULS-LZM conjugate in HK-2 cells 
The potential therapeutic effect of SB-ULS-LZM was evaluated in proximal tubular 
cell of human origin (HK-2 cells). Intracellular delivery of the conjugate is dependent on 
receptor-mediated endocytosis from the medium. The capability to internalize proteins is 
however rapidly lost in many kidney cell lines, which renders the conjugate ineffective in 
vitro, despite its efficient intratubular accumulation in vivo. HK-2 cells are known to 
internalize proteins (20) while the NRK-52E cells described earlier in this paper did not 
reabsorb LZM (data not shown). After incubation for 24 h with TGF-β1, we detected a 10-
fold higher gene expression for procollagen−Iα1 as compared to resting levels (Fig. 8). 




Treatment with SB-ULS-LZM conjugate for 48 h resulted in a significant reduction by 64% 
of the induced gene, as did the treatment with free SB202190 (10 µM). Treatment with the 
LZM carrier alone did not affect the TGF-β1−induced profibrotic signaling. From these 
results, we concluded that the conjugate was capable to deliver pharmacologically active 
drug into the designated target cells.  
Table 2.  Summary of the parameters to determine platinum−related nephrotoxicity in SB-ULS-LZM 
and cisplatin –treated animals.  






(ml/min) 1.0 ± 0.13 0.8 ± 0.03 1.1 ± 0.13 
Urinary protein levels 
(mg/d) 19.16 ± 1.3 29.6 ± 2.0
††
 
23 ± 3.6 
TUNEL positive cells 






N.D. 37.0 ± 1.2** 28.4 ± 0.8 
Change in body weight 
(%) -1.75 ± 2.25 +0.3 ± 1.2* -5.0 ± 0.6
††
 
Data for untreated and cisplatin groups are represented as mean ± SEM, n=4 at 24 h. The values for 
SB-ULS-LZM are shown as mean ± SEM, n=4 at 24, 32, 48 and 72 h except for TUNEL positive cells 
which is n=5 at 24 (n=2), 32, 48 and 72 h. The differences between cisplatin and SB-ULS-LZM 
groups are *p<0.05, **p<0.01. The differences versus untreated groups are †p<0.05, ††p<0.01. N.D., 
not detectable. 
Effect of SB-ULS-LZM conjugate in the I/R rat model 
The pharmacological efficacy of SB-ULS-LZM was evaluated in the renal I/R model 
which finally leads to fibrosis within a period of 1-4 days. Several studies have established 
the involvement of activated p38 in epithelial cells after I/R injury (21,22)  We 
hypothesized that a single dose of SB-ULS-LZM would afford sufficient amounts of active 
drug in the kidney due to its controlled drug release profile, as shown in Fig 6A. The 
conjugate was administered 2 h before ischemia so that the conjugate could accumulate 
completely within the kidneys. First, we examined the activation of p38 MAPkinase in the 
kidney by immunostaining for p-p38 positive cells. Our results confirmed that p38 was still 
activated after 4 days of I/R injury as compared to sham-operated animals. Vehicle−treated 
I/R rats had dilated and damaged tubules that strongly showed p-p38 positive cells (grade 
+++) in both renal cortex and medulla as compared to sham-operated animals (grade −/+). 
In the cortex, neither of the treatments showed any reduction in p-p38 positive cells. 
However, treatment with SB-ULS-LZM reduced the number of p-p38 positive cells in the 
medulla (grade +, Fig. 9B) but no reduction was found in SB202190−treated animals (grade 
+++, Fig. 9C).  
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Figure 6. Renal levels of SB-ULS-LZM (A). Symbols represent the % dose of SB202190 at each 
time point and the continuous line represents the pharmacokinetic data-fit curve. The curve-fitting 
was performed with Multi-fit software by two-compartment model including peripheral drug levels. 
Anti-LZM immunohistochemical staining (B-D) on kidney sections. Untreated animals (B); SB-ULS-
LZM treated animals at 1 h (C, D). Arrows in C and D indicate the staining for lysozyme in tubular 
cells. Panel C (magnification 200×) shows accumulation of SB-ULS-LZM in kidneys, which 
appeared to be allocated within the tubular cells as observed at magnification 400× (D). Masson 
staining shows renal morphology in untreated animals (E) and SB-ULS-LZM treated animals at 24 h 
(F) and 72 h (G), at 200× magnification. There is no change in the morphology of the proximal 
tubular cells after 24 h (E vs. F) or 72 h (E vs. G) after administration of the conjugate. 
Moreover, to study the effect of SB-ULS-LZM conjugate on fibrosis, we investigated 
the renal deposition of the fibrosis marker α-SMA by immunohistochemical analysis. We 




found that after 4 days of I/R injury, α-SMA expression was highly increased in the 
tubulointerstitial space of the renal cortex (grade +++, Fig. 9D) in comparison to sham-
operated animals (grade −/+). A single dose of the SB-ULS-LZM conjugate reduced α-
SMA expression (grade ++, Fig. 9E) whereas non-targeted SB202190 did not affect the 
expression of α-SMA (grade +++, Fig. 9F).  
Discussion 
Data from the present study confirm that blockade of p38 MAPkinase within renal 
tubular cells diminishes the activation of inflammatory and fibrosis related genes, which 
may be important for the treatment of renal fibrosis. We also demonstrated that we can 
deliver the p38 inhibitor SB202190 to proximal tubular cells in the kidney, and that the 
conjugate has a unique slow release profile. Moreover, after only a single dose of the 
targeted SB-ULS-LZM conjugate showed modest beneficial effects in renal ischemia-
reperfusion (I/R) injured rats.  
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Low molecular weight proteins like LZM accumulate in the kidneys via megalin-
mediated endocytosis and can be exploited as renal-specific drug carriers (11). In the 
present study, we describe the successful coupling of SB202190 to LZM using two 
different linkage strategies, either employing a carbamate bond or a coordinative bond 
between drug and carrier. Our in vitro stability experiments demonstrated that the 
carbamate linkage was sensitive to serum enzymes, most likely esterases. As a 
consequence, free drug will be prematurely released before the SB-carbamate-LZM 
conjugate can reach the kidney. In contrast, the conjugate prepared with ULS displayed 
high stability in serum and exhibited a slow release of the drug in kidney homogenate. This 
slow release phenomenon can be explained by the ligand-exchange kinetics of platinum 
(23). Transition metals like platinum make coordination bonds with the ligands that are 
weaker than covalent bonds. However, the ligand-exchange behavior of platinum-
Figure 7. Urinary excretion rate of free and 
linker−bound SB202190 after administering 
the conjugate. Symbols represent the % 
dose/ 24h of SB202190 at each time point 
and the continuous line represents the fitted 
curve. 
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coordinated compounds is quite slow, which gives them a high kinetic stability (23). GSH is 
a likely candidate to act as an intracellular ligand (24). Efficient drug displacement by GSH 
was proven for the present SB-ULS-LZM conjugate when it was incubated at the 
intracellular concentration of 5 mM GSH. In addition, the drug release might also be 
facilitated by cellular enzymes since kidney homogenates at pH 7.4 containing cytosolic 
active enzymes or at pH 5 at which lysosomal enzymes are active released SB202190 from 
SB-ULS-LZM. Among others, lysosomal degradation of the LZM protein which generates 
methionine and cysteine residues may facilitate drug release. Other enzymes that may favor 
intracellular drug release are glutathione generation enzymes like thioredoxin and 
glutathione reductases. Based on stability and release characteristics which were favorable 
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Figure 8. Effects of SB202190 and SB-ULS-LZM on the gene expressions of procollagen-Iα1 
induced by TGF-β1 in HK-2 cells. Cells were grown to the 80% confluency and then deprived from 
serum for 24 h. The SB-ULS-LZM conjugate (SB-ULS-LZM, 155 µg/ml) or methionine-modified 
LZM (LZM, 155 µg/ml) were incubated at the time of serum deprivation whereas SB202190 (10 µM) 
was added 1 h before adding TGF-β1 (10 ng/ml) to the cells. The cells were further cultured for 24 h. 
Then cells were harvested for RNA isolation. The mRNA expressions were determined by 
quantitative RT-PCR. Data represent the mean ± SEM for at least 3 experiments. Differences versus 
control is presented as †††p<0.001. Other differences are **p<0.01. 
Although platinum-containing compounds such as cisplatin are considered nephrotoxic 
(15,16), ULS or SB-ULS constructs did not produce any toxicity to NRK-52E renal tubular 
cells even at high (100 µM) concentrations. Moreover, in vivo treatment with the SB-ULS-
LZM conjugate did not produce any toxicity since there was no effect on renal function, 
renal morphology and body weight until 72 h. In addition, no increase in the number of 




apoptotic cells was observed, indicating the safety of SB-ULS-LZM conjugate to the 
kidneys.  
The pharmacokinetic study indicated that SB-ULS-LZM was quickly removed from 
the general circulation and subsequently slowly eliminated from the renal tissue. The 
localization of the carrier protein in the tubular cells detected by anti-LZM staining 
confirms that the conjugate was reabsorbed in the tubular cells. Within these cells, the free 
drug was released from the conjugate almost at a constant rate during 72 h and 
subsequently excreted in urine. Since we found both free and linker-bound drug in the 
urine, it is apparent that a part of SB-ULS-LZM was not completely converted to the free 
drug. This suggests that the carrier protein in the conjugate was degraded by the lysosomal 
enzymes and released in the form of various products SB-ULS-X, in which X represents a 
thiol compound like methionine or any other moiety that can bind to platinum. 
Subsequently, SB-ULS-X released free SB202190 which was excreted in the urine and 
detected as a free drug, or SB-ULS-X might be eliminated by tubular cells intactly into the 
urine.  
 
Figure 9. Representative photomicrographs of the immunohistochemical detection of p-p38 positive 
cells in renal medulla (A-C; 200×) and α-SMA expression in renal cortex (D-F; 100×), 4 days after 
unilateral ischemia−reperfusion injury. Vehicle−treated animals (A, D); SB-ULS-LZM−treated 
animals (B, E); SB202190−treated animals (C, F). Arrows in panels A-C indicate the 
immunolocalization (dark brown color) of p-p38 positive nuclei in the tubular cells corresponding to 
the dilated and injured tubules. Arrows in panels D-F indicate the localization of α-SMA in 
tubulointerstitial space with red color. 
Our in vitro incubation of tubular cells with SB202190 demonstrated a reduction in the 
gene expressions of MCP-1, procollagen−Iα1 and TIMP-1, either induced by BSA or TGF-
β1. These genes are highly relevant since they are upregulated during renal fibrosis as 
demonstrated by many studies (25-27). The effect of SB202190 on albumin−induced 
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fibrotic markers was less strong than at TGF-β1 induced genes. This may be explained by 
the nature of albumin-induced gene expression in tubular cells, which causes the activation 
of several other signaling pathways apart from p38 MAPkinase (28,29). We examined the 
activity of the SB-ULS-LZM conjugate in HK-2 cells which are known for their capacity to 
internalize proteins via endocytosis (20). Incubation of the HK-2 cells with TGF-β1 
activated profibrotic signaling, which was substantially (64 %) reduced by preincubation 
with the SB-ULS-LZM conjugate. Since our in vitro stability studies had demonstrated that 
less than 10 % of the coupled drug was released in the cell culture medium, such an effect 
can only be effectuated after internalization and processing of the conjugate into active 
drug.  
We examined the efficacy of SB-ULS-LZM after renal I/R injury since p38 is activated 
in renal tubular cells after ischemia (21,22) and I/R injury finally leads to fibrosis (30). Our 
data on p-p38 staining confirmed that p38 is still activated in tubular cells 4 days after I/R 
injury and p-p38 positive cells were well-correlated with the injured tubules. Furthermore, 
we demonstrated that a single dose of SB-ULS-LZM was capable of lowering p38 
activation, which is in line with the continuous levels of free drug. A reduction in p-p38 
positive cells was only found in the renal medulla but not in the cortex, which is the 
primary site of proximal tubular cells. Either SB202190, released from the conjugate, 
redistributed from the cortical tubular cells to the medulla and exerted the effect over there 
or the effect in the cortex was not visualized due to the very high activation of p38 in the 
cortex. Most likely, the latter is the case because the expression of the fibrosis marker α-
SMA in the cortex was reduced. In contrast to SB-ULS-LZM, non-delivered SB202190 did 
not affect the expression of either p-p38 or α-SMA, presumably since the free drug is 
rapidly eliminated from the body and does not reach the kidney in high levels during the 
four-day period. Since we have administered similar amounts of SB202190 in either 
treatment group, we can attribute the improved efficacy of SB202190 to its renal delivery. 
Further studies are however needed to elucidate the mechanism of action of the conjugate, 
and how p38 activation in different cell types is involved.  
We conclude that p38 MAPkinase inhibition in proximal tubular cells is in potential an 
interesting approach to treat renal fibrosis. Such a strategy involves the development of a 
renal specific conjugate that can successfully deliver p38 MAPkinase inhibitors to the renal 
tubular in the kidney. Our new linkage technology ULS produced drug-LZM conjugates 
that display a sustained release of the drug in tubular cells for several days, which is an 
advantageous characteristic for drugs against chronic diseases. In addition, a large number 
of drugs containing nitro-aromatic rings such as pyridine, pyrimidine or imidazole groups 
(31,32), may be potential candidates for the ULS coupling approach. 
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During renal insult, transforming growth factor-beta (TGF-β) activates tubular 
epithelial cells and fibroblasts eventually leading to fibrosis. TGF-β acts through its type-I 
receptor known as Activin Receptor Like Kinase (ALK)-5. We hypothesized that local 
blockade of ALK5 within kidneys might be a promising approach for the treatment of renal 
fibrosis. We examined the efficacy of an ALK5 inhibitor (3-(Pyridin-2-yl)-4-(4-quinonyl)-
1H-pyrazole; TKI) in normal rat kidney-(52E) tubular cells. TKI significantly inhibited the 
expression of albumin-induced monocyte chemoattractant protein (MCP)-1, tissue inhibitor 
of metalloproteinase (TIMP)-1, and alpha-smooth muscle actin (α-SMA) genes and TGF-
β1-induced procollagen-Iα1 and TIMP-1 genes. To achieve tubular cell-specific delivery, 
we conjugated TKI to lysozyme (LZM) using the Universal Linkage System (ULS™). 
TKI-LZM showed its activity by inhibiting TGF-β1-induced procollagen-Iα1 gene 
expression in cultured human renal tubular cells. In vivo, after a single intravenous dose of 
TKI-LZM, it accumulated rapidly and provided a local depot for at least 3 days in tubular 
cells. We evaluated the efficacy of TKI-LZM in the unilateral ureteral obstruction model in 
rats. A single dose of TKI-LZM inhibited renal MCP-1 gene expression significantly after 3 
days. This was associated with a marked reduction in inflammatory macrophages and 
inhibition of the profibrotic marker α-SMA. In contrast, free drug did not alter MCP-1 gene 
expression, although it also diminished the influx of immune cells and α-SMA expression. 
We conclude that ALK5 is a promising target for intervention in renal fibrosis, and that 
renal delivery of an ALK5 inhibitor may serve as a novel therapeutic strategy in renal 
fibrosis.  
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Introduction 
Transforming growth factor−beta (TGF-β), a multifunctional cytokine, plays a crucial 
role in the pathogenesis of renal fibrosis (1). During renal injury, the active form of TGF-β 
is either locally produced by resident or infiltrated cells, or systemically derived. 
Irrespective of its source, TGF-β can activate tubular epithelial cells causing their 
transformation into fibroblasts through epithelial-mesenchymal transition (2). Eventually, 
resident and epithelial cells derived fibroblasts are transformed into myofibroblasts and 
produce extracellular matrix (ECM) proteins such as collagens (types I, III, IV, V and VI) 
and fibronectin (3). TGF-β binds to its type-II receptor, which subsequently associates with 
the type-I receptor known as Activin Receptor Like Kinase 5 (ALK5) (4). ALK5 activates 
downstream Smad and mitogen-activated protein kinase (MAPK) pathways. Both Smad 
and MAPK participate in the development of renal fibrosis by regulating ECM deposition 
(5). Blockade of ALK5 in renal tubular cells therefore seems an attractive therapeutic 
strategy to prevent or attenuate tubulointerstitial fibrosis.  
Recently, ALK5 inhibitors have been developed and evaluated for the inhibition of 
TGF-β action in various in vitro systems (6). These inhibitors bind to the ATP-binding 
pocket of the kinase domain of the TGF-β type I receptor and inhibit the subsequent 
activation of downstream pathways (6,7). Recent studies have demonstrated beneficial 
effects of ALK5 inhibitors on lung, kidney and liver fibrosis in animal models (8-10). 
However, relatively high and multiple doses had to be administered to achieve therapeutic 
effects. Moreover, systemic administration of an ALK5 inhibitor may elicit immunological 
side-effects, since TGF-β plays an essential role in immune tolerance via the regulation of 
lymphocyte proliferation and differentiation (11). Administration of TGF-β−inhibiting 
compounds is therefore not without risk of severe side effects and, the development of 
TGF-β blocking drugs has been a challenge for several decades. In order to minimize the 
side effects and enhance efficacy in target cells, we now aim at inhibiting TGF-β locally 
within the kidney.  
We have developed a renal drug delivery system which is also applicable to the 
presently studied class of kinase inhibitors (12,13). Using platinum-based linking 
technology, the so-called Universal Linkage System (ULS™), organic drug molecules are 
coupled to the renal carrier protein lysozyme (LZM), providing drug-LZM conjugates that 
accumulate efficiently in the kidneys (14). In the present study, we applied this technology 
to a TGF-β receptor Kinase Inhibitor (TKI) which inhibits ALK5 and several other kinases 
including p38 MAPkinase (6). We first evaluated the capacity of TKI to inhibit 
inflammatory and fibrotic signaling events in cultured renal tubular cells. Next, we 
conjugated TKI to LZM, characterized the obtained TKI-LZM conjugate in renal tubular 
cells and studied its pharmacokinetics in healthy rats. Finally, we evaluated the therapeutic 
potential of TKI-LZM in the unilateral ureteral obstruction (UUO) model for renal fibrosis.  




Materials and Methods 
The ALK5 inhibitor [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole, (TKI) was 
purchased from Calbiochem (Darmstadt, Germany). Human recombinant TGF-β1 was 
purchased from Roche Diagnostics, Mannheim, Germany. Rhodamine-ULS was purchased 
from Kreatech Biotechnology, Amsterdam, The Netherlands.  
Synthesis of TKI-ULS-lysozyme and Rhodamine-ULS-lysozyme 
TKI was conjugated to LZM using ULS via platinum coordinative linkages. Since 
drug-ULS adducts react readily with methionine residues, the renal carrier LZM was 
enriched with surface-exposed methionine groups as described before (14). A freshly 
prepared solution of ULS-mononitrate-monochloride (20.5 mM, dissolved in DMF) was 
added in an equimolar amount to TKI (9.98 mg, 36.6 µmol) and reacted at 37oC overnight. 
TKI-ULS product was characterized by HPLC, Pt-NMR and LC-MS analyses. 
TKI-LZM was synthesized by reacting TKI-ULS (3.5 µmol, 7 mg/ml) to methionine-
LZM (0.7 µmol, 10 mg/ml in 0.02 M tricine/sodium nitrate buffer, pH 8.5). ESI-MS 
analysis confirmed the formation of TKI-LZM conjugate. The amount of conjugated drug 
was quantified after displacing TKI using sodium dithiocarbamate (Merck, Darmstadt, 
Germany). TKI-LZM was also characterized for its stability and drug-release properties. 
TKI-LZM (100 µg/ml) was incubated in PBS, 5 mM glutathione (GSH) in PBS, or serum at 
37°C for 24h. Then, samples were immediately processed for HPLC analysis as described 
below.  
To synthesize Rhodamine-ULS-LZM, Rhodamine-ULS (2.1 µmol, in DMF) was 
reacted to methionine−LZM (0.7 µmol) and purified according to the same protocol as 
described for TKI-LZM. The eventually provided red−colored conjugate was characterized 
by ESI-MS.  
HPLC analysis of TKI 
TKI was analysed by reverse-phase HPLC on a Waters system (Waters, Milford, MA, 
USA). Separations were achieved with a C18 reversed-phase SunFire™ column (Waters). 
TKI was monitored at 320 nm after eluting with the mobile phase (water-acetonitrile-
trifluoroacetic acid, 91:09:0.1, v/v/v; pH 2.0). TKI eluted at the retention time of 5.8 min. 
The peak heights were measured to quantify the drug concentrations. To determine TKI in 
serum and urine samples, 100 µl of the sample was extracted with 3 ml of diethylether 
twice. After evaporating the organic layer, the residue was reconstituted in 100 µl of mobile 
phase and 25 µl of it was injected into HPLC. To estimate TKI in tissue homogenates, 100 
µl of the sample was treated with 200 µl of methanol, vortex and centrifuged to precipitate 
proteins. 50 µl of the clear supernatant was injected into HPLC.  
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Cell Experiments 
Effects of TKI and TKI-LZM in renal tubular cells 
NRK-52E (normal rat kidney) tubular epithelial cells were kindly provided by Prof. 
Russel, University of Nijmegen, The Netherlands. Cells were cultured in DMEM medium 
(BioWhittaker, Verviers, Belgium) supplemented with 5% fetal calf serum (FCS, 
BioWhittaker), 4 mM L-glutamine, penicillin (50 units/ml) and streptomycin (50 ng/ml). 
Human kidney tubular cells (HK-2) were obtained from ATCC (Manassas, VA) and grown 
in RPMI-1640 medium supplemented with 10% FCS, 2 mM L-glutamine, penicillin (100 
units/ml) and streptomycin (100 ng/ml). To examine the effects of TKI and TKI-LZM, 
NRK-52E or HK-2 cells were treated with different compounds as described in the figure 
legends and processed for the mRNA determination by quantitative real-time RT-PCR as 
described below. 
Uptake study of Rhodamine-ULS-LZM in NRK-52E and HK-2 cells 
Since some renal tubular cell lines may loose their property to internalize proteins, we 
compared the protein uptake property of NRK-52E and HK-2 cells. In a subconfluent layer, 
cells were incubated with Rhodamine-ULS-LZM (100 µg/ml per well) for 2 h at 37°C. To 
compete for receptor−mediated endocytosis, cells were preincubated for 15 min with 100 
fold excess of LZM. Cells were washed with cold PBS 3 times, dried and examined under 
the fluorescent microscope to observe uptake of the conjugate. 
Animal Experiments 
Normal male Wistar rats (220-240 g) were obtained from Harlan (Zeist, The 
Netherlands). All experimental protocols for animal studies were approved by the Animal 
Ethics Committee of the University of Groningen. 
Pharmacokinetic studies with TKI-ULS-LZM and Rhodamine-ULS-LZM 
An intravenous dose of the TKI-LZM conjugate (20 mg/kg dissolved in 5% glucose) 
was administered. At indicated time points, animals were sacrificed and blood samples 
were collected by heart puncture and organs were isolated after gently flushing with saline 
through abdominal aorta. Urine samples were collected using metabolic cages. Kidneys 
were weighed, homogenized (1:3 w/v, PBS) and then stored at -80°C. Part of the organs 
was processed for immunohistochemical analysis. To measure drug levels, samples were 
treated with 0.5 M potassium thiocyanate (serum, kidney homogenates) or 0.1 M sodium 
dithiocarbamate (urine) at 80°C for 24h to release TKI from linker and then measured by 
HPLC as explained above. Localization of TKI-LZM in the kidneys was detected by anti-
LZM immunostaining on cryostat sections as described earlier (14).  
To investigate the cellular handling of drug-ULS-LZM lysozyme in the kidneys, rats 
were injected intravenously with Rhodamine-ULS-LZM conjugate (20 mg/kg dissolved in 




5% glucose) and sacrificed at 1h or 24h after administration. Localization of the conjugate 
was determined by fluorescence microscopy at cryosections. 
Effect of TKI-LZM in rats with unilateral ureteral obstruction 
The efficacy of TKI-LZM was studied in the Unilateral Ureteral Obstruction (UUO) 
model which is characterized by a significant induction of TGF-β production during the 
process of renal fibrosis. Animals were divided into 4 groups: normal rats (n=4) and UUO 
animals treated with either vehicle (5% glucose, n=5), TKI-LZM (25 mg/kg equivalent to 
630 µg/kg TKI, n=5) or free, unconjugated TKI (630 µg/kg, n=5). TKI was dissolved in 
20% hydroxylpropyl-β-cyclodextrin in water with 5% DMSO, whereas TKI-LZM was 
dissolved in 5% glucose. To allow unhindered uptake of the products in the kidneys, rats 
were injected intravenously with either of these compounds 2 h before the ureteral 
obstruction. Left kidneys and ureter were exposed via a flank-incision under anesthesia (2% 
isoflurane in 2:1 O2/N2O, 1 L.min-1), after which the ureter was ligated at 2 sites with 4-0 
silk near the hilum. After 3 days, animals were sacrificed and kidneys were gently flushed 
and harvested. Kidney cortex pieces were snap-frozen to isolate RNA. Kidney pieces were 
fixed in 4% formalin solution in PBS to make paraffin-embedded sections. 
Immunohistochemical stainings for the profibrotic marker alpha-smooth muscle actin (α-
SMA) and monocytes/macrophages (ED-1) were performed on paraffin−embedded 
sections.  
Immunohistochemistry 
Commercially available antibodies for α-SMA (clone 1A4, Sigma, MO, USA) and ED-
1 (Serotec, Oxford, UK) were used. A robotic DAKO Autostainer (DAKO Corporation, 
Carpinteria, California) was used for immunohistochemistry by the standard procedure as 
described earlier in detail (15). The extent of interstitial α-SMA expression and interstitial 
macrophage influx were determined in 30 fields per section by computerized morphometry 
as described previously (15). All morphometric measurements were performed by an 
observer in a blinded manner.  
Determination of mRNA expression  
Gene expression levels for the following genes were measured by real-time 
quantitative PCR using an ABI Prism 7900HT Sequence Detection System (Applied 
Biosystems., Foster City, CA). The primers for the rat species were obtained from Sigma-
Genosys (Haverhill, UK). The rat primers for Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), monocyte chemoattractant protein-1 (MCP-1), procollagen-Iα1 and tissue 
inhibitor of metalloproteinase-1 (TIMP-1) have been reported earlier (14) whereas primers 
for α-SMA were 5′-GACACCAGGGAGTGATGGTT-3′ and 5′-
GTTAGCAAGGTCGGATGCTC-3′. The TaqMan primers for Human species were 
obtained from Applied Biosystems (Assay−On−Demand). The cDNA amplification was 
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performed and the threshold cycle number (Ct) was calculated for each gene and then 
relative gene expressions were calculated after normalization to the expression of GAPDH. 
Statistical analysis 
The statistical analyses were performed using Student’s t-test with p<0.05 as the 
minimal level of significance. Results are presented as mean ± SEM. Pharmacokinetic 
analysis of the serum TKI concentrations was performed using the Multifit program 
(Department of Pharmacokinetics and Drug Delivery, University of Groningen, The 
Netherlands). 
Results 
Synthesis and characterization of TKI-ULS-LZM  
The synthesis scheme of TKI-LZM is shown in Fig. 1. TKI was efficiently coupled 
with ULS, yielded 77.3% of the TKI-ULS product. The analyses by HPLC, Pt-NMR and 
electronspray mass spectrometry (ESI-MS) confirmed a 1:1 coupling ratio of TKI and ULS. 
Subsequently, TKI-LZM conjugate was synthesized and characterized by ESI-MS of the 
whole conjugate and by HPLC analysis of the coupled drug. On average, 1-2 TKI 
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Figure 1 Synthesis scheme of TKI-ULS-lysozyme conjugates. LZM, lysozyme; ULS, Universal 
Linkage System.  




We found that the conjugate remained stable in PBS and serum since no drug was 
released after 24h at 37°C. In contrast, 4% of the coupled drug was released upon 
incubation with GSH, a likely intracellular ligand exchange molecule for platinum.  
Cell Experiments 
Effect of TKI in NRK-52E cells 
To investigate fibrotic events in renal tubular cells (NRK-52E), we treated the cells 
with natural activators such as albumin (BSA, 30 mg/ml) or TGF-β1 (10 ng/ml). Albumin 
stimulated the gene expression of the inflammation marker MCP-1 by 35-fold, which in 
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Figure 2. Effects of TKI on albumin or TGF-β1−induced gene expressions of MCP-1 (A), 
procollagen-Iα1 (B), TIMP-1 (C) and α-SMA (D) in NRK-52E renal tubular cells. Cells were grown 
to 80% confluency in 12-well plates and then deprived from serum for 24h. Thereafter, the cells were 
preincubated for 2 h with TKI (10 µM) and then activated with either BSA (30 mg/ml) or TGF-β1 (10 
ng/ml) for 24h. mRNA expressions were determined by quantitative real-time RT-PCR. Data 
represent the mean ± SEM for at least 3 different experiments. Differences versus control are 
presented as †p<0.05, ††p<0.01 and †††p<0.001. Differences versus other groups are *p<0.05, 
**p<0.01, ***p<0.001. 
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Furthermore, albumin induced fibrosis markers such as TIMP-1 and α-SMA 
significantly, while procollagen−Iα1 was not elevated significantly (Fig. 2B-D). Treatment 
with TKI reduced the expression of these genes to levels below basal expression, as was 
also observed in non-activated cells that were treated with the drug. Similarly, TKI 
inhibited TGF-β1−induced gene expressions of procollagen−Iα1 and TIMP−1 significantly 
(Fig. 2B-D). MCP-1 expression was not elevated by TGF-β1 treatment.  
Renal uptake study of Rhodamine-ULS-LZM  
Intracellular delivery of TKI by TKI-LZM is dependent on receptor-mediated 
endocytosis from the medium. We evaluated cellular uptake of drug-LZM conjugates in 
NRK-52E and HK-2 cells using Rhodamine-ULS-LZM. We found that proximal tubular 
cell of human origin (HK-2 cells) internalized the conjugate, while NRK-52E cells showed 
no uptake (Fig. 3A). To demonstrate that receptor−mediated uptake of the conjugate was 
involved, we competed for receptor binding and internalization with a high amount of non-
modified LZM, which clearly reduced the uptake of the fluorescent protein.  
Effect of TKI and TKI-LZM in HK-2 cells  
Next, we evaluated the inhibitory effect of TKI-LZM in HK-2 cells. After incubating 
the cells with TGF-β1 for 24h, gene expression of procollagen−Iα1 was 10-fold increased 
which was reduced over 90% after treatment with TKI-LZM conjugate, comparable to the 
inhibition produced by free TKI (10 µM). At lower concentrations, the conjugate inhibited 
procollagen−Iα1 expression to a lesser extent whereas the equivalent amount of free drug 
still reduced it by 75% (Fig. 3B). Treatment with the LZM carrier alone did not affect 
profibrotic signaling. From these results, we concluded that the conjugate was capable to 
deliver pharmacologically active drug.  
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Figure 3. (A) Fluorescent photomicrographs (a, c, d, f) showing lysosomal uptake in HK-2 cells and 
NRK-52E cells after incubating with Rhodamine-ULS-lysozyme (100 µg/ml) at 37°C for 2 h. For 
competition studies, lysozyme (10 mg/ml) was added 15 min before adding Rhodamine-ULS-
lysozyme. Light photomicrographs (b, e) demonstrate the confluency of the cells in culture plate. (B) 
Effects of TKI and TKI-lysozyme on procollagen-Iα1 gene expression in HK-2 cells. Cells were 
grown to 80% confluency and then deprived from serum for 24h. TKI-lysozyme (8 or 80 µg/ml are 
equivalent to 1 or 10 µM TKI, respectively) or methionine-modified lysozyme (LZM, 8 or 80 µg/ml) 
was added at the time of serum deprivation whereas TKI (1 or 10 µM) was added 1h before adding 
TGF-β1 to the cells. mRNA expressions were determined by quantitative real-time RT-PCR. Data 
represent the mean ± SEM for at least 3 experiments. Differences versus control is presented as 
†††p<0.001. Differences versus other groups are **p<0.01 and ***p<0.001. 
Animal Experiments 
Pharmacokinetics of the TKI-LZM conjugate 
We optimized the sampling protocol for the pharmacokinetic studies with TKI-LZM 
on the basis of our previous studies with drug-LZM conjugates (14). The chosen time 
points allowed reliable estimation of the pharmacokinetic parameters by curve-fitting in a 
multi-compartment model. The serum-disappearance curve of TKI-LZM followed a two-
compartment pharmacokinetic model (Fig. 4A). The pharmacokinetic data obtained from 
the serum-disappearance curve were as follows: distribution half-life (t1/2 α), 0.14 ± 0.03 h; 
elimination (t1/2 β) half-life, 22.3 ± 18.7 h; initial volume of distribution (V1), 5.2 ± 0.8 ml; 
initial serum clearance (CLinit), 21.6 ± 2.8 ml/h. Only carrier−bound TKI was detected in 
the serum, while free drug was absent. Furthermore, similar to other drug-LZM conjugates, 
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TKI-LZM accumulated efficiently in the kidneys within 1h following the intravenous 
injection (Fig. 4B). The accumulation of the conjugate in proximal tubular cells was 
confirmed by immunohistochemical staining for LZM on kidney sections (Fig. 4C). Urine 
levels of TKI (Fig. 4D) indicated a prolonged and continuous excretion of the drug which 
corresponded to the continuous release profile in the kidneys.  
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Figure 4. Serum (A), renal (B) and urine (D) levels of TKI-lysozyme. Symbols represent the levels of 
TKI as % of injected dose at each time point. The continuous line represents the pharmacokinetic 
data-fit curve (two-compartment model). Panel (C) shows the localization of the conjugate in tubular 
cells at t=1h by anti-LZM immunohistochemical staining. Magnification, 200×. 
The renal drug disappearance curve of the previous figure demonstrated that TKI-LZM 
conjugate resided in the kidneys for several days and released slowly. Since we were 
C 




interested in the fate of the drug-ULS part of the conjugates after their uptake by tubular 
cells, we injected Rhodamine-ULS-LZM as a model drug-LZM conjugate. We found that 
Rhodamine-ULS-LZM was accumulated in the tubular cells rapidly within 1h after 
intravenous injection (Fig. 5A and B) which was well correlated with anti-LZM staining. 
While the carrier protein was hardly detectable at t=24h, Rhodamine was still detectable in 
a vesicular pattern (Fig. 5C and D). From these results, we concluded that the conjugate 
resided primarily in the lysosomal compartment after degradation of the protein backbone, 
from which it released the drug slowly to the surrounding environment.  
 
Figure 5. Localization of Rhodamine-ULS-lysozyme conjugate in the kidney. Light photomicrograph 
showing anti-LZM immunohistochemical staining on kidney sections t=1h (A) and t=24h (C) after 
administration of a single dose of Rhodamine-ULS-lysozyme (20 mg/kg) at magnification 100×. 
Panel (B) and (D) show the fluorescence photomicrographs of rhodamine fluorescence in kidney 
sections at t=1h and t=24h, respectively at magnification, 100×. “g” indicate the localization of 
glomeruli in the non-fluorescent space in B and D. Note the pattern of the localization of anti-
lysozyme staining and rhodamine fluorescence. Lysozyme was degraded after 24h while rhodamine 
was still present in the tubules.   
Effect of TKI and TKI-LZM in UUO rats 
Proof-of-concept for the efficacy of TKI-LZM was investigated in the UUO model for 
renal fibrosis. Ureteral ligation causes the induction of inflammatory and fibrotic processes, 
which rapidly progress to end-stage renal disease. Since the renal accumulation of TKI-
LZM and prolonged release of TKI will provide continuous local drug levels, we 
administered only a single dose of the conjugate 2 h before ureteral obstruction. Three days 
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later, ureter obstructed animals had significantly increased expressions of the inflammation 
marker MCP-1 and the fibrosis marker procollagen-Iα1 in comparison to normal rats (Fig. 
6). Moreover, treatment with TKI-LZM substantially reduced the MCP-1 gene expression 
but did not inhibit procollagen-Iα1 expression. In contrast, a single dose of free TKI did not 
lower the expression either MCP-1 or procollagen-Iα1.  
In line with the lowered production of MCP-1, which is a chemoattractant for 
macrophages, we also detected significant reduced levels of infiltrated macrophages upon 
TKI-LZM treatment (ED-1 immunostaining, Fig 7). However, in contrast to the gene 
expression study, we also found a reduction of ED-1 immunostaining with free TKI. 
Moreover, the expression of the fibrosis marker α-SMA was also significantly decreased by 
TKI-LZM or TKI treatments, which indicates potential antifibrotic activity of both TKI and 
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Figure 6. Gene expression levels of MCP-1 (A) and procollagen-Iα1 (B) in renal cortex of normal 
rats and vehicle−treated, TKI-LZM−treated and TKI−treated rats after Unilateral Ureteral Obstruction 
(UUO). Each bar represents the mean ± SEM for n=5, except for normal rats (n=4). Differences 
between normal rats and vehicle-treated UUO rats are presented as ††p<0.01 and †††p<0.001. 
Differences versus other groups are *p < 0.05. 
Discussion 
In the present study, we demonstrate the potential effects of the ALK5 inhibitor TKI in 
cultured renal tubular cells and the unilateral ureteral obstruction (UUO) rat model, which 
stresses the importance of the TGF-β pathway in fibrotic signaling in renal interstitial 
fibrosis. We furthermore demonstrate that renal-specific inhibition of this pathway is 
affecting fibrotic events. For local deliver of TKI to proximal tubular cells in the kidney, we 
have developed a novel renal-specific conjugate. Our results indicate that inhibition of 




fibrotic and inflammatory kinase pathways can be an interesting strategy to treat 




















































TKI was conjugated to the low molecular weight protein LZM via the coordinative 
linker ULS. Our in vitro results as well as the in vivo pharmacokinetic data demonstrated 
that TKI-LZM remained stable in serum and accumulated in the targeted tubular cells in the 
kidney. Since thiols can compete for the drug-platinum linkage, GSH is a likely candidate 
to act as an intracellular release-triggering ligand (16), which is supported by our studies. 
Thus, we propose that TKI-LZM forms a depot in the lysosomes of tubular cells, from 
Figure 7. Representative photomicrographs of 
the immunohistochemical staining for ED-1 
positive cells (infiltrated macrophages) in 
normal rats (A) and 3 days after Unilateral 
Ureteral Obstruction (UUO) (B-D) rats in 
vehicle−treated (B), TKI-LZM−treated (C) and 
TKI−treated animals (D). Arrows indicate the 
immunolocalization of ED-1 in 
tubulointerstitial area. Magnification, 200×. 
Panel (E) shows the number of ED-1 positive 
cells per interstitial field. Each bar represents 
the mean ± SEM for n=5, except for normal 
rats (n=4). Differences between normal rats and 
vehicle-treated UUO rats are presented as 
†††p<0.001. Differences versus other groups 
are *p < 0.05.
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which TKI is released during a period of several days. It is very unlikely that a single dose 
of free TKI will provide similar renal drug levels during the investigated time period of 
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Activation of tubular cells is a crucial event during renal injury which can lead to 
chemoattraction, inflammation, and eventually fibrosis. Tubular cell activation can be 
caused by many factors such as filtered proteins, cytokines and oxidative stress during renal 
injury which initiates multiple events in the cells. In the present study, TKI inhibited 
Figure 8. Representative photomicrographs of 
the immunohistochemical staining of α-SMA 
in normal rats (A) and 3 days after Unilateral 
Ureteral Obstruction (UUO) (B-D) rats in 
vehicle−treated (B), TKI-LZM−treated (C) and 
TKI−treated animals (D). Magnification, 200×. 
Panel (E) shows the semi-quantification of α-
SMA positive area per interstitial field. Each 
bar represents the mean ± SEM for n=5, except 
for normal rats (n=4). Differences between 
normal rats and vehicle-treated UUO rats are 
presented as †††p<0.001. Differences versus 
other groups are *p < 0.05. 




proinflammatory and profibrotic events induced by either albumin or TGF-β1 in cultured 
rat kidney tubular cells. The inhibited genes are highly relevant since they are upregulated 
during renal fibrosis as demonstrated in multiple studies (10,17,18). In addition, TKI-LZM 
demonstrated its activity in human kidney tubular cells, which are capable of internalizing 
proteins, by inhibiting the TGF-β1−induced expression of procollagen-Iα1. Such an effect 
can only take place after internalization and processing of the conjugate into active drug, 
since less than 2% of the coupled drug was released from the conjugate upon prolonged 
incubation at 37°C in cell culture medium (data not shown).  
To evaluate the efficacy of TKI-LZM conjugate on renal fibrosis, we chose the UUO 
rat model since this model is well known to induce renal fibrosis and associated with 
abundant expression of TGF-β and its receptors (19,20). Vielhauer et al demonstrated that 
the expression of MCP-1 also increased continuously in time following ureteral obstruction 
(21), which is confirmed in the present study. Moreover, inhibition of MCP-1 using gene 
therapy or MCP-1 antagonists has been proven to be beneficial for the treatment of renal 
fibrosis in UUO (22,23). We now demonstrate local inhibition of MCP-1 in the kidneys 
with a single dose of TKI-LZM, and a substantial reduction of renal macrophage influx. In 
addition, the effectiveness of the conjugate on renal fibrosis was evidenced by the reduced 
interstitial α-SMA protein expression. Unexpectedly, however, a single intravenous dose of 
free TKI also reduced the influx of macrophages and α-SMA expression. Importantly, free 
drug distributed throughout the body and the observed effects are not likely due to a local 
renal action. Moreover, free TKI inhibited macrophage infiltration without affecting renal 
MCP-1 expression, underlining the different pharmacological profiles of TKI-LZM and 
free drug. A possible explanation is that free TKI probably exerted anti-inflammatory 
activity in immune cells, thereby also affecting the UUO-inflicted renal inflammation and 
fibrosis. Since TKI is a very potent compound, as evidenced in our in vitro studies, the 
relatively low dose given prior to UUO may have been sufficient to inhibit early 
inflammatory and pre-fibrotic events. Yet, the pharmacokinetic data of TKI-LZM clearly 
illustrate its renal accumulation and prolonged drug release, making it more likely that the 
conjugate exerted its activity locally in the kidney.  
In conclusion, the present study shows that targeting of a TGF-β kinase inhibitor to 
tubular cells is in potential a promising approach for the treatment of renal fibrosis. Cell-
specific delivery of such compounds can successfully be accomplished using this approach 
that affords a sustained release of drugs for several days. Moreover, prolonged inhibition of 
TGF-β action locally may serve as a novel therapeutic intervention for chronic diseases 
such as tubulointerstitial fibrosis. 
Acknowledgements  
J. Visser, C. Reker-Smit, P.A. Klok, M. Bulthuis and M. van Dalen are acknowledged 
for excellent technical assistance. Authors are also thankful to A. van Dam and M. 
Blockade of TGF-beta signaling in renal tubular cells 
 127 
Jeronimus-Stratingh for their assistance in mass spectrometry analysis, and acknowledge 
colleagues at Kreatech for critical reading of the manuscript.  
References 
 1.  Bottinger EP, Bitzer M: TGF-beta signaling in renal disease. J Am Soc Nephrol 13:2600-
2610, 2002 
 2.  Zeisberg M, Kalluri R: The role of epithelial-to-mesenchymal transition in renal fibrosis. J 
Mol Med 82:175-181, 2004 
 3.  Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7:2495-2508, 
1996 
 4.  Schnaper HW, Hayashida T, Poncelet AC: It's a Smad world: regulation of TGF-beta 
signaling in the kidney. J Am Soc Nephrol 13:1126-1128, 2002 
 5.  Laping NJ: ALK5 inhibition in renal disease. Curr Opin Pharmacol 3:204-208, 2003 
 6.  Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T, Jr., Herron 
DK, Li HY, McMillen WT, Mort N, Parsons S, Smith EC, Wagner JR, Yan L, Zhang F, 
Yingling JM: Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-
4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor 
kinase domain. Bioorg Med Chem Lett 14:3581-3584, 2004 
 7.  Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, 
Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S, Ling LE: 
Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I 
TGFbeta receptor kinase (TbetaRI). Bioorg Med Chem Lett 13:4355-4359, 2003 
 8.  Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, 
Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J: Progressive Transforming 
Growth Factor {beta}1-induced Lung Fibrosis Is Blocked by an Orally Active ALK5 
Kinase Inhibitor. Am J Respir Crit Care Med 171:889-898, 2005 
 9.  de Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, Gauthier JM, Papworth 
SA, Laroze A, Gellibert F, Huet S: Inhibition of TGF-beta signaling by an ALK5 inhibitor 
protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 145:166-
177, 2005 
 10.  Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ: 
Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-
beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 
313:943-951, 2005 
 11.  Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA: Transforming growth factor-beta 
regulation of immune responses. Annu Rev Immunol 24:99-146, 2006 
 12.  Franssen EJF, Moolenaar F, De Zeeuw D, Meijer DKF: drug targeting to the kidney with 
low-molecular-weight proteins. Adv Drug Deliv Rev 14:67-88, 1994 
 13.  Haas M, Moolenaar F, Meijer DKF, De Zeeuw D: Specific drug delivery to the kidney. 
Cardiovasc Drugs Ther 16:489-496, 2002 
 14.  Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld RQ, de BM, van GH, Henning 
RH, Proost JH, Moolenaar F, Keri G, Meijer DKF, Poelstra K, Kok RJ: Intracellular 
Delivery of the P38 MAPK Inhibitor SB202190 in Renal Tubular Cells: a Novel Strategy to 
Treat Renal Fibrosis. J Pharmacol Exp Ther 2006, in press. 
 15.  de Borst MH, Navis G, de Boer RA, Huitema S, Vis LM, van Gilst WH, van GH: Specific 
MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats. 
Lab Invest 83:1761-1770, 2003 




 16.  Ikeda K, Miura K, Himeno S, Imura N, Naganuma A: Glutathione content is correlated with 
the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the 
accumulation of platinum. Mol Cell Biochem 219:51-56, 2001 
 17.  Duymelinck C, Dauwe SE, De Greef KE, Ysebaert DK, Verpooten GA, De Broe ME: 
TIMP-1 gene expression and PAI-1 antigen after unilateral ureteral obstruction in the adult 
male rat. Kidney Int 58:1186-1201, 2000 
 18.  Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, Gutierrez-Ramos JC: 
RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the 
inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent 
formation and interstitial fibrosis. J Exp Med 185:1371-1380, 1997 
 19.  Sutaria PM, Ohebshalom M, McCaffrey TA, Vaughan ED, Jr., Felsen D: Transforming 
growth factor-beta receptor types I and II are expressed in renal tubules and are increased 
after chronic unilateral ureteral obstruction. Life Sci 62:1965-1972, 1998 
 20.  Fukuda K, Yoshitomi K, Yanagida T, Tokumoto M, Hirakata H: Quantification of TGF-
beta1 mRNA along rat nephron in obstructive nephropathy. Am J Physiol Renal Physiol 
281:F513-F521, 2001 
 21.  Vielhauer V, Anders HJ, Mack M, Cihak J, Strutz F, Stangassinger M, Luckow B, Grone 
HJ, Schlondorff D: Obstructive nephropathy in the mouse: progressive fibrosis correlates 
with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 
2- and 5-positive leukocytes. J Am Soc Nephrol 12:1173-1187, 2001 
 22.  Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, Asano M, Takeya M, Kuziel 
WA, Matsushima K, Mukaida N, Yokoyama H: Blockade of CCR2 ameliorates progressive 
fibrosis in kidney. Am J Pathol 165:237-246, 2004 
 23.  Wada T, Furuichi K, Sakai N, Iwata Y, Kitagawa K, Ishida Y, Kondo T, Hashimoto H, 
Ishiwata Y, Mukaida N, Tomosugi N, Matsushima K, Egashira K, Yokoyama H: Gene 
therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc 
Nephrol 15:940-948, 2004 
 Chapter 8 
Renal−Specific Delivery of  
ROCK Inhibitor Y27632 Inhibits 
Ischemia/Reperfusion−Induced 
Acute Renal Injury 
 
Jai Prakash, Martin H. de Borst, Marie Lacombe, Frank Opdam, Pieter 
A.Klok, Harry van Goor, Dirk K.F. Meijer, Frits Moolenaar, Klaas 











Since the Rho kinase (ROCK) pathway plays an important role in the cytoskeletal 
reorganization and transdifferentiation of epithelial cells as well as in the infiltration of 
inflammatory cells, we hypothesized that ROCK blockade within the kidney might be 
beneficial for the treatment of renal fibrosis. We therefore coupled the well-known ROCK 
inhibitor Y27632 to the renal-specific carrier lysozyme (LZM) and evaluated the 
pharmacological properties of the resulting conjugate in an ischemia-reperfusion induced 
renal injury rat model. Y27632-LZM conjugate was prepared by reacting the drug with the 
platinum-based Universal Linkage System (ULS™) and subsequent reaction of the linker 
with reactive groups in LZM. Y27632-LZM conjugate was stable in serum but released 
drug upon incubation with glutathione in vitro. After intravenous injection in healthy rats, 
the conjugate was rapidly accumulated in the kidneys as determined by HPLC analysis of 
renal drug levels. Immunostaining for the localization of the carrier in kidneys 
demonstrated its accumulation in renal tubular cells. Next, we investigated the effects of 
Y27632-LZM in the unilateral I/R rat model. Rats were daily treated with either vehicle (5 
% glucose), Y27632-LZM conjugate or Y27632 for 4 days. We found that I/R-induced 
gene expression of inflammatory markers (MCP-1) and fibrotic markers (TGF-β1 and α-
SMA) were significantly inhibited by Y27632-LZM after 4 days. In addition, Y27632-LZM 
also inhibited macrophage infiltration (ED-1 positive cells) and α-SMA protein expression 
as detected by immunostaining. In contrast, free Y27632 did not affect the gene expression 
and the protein expression of inflammatory and fibrotic factors. In conclusion, the renal-
specific inhibition of ROCK with Y27632-LZM can be a promising approach to inhibit 
renal injury and fibrotic processes. 
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Introduction 
Renal ischemia−reperfusion (I/R) injury is the main cause of acute renal failure after 
major renal surgery, trauma and transplantation. During I/R injury, proximal tubular cells 
loose polarity and detach from the tubules. This tubular cell detachment is due to the 
cytoskeletal reorganization which is mainly regulated by RhoGTPases (1,2). RhoGTPases 
belong to the Ras superfamily of GTP−binding proteins and act by stimulating downstream 
Rho effectors such as Rho-associated coiled-coil forming protein kinase (ROCK). In 
addition to cytoskeletal regulation, RhoGTPases are involved in the infiltration of 
inflammatory cells (3,4). During I/R injury, infiltration of inflammatory cells into the 
tubulointerstitial space is an important process as these infiltrated cells potentiate 
inflammation and renal damage by generating several cytokines and growth factors (5). 
Moreover, activation of RhoGTPases leads to the transdifferentiation of renal tubular cells 
to fibroblasts which eventually lead to fibrosis (6). So, the RhoGTPase−mediated ROCK 
pathway plays a crucial role in the instigation of inflammation and fibrosis caused by I/R 
injury.  
We hypothesized that blockade of Rho-ROCK pathway locally within kidneys may be 
an interesting approach to prevent I/R injury. Moreover, renal−specific delivery of 
signaling inhibitors is an attractive approach to investigate the renal−specific effects of 
these drugs, as it can avoid interactions with non-target cells in other organs and thereby 
decrease side-effects. Furthermore, drug delivery can enhance local drugs levels at the 
target site, thereby improving therapeutic efficacy. Several studies have shown the efficacy 
of a well-known ROCK inhibitor Y27632 in ischemia-reperfusion injury in different organs 
(7,8). Also, Y27632 exhibited beneficial effects in the unilateral ureteral obstruction model 
of renal fibrosis in mice (9). However, administration of ROCK inhibitors can also lead to 
systemic side-effects since the pathway is involved in the contraction of vascular smooth 
muscle cells (10,11) and in line with this, inhibition of ROCK with Y27632 at a dose of 1 
mg/kg produced a 50% reduction in mean arterial pressure in rats (12). Renal-specific 
delivery of Y27632 may prevent such systemic side effects.  
In earlier studies, we have shown that renal−specific drug delivery can be achieved 
using the low molecular weight protein lysozyme (LZM) as drug carrier (13). LZM filters 
through the glomerulus and is reabsorbed in the proximal tubule via the megalin receptor, 
thus accumulating in the lysosomal compartment of renal tubular cells (14,15) . We have 
recently developed a new strategy for the coupling of drugs to carrier systems, the so-called 
Universal Linkage System (ULS™) which creates a platinum coordination bond with the 
drug. Using the p38 MAPkinase inhibitor SB202190, we have demonstrated that drug-
ULS-LZM conjugates remain stable in serum but release drug slowly within the kidneys 
(16). In the present study, we considered the ROCK inhibitor Y27632 for renal targeting 
and conjugated Y27632 to LZM using the ULS linkage approach. We characterized the 
Y27632-LZM conjugate for its pharmacokinetics in healthy rats and evaluated the 




therapeutic efficacy of ROCK inhibition in the unilateral ischemia-reperfusion (I/R) injury 
model in rats, four days after I/R damage. 
Materials and Methods 
Synthesis and Characterization of Y27632-ULS-LZM Conjugate 
Y27632 [(+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide 
dihydrochloride monohydrate] was purchased from Tocris, UK. Lysozyme was obtained 
from Sigma-Aldrich, St. Louis, MO. Cis-[Pt(ethylenediamine)nitrate-chloride] (ULS) was 
freshly prepared from cis-[Pt(ethylenediamine)dichloride as described elsewhere (17). 
Y27632 (2.95 µmol, 10 mg/ml in water) was basified with 1 M NaOH to pH 8 and reacted 
with cisULS (4.43 µmol) at 50oC overnight. Consumption of the starting drug and 
formation of the products was followed by HPLC and LC-MS. The reaction mixture was 
evaporated to dryness under reduced pressure, affording a pale yellow solid (yield 50 %) 
that consisted of the desired 1:1 reaction product. Y27632-ULS was subsequently reacted 
with lysozyme according to a similar protocol as described elsewhere (16). In brief, 
lysozyme (0.7 µmol) equipped with surface-exposed methionine groups by the Boc-L-
methionine hydroxysuccinimide ester reagent, was dissolved in 0.02 M tricine/sodium 
nitrate buffer, pH 8.5. After addition of Y27632-ULS (3.5 µmol), the mixture was reacted 
at 37°C for 24 h. The product was purified by dialysis against water for 48 h, filtered, 
lyophilized and stored at -20°C. MS analysis confirmed the formation of Y27632-LZM 
conjugate. The amount of conjugated drug was quantified after competitive displacement of 
the drug from the conjugate by overnight incubation with 0.5 M potassium thiocyanate in 
PBS at 80°C, by HPLC analysis as described below. The absence of free drug in the 
preparation was investigated by HPLC analysis of freshly prepared dilutions of the 
conjugate in PBS.  
Y27632-LZM was characterized for its stability and drug-release properties. The 
conjugate (100 µg/ml) was incubated in different media: 0.1 M PBS, 5 and 50 mM 
glutathione (reduced form) in PBS, and serum. After 24 h incubation at 37°C, 100 µl 
aliquots were taken and processed immediately for HPLC analysis of Y27632.  
HPLC analysis of Y27632 
Y27632 was analysed on a Waters liquid chromatograph (Waters, Milford, MA, USA) 
consisting of a 510 pump, an autoinjector 715, and a column oven set at 40°C (Waters, 
Milford, MA, USA) in combination with a Spectroflow 757 UV detector (Kratos, 
Kanagawa, Japan). Separations were performed on a C18 reversed-phase SunFire™ column 
(150 x 4.6 mm i.d., 5-µm particle size, Waters) preceded by a C18 guardPak precolumn 
(Waters), using a mobile phase of water-methanol-trifluoroacetic acid (86:14:0.1, v/v/v; pH 
2.0) at a flow rate of 1 ml/min. The effluents were monitored at 270 nm. Y27632 eluted at a 
retention time of 5.7 min. Clear solutions were injected without pretreatment in the HPLC, 
while serum and kidney homogenates (200 µl) were extracted twice with 2 ml of diethyl 
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ether after adding 100 µl of 2 N NaOH. After freezing of the aqueous layer in liquid 
nitrogen, the organic layer was decanted and evaporated at 50°C. The residue was 
reconstituted in 200 µl of mobile phase, and 50 µl was injected into the HPLC. The peak 
heights were recorded and related to calibration curves in the corresponding biological 
matrices to quantify drug levels.  
Animal Experiments 
All experimental protocols for animal studies were approved by the Animal Ethics 
Committee of the University of Groningen. Normal male Wistar rats (220-240 g) were 
obtained from Harlan (Zeist, The Netherlands). 
 Pharmacokinetics of Y27632-LZM 
Male Wistar rats (n=5) were injected intravenously with a single dose of the Y27632-
LZM conjugate (20 mg/kg equivalent to 555 µg/kg of Y27632, dissolved in 5 % glucose). 
Injections were performed in the penile vein under inhalation anesthesia (2 % isoflurane in 
2:1 O2/N2O, 1 L.min-1). Animals were placed in metabolic cages for collection of urine, and 
sacrificed at 5, 30, 60, 120 and 360 min under anesthesia, n=1 per time point according to 
the protocol described earlier (16). Blood samples were collected by heart puncture and 
kidneys were isolated after gently flushing of the organs with saline through the abdominal 
aorta. Urine was collected from the urinary bladder and combined with the urine collected 
in the metabolic cages. Kidneys were weighed, homogenized (1:3 w/v, PBS) and then 
stored at −80°C. To determine Y27632 in serum or tissues, samples were incubated with 
0.5 M potassium thiocyanate at 80°C for 24 h to release Y27632 from the linker followed 
by HPLC analysis as explained earlier. Anti-LZM immunostaining was performed on 
frozen kidney sections to detect the cellular localization of the conjugate in the kidneys as 
described below. 
Effect of Y27632-LZM in unilateral renal Ischemia−Reperfusion (I/R) injury in rats  
The pharmacological efficacy of Y27632-LZM was evaluated in the unilateral 
ischemia-reperfusion (I/R) rat model. Animals were divided into 4 groups: untreated 
normal rats (n=4), vehicle treated I/R rats (5% glucose, n=10), Y27632-LZM + I/R (20 
mg/kg equiv. to 555 µg/kg Y27632, n=3), Y27632 + I/R (555 µg/kg, n=6). At 2 h prior to 
the ischemia procedure, rats were pre-injected with either of these compounds. Compounds 
were administered intravenously via the penis vein as described above. Animals were 
allowed to recover and placed back into the cages until the induction of renal ischemia. 
Animals were incised from the abdomen under anesthesia and the left renal artery and vein 
were clamped for 45 min to stop renal blood flow. Clamps were removed and reperfusion 
of the kidney was observed before closing of the wound. Rats were re-injected with the 
compounds at t=24, 48, and 72h after I/R. After 4 days, animals were sacrificed and blood 
samples were collected from the abdominal aorta. Kidneys were isolated after gentle 
perfusion with saline. Kidney pieces were snap-frozen in liquid nitrogen for mRNA 




isolation, in ice-cold isopentane for preparation of cryosections or put in formalin solution 
(4% in PBS) to make paraffin-embedded sections.  
Determination of mRNA expression 
Total RNA was isolated from renal cortex using Bio-Rad’s Aurum Total RNA Mini kit 
(Bio-Rad, Hercules, CA). RNA content was measured by a nanodrop UV-detector 
(NanoDrop Technologies, Wilmington, DE). cDNA was synthesized from similar amounts 
of RNA using the Superscript III first strand synthesis kit (Invitrogen, Carlsbad, CA). Gene 
expression levels for the following genes were measured by quantitative real-time RT-PCR 
(Applied Biosystems., Foster City, CA). The primers for rat species obtained from Sigma-
Genosys (Haverhill, UK) were as follows: monocyte chemoattractant protein-1 (MCP-1; 5'-
TCCTCCACCACTATGCAGGT-3' and 5'-TTCCTTATTGGGGTCAGCAC-3', 255 bp), 
tissue inhibitor of metalloproteinase-1 (TIMP-1; 5′-GAGAGCCTCTGTGGATATGT-3′ 
and 5′-CAGCCAGCACTATAGGTCTT-3′, 334 bp), procollagen-Iα1 (5′-
AGCCTGAGCCAGCAGATTGA-3′ and 5′-CCAGGTTGCAGCCTTGGTTA-3′, 145 bp), 
alpha smooth muscle actin (α-SMA; 5′-GACACCAGGGAGTGATGGTT-3′ and 5′-
GTTAGCAAGGTCGGATGCTC-3′, 202 bp), TGF-β1 (5'-
ATACGCCTGAGTGGCTGTCT and 5'-TGGGACTGATCCCATTGATT-3’, 153 bp) and 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 5′-
CGCTGGTGCTGAGTATGTCG-3′ and 5′-CTGTGGTCATGAGCCCTTCC-3′, 179 bp).  
SYBR® Green PCR Master Mix (Applied Biosystems, Warrington, UK) was used as a 
fluorescent probe for real-time RT-PCR. For each sample, 1 µl of cDNA was mixed with 
0.4 µl of each gene-specific primer (50 µM), 0.8 µl DMSO, 8.4 µl water and 10 µl SYBR 
Green PCR Master Mix. The cDNA amplification was performed until 40 cycles followed 
by dissociation cycle. The final product was examined to provide a single peak in the 
dissociation curve. Finally, the threshold cycle number (Ct) was calculated for each gene 
and relative gene expressions were calculated after normalizing for the expression of the 
control gene GAPDH. 
Histology and Immunohistochemistry  
Cryostat kidney sections (4-µm thick) were cut with a Leica cryostat (Wetzlar, 
Germany). Sections were incubated with rabbit anti-LZM polyclonal antibody to detect the 
localization of Y27632-LZM, as described previously (16).  
Anti-α-SMA and ED-1 immunohistochemical staining were performed on 4-µm thick 
paraffin−embedded sections. Sections were deparaffinized in xylene and rehydrated in 
alcohol and distilled water. Heat-induced antigen retrieval was achieved by incubation in 
0.1 M Tris/HCl buffer (pH 9.0) overnight at 80°C. For immunohistochemistry, a DAKO 
Autostainer was used (DAKO Corp, Carpinteria, CA, USA). Sections were washed in PBS, 
treated with endogenous peroxidase blocking reagent containing 0.03% H2O2 / sodium 
azide for 5 min. Slides were then incubated with primary antibodies against α-SMA (clone 
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1A4, Sigma, MO, USA) or the rat macrophage marker ED-1 (Serotec, Oxford, UK), diluted 
in PBS containing 1 % bovine serum albumin (BSA) for 60 min at room temperature. 
Binding was detected by sequential incubation with peroxidase-labelled rabbit anti-mouse 
and goat anti-rabbit polyclonal antibodies (DAKO, Glostrup, Denmark), respectively, in the 
presence of 1% normal rat serum for 30 min. The peroxidase activity was visualised using 
3,3’-diaminobenzidine tetrahydrochloride (DAB+, DAKO) for 10 min, and sections were 
mounted with Kaiser’s glycerin gelatin. Periodic acid Schiff’s base (PAS) staining was 
performed according to standard protocols to observe renal morphology. The extent of 
interstitial α-SMA expression and interstitial macrophage influx were determined by 
computerized morphometry. For that purpose, 30 interstitial rectangular fields per section 
were screened using a light microscope, equipped with a camera device connected to a 
computer system. Glomeruli and vascular areas were manually excluded. The amount of 
brown precipitate was measured and represented as either a percentage of the total selected 
area (α-SMA) or as estimated number of macrophages in the selected area. Averages were 
calculated from 30 fields per section, representing ultimate interstitial α-SMA and 
macrophage scores. All morphometry measurements were performed by a blinded observer.  
Statistical Analysis 
The statistical analyses were performed using Student’s t-test with p<0.05 as the 
minimal level of significance. Results are presented as mean ± standard error mean. 
Pharmacokinetic analysis of the serum Y27632 concentrations was performed using the 
Multifit program (Department of Pharmacokinetics and Drug Delivery, University of 
Groningen, The Netherlands). 
Results 
Synthesis and Characterization of Y27632-ULS-LZM  
As illustrated in Fig. 1, Y27632 was first conjugated to ULS and then coupled to the 
carrier lysozyme. The final product was found to have a 1:1 drug to protein ratio when 
characterized for the amount of coupled drug by HPLC or by ESI-MS to analyze the intact 
conjugate. Prior studies with other drug-ULS-LZM conjugates (16) indicated that this type 
of conjugate is highly stable in buffers and serum, but releases the conjugated drug slowly 
upon ligand exchange with GSH. Stability studies with Y27632-LZM were in good 
agreement with these data. No release of the coupled drug was observed upon incubation in 
PBS or serum at 37°C. In contrast, addition of GSH to the medium afforded competitive 
release of drug that was concentration-dependent. Approximately 5 % and 9 % of the bound 
drug was released in 5 and 50 mM GSH, respectively, in 24 h. From these data, we 
postulated that drug release rates will be mainly governed by the applied ULS linkage, 
rather than by the coupled drug.   
 












































Figure 1. Synthesis of Y27632-ULS-lysozyme. ULS, Universal Linkage System; LZM, lysozyme. 
Pharmacokinetics of the Y27632-LZM conjugate 
In addition to in vitro stability studies, we also investigated the stability of Y27632-
LZM after administration to rats. The serum-disappearance curve of Y27632-LZM, which 
followed a two-compartment pharmacokinetic model, is shown in Fig. 2A. Only carrier-
bound Y27632 was detected in the serum, while free drug was absent. Furthermore, in 
accordance with other drug-LZM conjugates, Y27632-LZM accumulated efficiently in the 
kidneys within 30 min following the intravenous injection (Fig. 2B). The accumulation of 
the conjugate in kidneys was confirmed by anti-LZM immunohistochemical staining on 
kidney sections (Fig. 2C). A clear and selective accumulation of LZM in renal tubular cells 
was found. 
Effect of Y27632-LZM in the I/R Injury model in rats 
The antifibrotic efficacy of Y27632-LZM was evaluated in the unilateral I/R model. 
This animal model is characterized by an early inflammatory phase which finally leads to 
fibrosis. Typically, I/R treated rats display a mild stage of fibrosis after 4 days, which was 
confirmed in the present study. In comparison to normal rats, vehicle−treated I/R animals 
had a significant increase in the gene expression of the inflammation marker MCP-1 and of 
fibrosis markers α-SMA, TGF-β1, procollagen-Iα1 and TIMP-1 (Fig. 3). Moreover, 
immunohistochemical evaluation of the kidneys showed a significant increase of the 
number of macrophages in the tubulointerstitial space and the tubular lumen of I/R rats 
(Fig. 4). As illustrated by the PAS staining, tubular cells were lost from the renal tubules in 
I/R rats and abundant macrophage infiltration in the lumen was seen (Fig. 4B). These 
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results are in good agreement with the enhanced expression of MCP-1 since MCP-1 is an 
important chemotactic cytokine to attract monocytes and macrophages.  
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In addition, to determine the induction of fibrogenesis in this model we detected the 
expression of the fibroblast marker α-SMA in kidneys. In normal rats, only blood vessels 
were positive for α-SMA (Fig. 5A) whereas after I/R injury, there was a significant 
increase in α-SMA expression in the tubulointerstitial space of the renal cortex (Fig. 5B). 
These data confirm that tubulointerstitial fibrosis was initiated after 4 days of I/R injury. 
Finally, we observed changes in renal morphology by PAS staining (Fig. 4, 5, pink color) 
which clearly showed the dilation of tubules with loss of tubular brush border as well as 
tubular cells itself after I/R injury. Treatment with Y27632-LZM substantially improved 
almost all parameters, while free Y27632 showed no beneficial effects. The elevated gene 
expression of MCP-1, α-SMA and TGF-β1 was blunted by Y27632-LZM, whereas gene 
expression of procollagen-Iα1 and TIMP-1 was not reduced significantly (Fig 3). 
Furthermore, treatment with Y27632-LZM significantly reduced the influx of macrophages 
both in the tubular interstitium and lumen as indicated by ED-1 staining, which is in good 
agreement with the reduced renal expression of MCP-1 seen after administration of 
C 
Figure 2. (A) Serum levels and (B) renal 
levels of Y27632-LZM. Symbols 
represent the % dose of Y27632 at each 
time point; the continuous line represents 
the pharmacokinetic data-fit curve (two-
compartment model). Panel (C) 
represents the localization of the 
conjugate in tubular cells at 30 min by 
anti-LZM immunohistochemical staining. 
Magnification, 200×. 
 




Y27632-LZM. In contrast, free Y27632 did not reduce the expression of any of the studied 
genes and did not affect the number of ED-1 positive cells (Fig 4).  In addition to the 
beneficial effect on inflammation, we found a significant reduction in α-SMA staining after 
Y27632-LZM treatment, whereas free drug did not show any effect on α-SMA expression 
(Fig 5). Finally but importantly, the conjugate treatment improved the renal morphology 
since there was less tubular dilation and more intact tubular cells. However, free drug 
hardly induced any improvement in morphology. Thus, drug delivery by means of Y27632-
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Figure 3. Gene expression of MCP-1, TGF-β1, α-SMA and procollagen-Iα1 in renal cortex of 
normal rats (n=4) and vehicle−treated (n=10), Y27632-LZM−treated (n=3) and Y27632−treated (n=6) 
rats after unilateral ischemia-reperfusion injury. Data represents mean ± SEM. ††p<0.01 and 
†††p<0.001 represent the difference between normal rats and vehicle-treated I/R rats. Differences 
between other groups are indicated as *p < 0.05 and **p < 0.01. 
Discussion 
The Rho-ROCK system is an endogenous regulator of proliferation, migration and 
apoptosis of renal tubular cells (18). Moreover, the ROCK pathway participates in 
inflammatory and fibrotic processes by regulating infiltration of inflammatory cells and the 
transdifferentiation of epithelial tubular cells into fibroblasts (3,4,6). Since all of these 
processes are important aspects of fibrosis, ROCK inhibition is an attractive antifibrotic 
strategy. In the present study, we delivered the ROCK inhibitor Y27632 to the kidneys to 
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confine its effects locally to the kidneys. Such a strategy will increase the cellular 
specificity of the drug for renal tubular cells, thereby avoiding other cells that respond to 
ROCK inhibition, like vascular smooth muscle cells. Activation of ROCK causes the 
contraction of vascular smooth muscles and inhibition of ROCK with Y27632 inhibits their 





















































Figure 4. Representative photomicrographs of 
the macrophage immunostaining (ED-1) in 
normal rats, n=4 (A) and 4 days after unilateral 
ischemia-reperfusion injury (B-D) rats. 
Vehicle−treated, n=10 (B); Y27632-
LZM−treated, n=3 (C); Y27632−treated, n=6 
(D) animals. Arrows indicate the 
immunolocalization of ED-1 positive cells 
(brown color) in tubulointerstitial area. PAS 
counterstaining depicts the renal morphology. 
Magnification, 200×. Panel (E) shows the 
number of ED-1 positive cells per interstitial 
field. †††p<0.001 represent the difference 
between normal rats and vehicle-treated I/R rats. 
Differences between other groups are indicated 
as **p < 0.01.  
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Coupling of Y27632 via ULS to LZM provided a serum-stable conjugate that 
accumulated rapidly into the kidneys. Furthermore, the pharmacokinetic profile of Y27632-
LZM is quite similar to the earlier reported SB202190-ULS-LZM conjugate (16), both with 
respect to serum disappearance and the extent of renal accumulation (about 20% of the 
injected dose after 1-2 h). In the previous study, we demonstrated that SB202190-LZM 
provided continuous renal drug levels during a prolonged period of several days after its 
administration. Although we now examined the pharmacokinetics of Y27632-LZM only 
Figure 5. Representative photomicrographs 
of the immunostaining for alpha-smooth 
muscle actin (α-SMA) in normal rats, n=4 
(A) and 4 days after unilateral ischemia-
reperfusion injury (B-D) rats. 
Vehicle−treated, n=10 (B); Y27632-
LZM−treated, n=3 (C); Y27632−treated, n=6 
(D) animals. PAS counterstaining shows the 
renal morphology. Magnification, 200×. 
Panel (E) shows the semi-quantification of 
α-SMA positive area per interstitial field. 
†††p<0.001 represent the difference between 
normal rats and vehicle-treated I/R rats. 
Differences between other groups are 
indicated as *p < 0.05. 
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until 6 h after its injection, it is fair to expect similar continuous drug release, in view of the 
similar release characteristics. Moreover, the in vitro release of Y27632 by glutathione 
suggests that drug will be released inside the target cells after the accumulation (16,20) 
where glutathione levels are relatively high. It is important to notice that Y27632 did not 
release from the conjugate in serum as determined by in vitro drug release study as well as 
by pharmacokinetic data in vivo.  Thus, the renal delivery Y27632 can avoid systemic side-
effects of the free drug such as the fall in blood pressure (12).  
We investigated the effects of Y27632-LZM in I/R injury model, in which both 
inflammatory and fibrotic processes contribute to the renal pathology. In view of the 
continuous drug levels in the kidney after a single dose, we designed a protocol in which 
Y27632-LZM was administered once daily. Inhibition of MCP-1 gene expression and 
immune cells infiltration by Y27632-LZM indicated that ROCK pathway is an essential 
pathway in the regulation of inflammation during I/R injury. MCP-1 has shown to be a 
crucial gene during fibrogenesis (21,22). Moreover, local inhibition of ROCK with 
Y27632-LZM reduced the I/R-induced fibrotic genes (TGF-β1 and α-SMA) and the α-
SMA expression which is a marker of fibroblast activation. This demonstrates the 
beneficial effects of Y27632-LZM on fibrotic signaling after I/R injury. Since the anti-
inflammatory and anti-fibrotic effects were only observed after treatment with Y27632-
LZM and not after administration of free drug, we inferred that these effects were due to the 
local inhibition of ROCK within tubular cells, rather than by systemic effects of the drug. 
Although the therapeutic efficacy of Y27632-LZM is obvious, explaining the mechanism of 
action is more difficult from the present data. The possible mechanism is that 
transformation of tubular cells into fibroblast is inhibited, combined with a reduced 
secretion of profibrotic and proinflammatory mediators, which lowered subsequent influx 
of immune cells. In addition to the beneficial effects on inflammatory and fibrotic 
signaling, the conjugate also improved the renal morphology significantly by preventing the 
loss of tubular cells. This can be explained by the studies showing that the blockade of 
ROCK within tubular cells inhibited the cytoskeletal reorganization induced by I/R injury 
which is the main cause for the loss of tubular cells (1,2). Local inhibition of ROCK within 
non-tubular cells in the kidney can not be excluded, since Y27632 might redistribute from 
the initial target cells after release from the carrier. Lastly, the absence of beneficial effects 
of free drug might be due to either rapid elimination of the drug and/or poor distribution to 
kidneys. Regardless of these considerations, however, the clear differences between renally 
delivered Y27632 and free drug clearly illustrate the improved efficacy of the novel 
compound.  
In conclusion, the present study demonstrates that renal-specific delivery of ROCK 
inhibitor Y27632 can be successfully achieved using the Y27632-LZM conjugate. 
Blockade of ROCK pathway locally within kidneys with Y27632-LZM produced 
significant antifibrotic effects and can be a promising approach to treat renal injury.  
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Summary and Discussion 
Renal fibrosis is one of the major health problems in the world. It is characterized by 
deposition of extracellular matrix in kidneys which results into end-stage renal disease 
(ESRD) (1). In recent years, a tremendous increase in the incidence of ESRD world-wide 
has been reported. Diabetes and hypertension are found to be the main causes of ESRD. 
Moreover, other chronic renal diseases such as glomerulonephritis, cystic diseases and 
tubulointerstitial fibrosis also represent a large population of ESRD (2). Only available 
treatment for ESRD patients is either dialysis or renal transplantation which has increased 
the total public health burden enormously. In relation to this, an increase in the annual 
expenditure is expected from US$9 billion (1995) to US$28 billion by 2010 only in the 
USA (2,3). Therefore, there is an emergence to develop new therapies for the treatment of 
renal fibrosis.  
Expanding research in this field has explored new pathways and mechanisms involved 
in the pathogenesis of renal fibrosis. Subsequently, new chemical entities modulating these 
pathways have been developed. However, most of these developed compounds possess 
unfavorable pharmacokinetics due to, among others, rapid body elimination or poor renal 
distribution. In addition, these compounds may exhibit several systemic side-effects by 
interfering with the normal physiological functions. As summarized in Chapter 1, the 
present thesis is focused on the development of a novel therapeutic system by which anti-
fibrotic drugs can be delivered selectively to the kidneys. Renal−selective therapies aim to 
increase the therapeutic efficacy of drugs by increasing the amount of drugs locally within 
kidneys (4). In addition, renal targeting can avoid the interaction of the drug with other 
organs which can prevent the extra-renal side-effects of drugs.  
To achieve renal selective delivery of drugs, we used low molecular weight protein 
(LMWP) lysozyme (LZM) as a drug carrier. In the kidneys, LZM filters freely through the 
glomerulus and is absorbed by proximal tubular cells via megalin receptor-mediated 
endocytosis. This has been demonstrated in our laboratory (5,6). Kok et al. have 
demonstrated that an angiotensin converting enzyme (ACE) inhibitor captopril could be 
targeted to kidneys using LZM. Moreover, renal−targeted captopril-LZM inhibited renal 
ACE activity effectively and selectively in comparison to non-targeted captopril after 
intravenous injection (7). In Chapter 2 and 3, we explored the possibility to administer 
captopril-LZM conjugate via the subcutaneous route. Such an administration route is more 
convenient to both patients and animals, and may prolong the action of the conjugate. We 
demonstrated that after subcutaneous administration, radiolabeled LZM accumulated 
gradually into the kidneys during 24 h and showed a better renal uptake profile in renal 
diseased (proteinuria) state in comparison to intravenous administration. Moreover, we 
found that subcutaneously administered captopril-LZM was accumulated slowly into 
kidneys and inhibited renal ACE activity gradually and selectively (8). Furthermore, 
chronic treatment with subcutaneously administered captopril-LZM in adriamycin−induced 
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nephrotic rats displayed beneficial effects as it decreased proteinuria without affecting 
systemic blood pressure. In contrast, untargeted captopril did not reduce proteinuria but 
showed systemic side-effect by causing hypotension (9). From this study, we concluded 
that drug-LZM conjugates, in principle, can be administered subcutaneously. However, the 
rapid elimination of released captopril from the kidneys reduced the efficacy of the 
conjugate. Therefore, we focused our research at other drugs that could become more 
effective in the kidneys, either due to an improved pharmacokinetic profile (improved 
residence-time in the kidney) or to a more potent pharmacodynamic profile. In addition, we 
applied a novel type of drug linkage chemistry, the so-called Universal Linkage System 
(ULS™) which makes coordinative (non-covalent) bonds with the drug and the carrier 
protein. We succeeded in the coupling of the angiotensin II (AT II) type I receptor 
antagonist losartan to lysozyme using ULS. Our in vitro studies showed that losartan-LZM 
remained stable in serum while it released the drug in kidney homogenates at a slow rate, 
amounting to 20% release after 24h. When administered to rats, losartan-LZM disappeared 
from the circulation and accumulated into the kidneys in a manner similar to other drug-
LZM conjugates. We subsequently evaluated the efficacy of the conjugate in the unilateral 
renal ischemia-reperfusion (I/R) injury model in rats for 4 days. We chose the I/R model to 
test the conjugate, since this model is a short-term model and induces inflammation and 
mild fibrosis by activating tubular cells, the target cell in our approach. In contrast to the 
earlier-used adriamycin-induced nephrosis model, it is a long-term model and represents 
both tubulointerstitial and glomerular fibrosis. Moreover, the I/R model showed less 
variation in-between animals than the adriamycin-induced nephrosis model. Although we 
only observed minor effectivity of losartan-LZM after multiple dosing for 4 days (data not 
shown), the combined results clearly demonstrated the feasibility of the applied drug 
delivery approach.  
 We also reviewed which other pathways and drugs play crucial roles in the 
pathogenesis of renal fibrosis, with the aim to establish which of the inhibitors might 
benefit from renal drug delivery (Chapter 4). Since our delivery strategy is focused at renal 
tubular cells, we especially studied the role of renal tubular cells in the pathological events. 
During renal injury, tubular cells are activated and produce several cytokines and growth 
factors which initiate inflammation thereby elicit a fibrotic process. Various signaling 
pathways such as mitogen−activated protein kinase (MAPK) and tyrosine kinase pathways 
participate in the activation of tubular cells and production of cytokines from tubular cells, 
and potent inhibitors of these cascades have been described in recent years. However, in 
these studies quite high dose of these inhibitors were administered (10-12). Since such 
potent compounds may exert side effects in other tissues beside the kidney, we 
hypothesized that renal selective delivery of kinase inhibitors might be an interesting 
approach to treat renal fibrosis. Moreover, local inhibition of a signaling pathway within 
tubular cells would provide an insight on the regulation of fibrosis by a specific pathway in 
these cells. 




We first screened different kinase inhibitors on the basis of their efficacy in cultured 
renal tubular cells. Tubular cells were activated by natural activators such as albumin or 
transforming growth factor-beta1 (TGF-β1) and we evaluated the efficacy by gene 
expression for inflammation (MCP-1) and fibrotic (procollagen-Iα1, TIMP-1 and α-SMA) 
markers. Among different signaling inhibitors, we found that p38 MAPK inhibitor 
SB202190 and TGF-β1 receptor kinase inhibitor (ALK5 inhibitor; TKI) inhibited both 
inflammatory and fibrotic markers significantly. As described in Chapter 5, we studied the 
pharmacokinetics of SB202190 in rats to determine whether it efficiently distributes to 
kidneys (13). To measure SB202190 levels in different organs, we first developed a HPLC 
method that allows measurements of SB202190 after isolating it from different biological 
matrices with a liquid-liquid extraction method. The pharmacokinetics study demonstrated 
that SB202190 was rapidly eliminated from blood and poorly distributed to the kidneys. 
These results underlined the need to target SB202190 to the kidney for the treatment of 
renal fibrosis. In Chapter 6, we described the cell-specific delivery of SB202190 to renal 
tubular cells using LZM (14). We coupled SB202190 (SB) to LZM via two different 
linkages, i.e. a carbamate linkage and the ULS coordinative linkage. These were the only 
two available options to couple this drug to a protein. Carbamate linkage released the drug 
rapidly in serum which makes it unsuitable for renal targeting. However, SB-ULS-LZM 
conjugate remained stable in serum but released the drug in kidney homogenates slowly in 
vitro. Moreover, a single intravenous injection of the conjugate resulted into rapid 
accumulation in kidneys where it released drug slowly. Since ULS contains platinum which 
is known to cause nephrotoxicity, we examined the toxicity of the conjugate in renal tubular 
cells in vitro by cell-viability assays and in rats until 72 h by studying renal function, renal 
morphology and apoptosis in tubular cells. No sign of toxicity with the conjugate was 
observed both in vitro and in vivo. Finally, we investigated the effect of SB-ULS-LZM in 
human renal tubular cells in vitro. We found that application of conjugate to tubular cells in 
vitro substantially inhibited the TGF-β1−induced procollagen-Iα1 gene expression. In vivo, 
we tested the efficacy of SB-ULS-LZM in the unilateral I/R model. An important 
consideration in this respect is that p38 is highly activated in tubular cells in this model, 
which has been associated with renal inflammation and fibrosis. A single dose of SB-ULS-
LZM displayed its activity after 4 days of I/R injury in rats by inhibiting phosphorylation of 
p38 and showed a significant effect on fibrosis by inhibiting α-SMA expression which is a 
marker for fibroblast activation, the crucial event during fibrogenesis. This study concluded 
that p38 MAPkinase inhibitor SB202190 can successfully be targeted to renal tubular cells 
where it is pharmacologically active. This targeted compound may therefore be used for the 
treatment of renal fibrosis.  
During renal injury, TGF-β1 plays a pivotal role in the pathogenesis of renal fibrosis as 
it activates tubular cells. In response to TGF-β1, tubular cells transdifferentiate into 
fibroblasts via epithelial-mesenchymal transition process and further fibroblasts produces 
fibrogenic materials. TGF-β1 acts through its type I (Activin-Receptor Like Kinase-5, 
ALK5) and II receptors by activating (phosphorylating) Smad2/3 and MAPK pathways. We 
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hypothesized that blockade of TGF-β1 action locally within kidneys may provide an 
attractive means to treat renal fibrosis. In Chapter 7, we describe the studies in which we 
examined the effect of local inhibition of TGF-β in kidneys by renal-selective delivery of 
an ALK5 inhibitor (TKI) using LZM. Therefore, we conjugated TKI to lysozyme using the 
ULS™ strategy. Similar to the SB202190-ULS-LZM conjugate, TKI-LZM also 
accumulated rapidly in tubular cells and provided a local depot locally for 3 days. In 
addition, we conducted a study with rhodamine-ULS-LZM and proved that drug-ULS-LZM 
conjugate stays inside the tubular cells and releases the marker drug locally. Moreover, 
TKI-LZM displayed its activity by inhibiting TGF-β1−induced procollagen-Iα1 gene 
expression significantly in vitro in HK-2 cells. Subsequently, we evaluated the efficacy of 
TKI-LZM conjugate in vivo in the unilateral ureteral obstruction (UUO) rat model, since 
the involvement of TGF-β in this model has been well established in the literature. Of note, 
the UUO model displays advantages as it is a rapid model for tubulointerstitial fibrosis. 
However, the UUO model is not suitable for long-term studies with multiple dosing of the 
conjugates since blockade of glomerular filtration after ureteral ligation will result in 
blockade that prevent further accumulation of the conjugate in the kidney. Interestingly, a 
single dose of TKI-LZM administered at day 1 significantly inhibited MCP-1 gene 
expression, macrophage infiltration (ED-1 positive cells) and α-SMA protein expression 
after 3 days of ureteral ligation. Although we administered a low dose only once, we 
observed effects, which illustrate the potency of this compound. From this study, we 
concluded that blockade of the action of TGF-β within kidneys using the ALK5 inhibitor 
can be an important strategy for the treatment of renal fibrosis.  
Recently, RhoGTPase mediated signaling has been recognized to play also an 
important role in the pathogenesis of renal fibrosis. RhoGTPases regulate cytoskeletal 
reorganization, transdifferentiation of tubular epithelial cells and neutrophil infiltration 
(15). RhoGTPases act by stimulating downstream Rho effectors such as Rho-associated 
coiled-coil forming protein kinase (ROCK). We investigated the consequence of ROCK 
blockade within the kidneys with our renal−targeting approach (Chapter 8). The well-
known ROCK inhibitor Y27632 was conjugated to LZM using ULS and we studied the 
pharmacokinetics of Y27632-LZM conjugate in healthy rats. Similar to other drug-LZM 
conjugates, Y27632-LZM accumulated rapidly within the kidney. Next, we evaluated the 
efficacy of Y27632-LZM in the I/R rat model. Evaluation of Y27632-LZM in this model is 
relevant since the ROCK pathway regulates the cytoskeletal reorganization as well as the 
infiltration of inflammatory cells and both are affected during the disease. After 4 days 
therapy with Y27632-LZM, we found that Y27632-LZM substantially inhibited the gene 
expression of inflammatory (MCP-1) and fibrotic (TGF-β1 and α-SMA) genes. Moreover, 
it also significantly inhibited macrophages infiltration into kidneys. In contrast, free 
Y27632 did not reduce any of the parameters after 4 days of treatment. We conclude that 
local inhibition of the ROCK pathway within the kidneys enhances the activity of the 




compound, and therefore it can also be explored as a treatment for renal inflammation and 
fibrosis.   
Conclusions and future perspectives 
The present thesis provides sufficient evidence for its overall technological aim, i.e. 
renal-specific delivery of anti-fibrotic compounds in rats with renal fibrosis. In this frame 
work, we employed different linkage techniques to couple drugs to LZM. The novel ULS 
linker showed superiority over other linkages as it is easy-to-use and provides good stability 
of conjugate in serum and slow release of drug in kidneys for several days. Moreover, for 
some drugs it is the only option to couple it to a protein. In vivo efficacy of drug-LZM 
conjugates was confirmed since they showed beneficial effects in the relevant animal 
models for renal fibrosis. Blockade of different pathways such as p38 MAPK, TGF-β1 
receptor-I kinase and ROCK pathways within kidneys, using our renal-specific drug 
delivery approach, produced beneficial effects on both inflammation and fibrosis. 
Moreover, these studies also gave insight into the role of different pathways in the 
regulation of disease. For instance, in the I/R injury model, blockade of ROCK pathway 
with Y27632-LZM showed the most promising effects compared to the blockade of p38 
MAPK or angiotensin II-mediated pathways. Since different doses and dosage schedules 
were used for Y27632-LZM and SB-ULS-LZM conjugates, more studies are required to 
confirm that inhibition of ROCK pathway is the most promising of the investigated 
approaches. Moreover, we the effectivity of TKI-LZM can not be compared directly to the 
other conjugates since we tested it in a different model of renal fibrosis. Therefore, it would 
be quite interesting to further examine the effecivity of different conjugates in different 
animal models.  
For future studies, several steps can still be taken to improve the chosen renal drug 
targeting approach. Some potential limitations related to drug delivery using lysozyme, 
such as low drug to protein coupling ratio, possible immunogenicity and lower shelf-life, 
can presumably be solved by adopting polymers as renal drug carriers. For example, we 
have conducted pilot experiments with PAMAM dendrimers that filter freely through the 
glomerulus and are deposited into tubular cells (16). Coupling of drugs to dendrimers may 
enhance the drug loading to carrier and avoid immunogenicity. Pilot syntheses with this 
type of dendrimer were conducted successfully, and may lead to substantial improvement in 
the field of renal targeting.  
Since our aim is to deliver drug specifically to tubular cells and subsequently intervene 
in renal fibrosis, we used a renal tubular cell culture system to screen for pharmacologically 
interesting drugs. Although we primarily used profibrotic activators, albumin and TGF-β, 
various other activating factors (IL-1β, TNF-α or angiotensin II) and activating conditions 
(hypoxia and high glucose) can be employed to mimic different renal disease activators and 
to activate different signaling pathways. A more extensive testing of kinase inhibitors and 
other anti-inflammatory and antifibrotic agents is needed to identify potential drug targets. 
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In the present study, we used gene expression analysis as a main tool to examine the 
efficacy of the drug and drug-LZM conjugates in vitro. Yet, drugs may act by affecting one 
or more processes such as the expression of cytokines/growth factors, kinase activity, cell-
size, cell migration or cell growth. Moreover, blockade of a signaling pathway may cause 
the activation of another pathway due to the cross-talks between signaling pathways. 
Therefore, different read-out systems such as determination of secreted cytokines in cell 
culture medium, kinase activity assays, proliferation assay and microarray techniques can 
also facilitate to select the most effective drug or a suitable combination of drugs. 
Furthermore, such read-out systems can also be employed to study the in vivo effects of the 
conjugates.   
Understandably, such extensive testing of antifibrotic compounds requires huge efforts 
and was not performed in selection of the presently studied compounds which were selected 
after reviewing of the available literature. In addition, chemical properties of the 
compounds need to be considered in view of drug linking technology and pharmacokinetic 
fate of the compounds. Nevertheless, the conjugates that have been prepared showed highly 
promising activity in both renal proximal tubular cells and in animal models of renal 
fibrosis, and thus may represent promising compounds in the management of renal fibrosis.  
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Nier fibrose is een vergevorderd stadium van nierbeschadiging, waarbij er een 
voortdurende verslechtering van de nierfunctie optreedt. Eén van de belangrijkste 
kenmerken van nierfibrose is de vorming van littekenweefsel, hoofdzakelijk veroorzaakt 
door een overmatige productie van extracellulaire matrix en proliferatie van fibroblasten. 
Het eindstadium van nierfibrose wordt end-stage renal disease (ESRD) genoemd. ESRD 
patiënten hebben een zo slechte nierfunctie dat nierdialyse of transplantatie noodzakelijk is 
geworden. Wereldwijd is een toename van het aantal ESRD patiënten gerapporteerd, o.a als 
gevolg van een toename in ziektes als diabetes en hypertensie. Nierbeschadiging is één van 
de complicaties die optreden bij deze ziektebeelden. De ontwikkeling van nieuwe 
therapieën die nierfibrose kunnen remmen is dan ook een belangrijke medische 
vraagstelling. Dit proefschrift beschrijft hoe renale drug targeting daaraan een bijdrage kan 
leveren. 
In hoofdstuk 1 wordt de vraagstelling van dit proefschrift behandeld. De afgelopen 
decennia is de kennis van inflammatoire en fibrotische processen sterk toegenomen, en zijn 
veel antifibrotische geneesmiddelen voorgedragen. De werkzaamheid van deze 
verbindingen wordt in veel gevallen belemmerd door bijwerkingen en een slechte 
distributie van het geneesmiddel naar het nierweefsel. Het uitgangspunt van dit proefschrift 
is dat drug targeting de balans tussen therapeutische effecten en bijwerkingen kan 
verbeteren door de weefseldistributie van het geneesmiddel te veranderen ten gunste van de 
nieren. Een dergelijke nier-selectieve aflevering van het geneesmiddel wordt tot stand 
gebracht met zogeheten ‘conjugaten’, die gemaakt worden door het geneesmiddel aan een 
dragermolecuul te koppelen (conjugeren). Het dragermolecuul voor niertargeting dat in dit 
proefschrift gebruikt wordt is het eiwit lysozym (LZM). LZM hoopt efficiënt op in de 
niertubuluscellen, en daarmee zal een geneesmiddel dat aan de carrier is gekoppeld dat ook 
doen. Dit concept wordt al een aantal jaren succesvol toegepast in onze groep. In het 
huidige onderzoek zijn deze carriers gebruikt om de nieuwste en krachtigste experimentele 
geneesmiddelen tegen nierfibrose te sturen naar de nier. Hierbij is tevens een nieuwe 
manier om het geneesmiddel te koppelen aan zijn drager uitgetest.. Het beschreven 
onderzoek omvat het hele preklinische traject, van ontwerp en synthese van de conjugaten 
tot het testen in verschillende diermodellen van nierfibrose. 
Hoofdstuk 2 en 3 behandelen het conjugaat captopril-LZM, een conjugaat dat al een 
aantal jaren geleden binnen ons lab ontwikkeld was. Aangezien macromoleculen niet vanuit 
het maagdarmkanaal geabsorbeerd worden en de eiwitachtige structuur van de carrier in het 
maagdarmkanaal afgebroken wordt, kunnen geneesmiddel-LZM conjugaten niet via orale 
toediening gegeven worden. Dit is natuurlijk een nadeel bij chronische ziekten waarbij 
medicijnen langdurig toegediend moeten worden.Wij hebben daarom gezocht naar een 
patiënt vriendelijker alternatief voor intraveneuze injectie van de preparaten. Hoofdstuk 2 
laat zien dat LZM en het captopril-LZM conjugaat goed geabsorbeerd worden van de 
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subcutane injectieplek, en uiteindelijk zelfs beter in de nieren accumuleren dan na 
intraveneuze injectie. Hoofdstuk 3 behandelt de studies die uitgevoerd zijn in ratten met 
een nierbeschadiging ten gevolge van de toxische stof adriamycine. De nierbeschadiging uit 
zich onder andere in proteïnurie (eiwitverlies in de urine) en therapieën richten zich vooral 
op het bestrijden van deze proteïnurie. Niet getarget captopril had een verlagend effect op 
de systemische bloeddruk, maar had geen invloed op de proteïnurie. Subcutaan toegediend 
captopril-LZM verlaagde juist wel de proteïnurie en veroorzaakte geen bloeddrukdaling. 
Dit resultaat laat zien dat subcutaan captopril-LZM werkzaam is en dat de nierselectiviteit 
van het conjugaat verbeterd is ten opzichte van vrij captopril. 
In het vervolgonderzoek werd de voorkeur gegeven aan geneesmiddelen die sterker 
werkzaam zijn dan captopril. Een gemeenschappelijk kenmerk van de geselecteerde 
geneesmiddelen is dat ze aangrijpen op kinases, eiwitten die intracellulaire processen 
regelen door middel van phosphorylatie van andere kinases en transcriptiefactoren. Deze 
geneesmiddelen staan tegenwoordig sterk in de belangstelling omdat ze zeer krachtig zijn 
en vele processen kunnen remmen. Hoofdstuk 4 geeft een overzicht van de rol die kinases 
spelen in nierfibrose, en welke kinase remmers mogelijk geschikt zijn voor de remming van 
fibrotische processen in de nier. Hierbij is met name aandacht geschonken aan kinases die 
geactiveerd worden in de niertubuluscellen, het celtype dat ook het doelwit is van onze drug 
targeting strategie. Tijdens nierziekte worden de tubuluscellen geactiveerd door o.a. 
groeifactoren en albumine dat door het beschadigde nierfilter in de urine terecht komt. We 
hebben dit activatie proces in gekweekte tubuluscellen kunnen nabootsen, en aangetoond 
dat o.a. remmers van de p38 MAPkinase route fibrotische processen remmen (hoofdstuk 
6,7); maar ook remming van Rho-associated kinase route bleek een veelbelovende 
antifibrotische strategie (hoofdstuk 8).  
Een belangrijke technologische ontwikkeling die in dit proefschrift beschreven wordt is 
een nieuwe bereidingswijze van de geneesmiddel-eiwit conjugaten. Veel farmacologisch 
interessante geneesmiddelen zijn niet aan eiwitten te koppelen. De synthese van de 
preparaten is dan technisch niet mogelijk of erg complex. In dit proefschrift is een nieuwe 
koppelingstechniek toegepast, het zogeheten Universal Linkage System (ULS™). De kern 
van het ULS is een platina atoom dat coördinatie bindingen kan vormen met het 
geneesmiddel. ULS werd succesvol toegepast voor de bereiding van alle nierspecifieke 
conjugaten die in de hoofdstukken 6 t/m 8 behandeld worden. In hoofdstuk 6 wordt verder 
een vergelijking gemaakt tussen twee koppelingsstrategieën, zoals verderop wordt 
besproken. 
Een belangrijk uitgangspunt van dit onderzoek is dat de werkzaamheid van de 
geselecteerde kinase remmers verbeterd kan worden middels drug targeting naar de nier. 
Ter onderbouwing van deze hypothese hebben we de farmacokinetiek van de p38 
MAPkinase remmer SB202190 in ratten onderzocht (hoofdstuk 5). Dit hoofdstuk beschrijft 
allereerst de HPLC methode die ontwikkeld werd voor de bepaling van het geneesmiddel in 
verschillende weefsels, maar laat ook zien dat de weefseldistributie van SB202190 vanuit 




het bloed naar de nieren zeer inefficiënt is. De weefseldistributie van hydrofobe kinase 
remmers kan dus sterk verbeterd worden, en er zal dus ook een therapeutische verbetering 
mogelijk zijn middels nierspecifieke aflevering.  
Dat targeting van SB202190 naar de nier daadwerkelijk mogelijk is wordt behandeld in 
hoofdstuk 6. Voor de synthese van SB202190-LZM conjugaat werden twee verschillende 
strategieën vergeleken, de al eerder besproken nieuwe ULS methodiek en een andere 
benadering waarbij een carbamaat van SB202190 gemaakt werd. Het SB-carbamaat-LZM 
conjugaat werd echter snel afgebroken in serum, en dit type conjugaat zal daarom de nieren 
niet intact bereiken. Het SB-ULS-LZM conjugaat bleek echter wel stabiel in serum, en na 
toediening aan ratten hoopte het SB-ULS-LZM inderdaad efficiënt op in de nieren.  
Uit de eerdere studies met captopril-LZM was gebleken dat het afgeleverde 
geneesmiddel snel uit de nieren verwijderd werd. Deze snelle eliminatie beperkt de 
werkzaamheid van het captopril, of vereist een meer frequente dosering van het conjugaat. 
De vrijgifte van het SB202190 uit het SB-ULS-LZM conjugaat vertoonde een zogeheten 
vertraagd afgifte profiel, waarbij gedurende meerdere dagen geneesmiddel in de nieren 
vrijgegeven werd. Dit vertraagde afgifte profiel is later ook bij andere conjugaten 
aangetoond, en resulteerde in langdurige beschikbaarheid van het geneesmiddel in de 
nieren na een enkele dosering. Dit lijkt een gunstig gegeven, omdat nierfibrose een 
chronische ziekte is, die langdurig behandeld moet worden. 
Platina verbindingen zijn berucht voor hun nierbeschadigende werking, en daarom zijn 
de ULS-conjugaten hierop nauwgezet gecontroleerd. Van SB-ULS-LZM konden echter 
geen schadelijke effecten worden waargenomen in de gebruikte doseringen , zowel in 
gekweekte niertubuluscellen als in de nieren van gezonde ratten die met het conjugaat 
behandeld zijn. Er werden wel therapeutische effecten van SB-ULS-LZM gevonden, zowel 
in gekweekte tubuluscellen als in zieke ratten (ischemie/reperfusie model) die behandeld 
werden met SB-ULS-LZM. Een enkelvoudige dosis van het conjugaat had zowel een effect 
op de activatie van het doelwit kinase (p38 MAPkinase) als op de vorming van de 
fibrotische marker α-smooth muscle actin (α-SMA).  
Eén van de belangrijkste activatoren van niertubuluscellen is transforming growth 
factor-β1 (TGF-β1) en remming van deze activatie route zou dus een efficiënte 
therapeutische strategie kunnen zijn.. In hoofdstuk 7 is de nierspecifieke remming van een 
krachtige TGF kinase remmer (TKI) onderzocht. TKI werd middels ULS aan LZM 
gekoppeld, en het TKI-LZM conjugaat vertoonde een vergelijkbaar vertraagd afgifte profiel 
als hierboven beschreven is voor SB-ULS-LZM. De therapeutische effectiviteit van TKI-
LZM werd vervolgens onderzocht in het urether-obstructie model, een model waarin 
afbinding van de urineverzamelbuis leidt tot een snelle nierfibrose. Een enkelvoudige dosis 
van het conjugaat vertoonde anti-inflammatoire en antifibrotische effecten, zoals o.a. een 
remming van de infiltratie van immuuncellen in de nier en een verminderde productie van 
de fibrose marker α-SMA.  
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Een derde conjugaat was gericht op de remming van RhoGTPase gemediëerde 
processen in niertubuluscellen (hoofdstuk 8).Ook deze activatieroute lijkt belangrijk bij het 
ontstaan van nierfibrose. De remmer van het ROCK kinase, Y27632, werd opnieuw met 
ULS aan LZM gekoppeld, en Y27632-LZM conjugaat accumuleerde wederom efficiënt in 
de nieren. De werkzaamheid tegen nierfibrose werd in het ischemie-reperfusie model 
getest, nu middels 4 injecties die dagelijks gegeven werden. Deze behandeling van 
nierfibrose met Y27632-LZM bleek zeer effectief, terwijl vrij Y27632 geen therapeutische 
effecten vertoonde. Het therapeutisch effect van het conjugaat werd daarom toegeschreven 
aan de locale remming van ROCK in de nieren, middels de nierspecifieke aflevering met 
het conjugaat.  
Concluderend kan gesteld worden dat het doel van dit onderzoek bereikt is. Middels 
een nieuwe strategie zijn nieuwe nierspecifieke preparaten ontwikkeld die relevante 
processen remmen in de doelcellen en de werkzaamheid is in verschillende experimentele 
modellen aangetoond. De ontwikkelde preparen zullen in vervolgonderzoek nog verder 
onderzocht worden. Daarnaast biedt dit proefschrift tal van aanknopingspunten voor nieuw 
onderzoek, zoals een verdere uitbreiding met andere kinase remmers of andere 
antifibrotische geneesmiddelen.  
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α-SMA alpha-Smooth Muscle Actin 
ACE Angiotensin Converting Enzyme 
AIC Akaike's Information Criterion 
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BMP Bone Morphogenic Protein 
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CTGF Connective Tissue Growth Factor 
DMF Dimethyl Formamide 
ECM Extracellular Matrix 
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Kinase 
ERKs Extracellular Signal-Regulated 
Kinases 
ESI-MS Electron-Spray Ionization Mass 
Spectrometry 
ESRD End Stage Renal Diseases 
FCS Fetal Calf Serum 
GSH Glutathione 
HGF Hepatocyte Growth Factor 




HPLC High Performance Liquid 
Chromatography 
I.S. Internal Standard 
I/R Ischemia/Reperfusion 
IL-10 Interleukin-10 
JNK c-jun N-terminal protein kinase 
LLOD Lower Limits of Detection 
LLOQ Lower Limits of Quantitation 
LMWP Low Molecular Weight Protein 
MAPK Mitogen Activated Protein Kinase 
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Protein-1 
MMPs Matrix Metalloproteinases 
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PAI-1 Plasminogen Activator Inhibitor-1 
PAN Puromycin aminonucleoside 
PAS Periodic Acid Schiff’s base 
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RAS Renin Angiotensin System 
ROCK Rho-Associated Kinase 
SB SB202190 
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TGF-β Transforming Growth Factor-beta 
TIMP-1 Tissue Inhibitor of 
Metalloproteinase-1 
TKI TGF-beta Receptor Kinase 
Inhibitor 
TNF-α Tumor Necrotic Factor-alpha 
ULS™ Universal Linkage System 








Figure 6. Anti-LZM immunohistochemical staining (B-D) on kidney sections. Untreated animals (B); 
SB-ULS-LZM treated animals at 1 h (C, D). Arrows in C and D indicate the staining for lysozyme in 
tubular cells. Panel C (magnification 200×) shows accumulation of SB-ULS-LZM in kidneys, which 
appeared to be allocated within the tubular cells as observed at magnification 400× (D). Masson 
staining shows renal morphology in untreated animals (E) and SB-ULS-LZM treated animals at 24 h 
(F) and 72 h (G), at 200× magnification. There is no change in the morphology of the proximal 
tubular cells after 24 h (E vs. F) or 72 h (E vs. G) after administration of the conjugate. 
 
This figure has been selected for the cover of the Journal of Pharmacology and 
Experimental Therapeutics in October 2006 issue. 
 
 










Figure 9. Representative photomicrographs of the immunohistochemical detection of p-p38 positive 
cells in renal medulla (A-C; 200×) and α-SMA expression in renal cortex (D-F; 100×), 4 days after 
unilateral ischemia−reperfusion injury. Vehicle−treated animals (A, D); SB-ULS-LZM−treated 
animals (B, E); SB202190−treated animals (C, F). Arrows in panels A-C indicate the 
immunolocalization (dark brown color) of p-p38 positive nuclei in the tubular cells corresponding to 
the dilated and injured tubules. Arrows in panels D-F indicate the localization of α-SMA in 




Chapter 7, Fig. 3A 
 
 
Figure 3. (A) Fluorescent photomicrographs (a, c, d, f) showing lysosomal uptake in HK-2 cells and 
NRK-52E cells after incubating with Rhodamine-ULS-lysozyme (100 µg/ml) at 37°C for 2 h. For 
competition studies, lysozyme (10 mg/ml) was added 15 min before adding Rhodamine-ULS-
lysozyme. Light photomicrographs (b, e) demonstrate the confluency of the cells in culture plate. 
 
Chapter 7, Fig. 4C 
 
Figure 4. Panel (C) shows the localization of the conjugate in tubular cells at t=1h by anti-LZM 
immunohistochemical staining. Magnification, 200×. 











Figure 5. Localization of Rhodamine-ULS-lysozyme conjugate in the kidney. Light photomicrograph 
showing anti-LZM immunohistochemical staining on kidney sections t=1h (A) and t=24h (C) after 
administration of a single dose of Rhodamine-ULS-lysozyme (20 mg/kg) at magnification 100×. 
Panel (B) and (D) show the fluorescence photomicrographs of rhodamine fluorescence in kidney 
sections at t=1h and t=24h, respectively at magnification, 100×. “g” indicate the localization of 
glomeruli in the non-fluorescent space in B and D. Note the pattern of the localization of anti-
lysozyme staining and rhodamine fluorescence. Lysozyme was degraded after 24h while rhodamine 









Figure 7. Representative photomicrographs of the immunohistochemical staining for ED-1 positive 
cells (infiltrated macrophages) in normal rats (A) and 3 days after Unilateral Ureteral Obstruction 
(UUO) (B-D) rats in vehicle−treated (B), TKI-LZM−treated (C) and TKI−treated animals (D). 
Arrows indicate the immunolocalization of ED-1 in tubulointerstitial area. Magnification, 200×. 
 









Figure 8. Representative photomicrographs of the immunohistochemical staining of α-SMA in 
normal rats (A) and 3 days after Unilateral Ureteral Obstruction (UUO) (B-D) rats in vehicle−treated 
(B), TKI-LZM−treated (C) and TKI−treated animals (D). Magnification, 200×.  
 
Chapter 8, Fig. 2 
 
Figure 2. Panel (C) represents the localization of the conjugate in tubular cells at 30 min by anti-








Figure 4. Representative photomicrographs of the macrophage immunostaining (ED-1) in normal 
rats, n=4 (A) and 4 days after unilateral ischemia-reperfusion injury (B-D) rats. Vehicle−treated, n=10 
(B); Y27632-LZM−treated, n=3 (C); Y27632−treated, n=6 (D) animals. Arrows indicate the 
immunolocalization of ED-1 positive cells (brown color) in tubulointerstitial area. PAS 
counterstaining depicts the renal morphology. Magnification, 200×.  










Figure 5. Representative photomicrographs of the immunostaining for alpha-smooth muscle actin (α-
SMA) in normal rats, n=4 (A) and 4 days after unilateral ischemia-reperfusion injury (B-D) rats. 
Vehicle−treated, n=10 (B); Y27632-LZM−treated, n=3 (C); Y27632−treated, n=6 (D) animals. PAS 
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